

From: Biol. Abstr. 36, Abstr. No. 677 (1901).
DT Journal
LA Unavailable

=> d his

(FILE 'HOME' ENTERED AT 15:16:16 ON 02 DEC 2002)

FILE 'REGISTRY' ENTERED AT 15:16:24 ON 02 DEC 2002

L1 122 S ACETAMINOPHEN
L2 0 S ASPRIN
L3 50 S ASPIRIN
E STATIN
L4 1577 S E3
L5 29 S VITAMIN C
L6 77 S VITAMIN E
L7 8 S ATORVASTATIN
E STANOL
L8 12 S E3
L9 3 S TIROFIBAN

FILE 'CAPLUS' ENTERED AT 15:25:14 ON 02 DEC 2002

E ATHEROSCLEROSIS
L10 33111 S E3
L11 10111 S L1
L12 12 S L11 AND L10
L13 15536 S L3
L14 196 S L13 AND L10
L15 50997 S L4
L16 327 S L15 AND L10
L17 49222 S L5
L18 420 S L17 AND L10
L19 26899 S L6
L20 800 S L19 AND L10

=> s 17

L21 697 L7

=> s l21 and l10

L22 130 L21 AND L10

=> d l22 100-130

L22 ANSWER 100 OF 130 CAPLUS COPYRIGHT 2002 ACS

AN 1999:613662 CAPLUS

DN 131:248237

TI Statin-matrix metalloproteinase inhibitor combinations

IN Newton, Roger Schofield; Roth, Bruce David

PA Warner-Lambert Company, USA

SO PCT Int. Appl., 153 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9947138	A1	19990923	WO 1998-US24681	19981120

W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HR, HU, ID, IL,
IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL,
RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG,
KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2309588	AA	19990923	CA 1998-2309588	19981120
AU 9915916	A1	19991011	AU 1999-15916	19981120
BR 9815745	A	20001114	BR 1998-15745	19981120
EP 1063991	A1	20010103	EP 1998-960279	19981120

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO

JP 2002506818	T2	20020305	JP 2000-536378	19981120
ZA 9902106	A	19990930	ZA 1999-2106	19990316
US 2002049237	A1	20020425	US 2001-977162	20011012

PRAI US 1998-78265P P 19980317
WO 1998-US24681 W 19981120
US 1999-297592 B1 19990503

OS MARPAT 131:248237

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 101 OF 130 CAPLUS COPYRIGHT 2002 ACS

AN 1999:609873 CAPLUS

DN 131:223312

TI Efficacy and safety of atorvastatin and pravastatin in patients with
hypercholesterolemia

AU Assmann, G.; Huwel, D.; Schussman, K.-M.; Smilde, J. G.; Kosling, M.;
Withagen, A. J. A. M.; Wunderlich, J.; Stoel, I.; Van Dormaal, J. J.;
Neuss, J.; Oldenbroek, C.; Cuppers, M. C.; Von Eckardstein, A.; Schulte,
H.; Wagner, B.; McLain, R.; Black, D. M.

CS Institut fur Klinische Chemie und Laboratoriumsmedizin,
Zentrallaboratorium, Munster, 48149, Germany

SO European Journal of Internal Medicine (1999), 10(1), 33-39
CODEN: EJIMEJ; ISSN: 0953-6205

PB Elsevier Science Ireland Ltd.

DT Journal

LA English-

RE.CNT 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 102 OF 130 CAPLUS COPYRIGHT 2002 ACS

AN 1999:538570 CAPLUS

DN 131:295415

TI Hypocholesterolemic effects of 3-hydroxy-3-methylglutaryl coenzyme A
(HMG-CoA) reductase inhibitors in the guinea pig. Atorvastatin versus
simvastatin

AU Conde, K.; Pineda, G.; Newton, R. S.; Fernandez, M. L.

CS Department of Nutritional Sciences, Lipid Metabolism Laboratory,
University of Connecticut, Storrs, CT, USA

SO Biochemical Pharmacology (1999), 58(7), 1209-1219
CODEN: BCPCA6; ISSN: 0006-2952

PB Elsevier Science Inc.

DT Journal

LA English

RE.CNT 62 THERE ARE 62 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 103 OF 130 CAPLUS COPYRIGHT 2002 ACS

AN 1999:501721 CAPLUS

DN 131:153629

TI Long-term safety and efficacy of combination gemfibrozil and HMG-CoA
reductase inhibitors for the treatment of mixed lipid disorders

AU Murdock, David K.; Murdock, Anthony K.; Murdock, Robert W.; Olson, Karen
J.; Frane, Arlyne M.; Kersten, Mary E.; Joyce, Diane M.; Gantner, Sue E.

CS The Lipid Clinic of Cardiovascular Associates of Northern Wisconsin and
The CARE Foundation, Wausau, WI, USA
SO American Heart Journal (1999), 138(1, Pt. 1), 151-155
CODEN: AHJOA2; ISSN: 0002-8703
PB Mosby, Inc.
DT Journal
LA English
RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 104 OF 130 CAPLUS COPYRIGHT 2002 ACS
AN 1999:489710 CAPLUS
DN 131:331943
TI Platelet deposition on eroded vessel walls at a stenotic shear rate is
inhibited by lipid-lowering treatment with atorvastatin
AU Alfon, Jose; Royo, Teresa; Garcia-Moll, Xavier; Badimon, Lina
CS Cardiovascular Research Center, CSIC-HSCSP-UAB; Barcelona, Spain
SO Arteriosclerosis, Thrombosis, and Vascular Biology (1999), 19(7),
1812-1817
CODEN: ATVBFA; ISSN: 1079-5642
PB Lippincott Williams & Wilkins
DT Journal
LA English
RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 105 OF 130 CAPLUS COPYRIGHT 2002 ACS
AN 1999:464665 CAPLUS
DN 131:295408
TI Nitric oxide synthase II (NOS II) gene expression correlates with
atherosclerotic intimal thickening. Preventive effects of HMG-CoA
reductase inhibitors
AU Alfon, Jose; Guasch, Joan F.; Berrozpe, Maria; Badimon, Lina
CS CSIC-HSCSP-UAB, Cardiovascular Research Center, Barcelona, 08034, Spain
SO Atherosclerosis (Shannon, Ireland) (1999), 145(2), 325-331
CODEN: ATHSBL; ISSN: 0021-9150
PB Elsevier Science Ireland Ltd.
DT Journal
LA English
RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 106 OF 130 CAPLUS COPYRIGHT 2002 ACS
AN 1999:442143 CAPLUS
DN 131:306908
TI Lipophilic statins induce apoptosis of human vascular smooth muscle cells
AU Guijarro, Carlos; Blanco-Colio, Luis Miguel; Massy, Ziad A.; O'Donnell,
Michael P.; Kasiske, Bertram L.; Keane, William F.; Egido, Jesus
CS Research Laboratories, Instituto de Investigacion Medica, Fundacion
Jimenez Diaz, Universidad Autonoma de Madrid, Madrid, Spain
SO Kidney International, Supplement (1999), 71, S88-S91
CODEN: KISUDF; ISSN: 0098-6577
PB Blackwell Science, Inc.
DT Journal
LA English
RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 107 OF 130 CAPLUS COPYRIGHT 2002 ACS
AN 1999:282039 CAPLUS
DN 130:306593
TI Combination therapy using a HMG-CoA reductase inhibitor and a

Welcome to STN International! Enter x:x

LOGINID:sssptaul25rxt

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 Apr 08 "Ask CAS" for self-help around the clock
NEWS 3 Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 4 Apr 09 ZDB will be removed from STN
NEWS 5 Apr 19 US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 6 Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 7 Apr 22 BIOSIS Gene Names now available in TOXCENTER
NEWS 8 Apr 22 Federal Research in Progress (FEDRIP) now available
NEWS 9 Jun 03 New e-mail delivery for search results now available
NEWS 10 Jun 10 MEDLINE Reload
NEWS 11 Jun 10 PCTFULL has been reloaded
NEWS 12 Jul 02 FOREGE no longer contains STANDARDS file segment
NEWS 13 Jul 22 USAN to be reloaded July 28, 2002;
saved answer sets no longer valid
NEWS 14 Jul 29 Enhanced polymer searching in REGISTRY
NEWS 15 Jul 30 NETFIRST to be removed from STN
NEWS 16 Aug 08 CANCERLIT reload
NEWS 17 Aug 08 PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 18 Aug 08 NTIS has been reloaded and enhanced
NEWS 19 Aug 19 Aquatic Toxicity Information Retrieval (AQUIRE)
now available on STN
NEWS 20 Aug 19 IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS 21 Aug 19 The MEDLINE file segment of TOXCENTER has been reloaded
NEWS 22 Aug 26 Sequence searching in REGISTRY enhanced
NEWS 23 Sep 03 JAPIO has been reloaded and enhanced
NEWS 24 Sep 16 Experimental properties added to the REGISTRY file
NEWS 25 Sep 16 Indexing added to some pre-1967 records in CA/CAPLUS
NEWS 26 Sep 16 CA Section Thesaurus available in CAPLUS and CA
NEWS 27 Oct 01 CASREACT Enriched with Reactions from 1907 to 1985
NEWS 28 Oct 21 EVENTLINE has been reloaded
NEWS 29 Oct 24 BEILSTEIN adds new search fields
NEWS 30 Oct 24 Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 31 Oct 25 MEDLINE SDI run of October 8, 2002
NEWS 32 Nov 18 DKILIT has been renamed APOLLIT
NEWS 33 Nov 25 More calculated properties added to REGISTRY

NEWS EXPRESS October 14 CURRENT WINDOWS VERSION IS V6.01,
CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP),
AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific

research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 15:16:16 ON 02 DEC 2002

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 15:16:24 ON 02 DEC 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 1 DEC 2002 HIGHEST RN 474745-06-7

DICTIONARY FILE UPDATES: 1 DEC 2002 HIGHEST RN 474745-06-7

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNnote 27, Searching Properties in the CAS Registry File, for complete details:

<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> s acetaminophen

L1 122 ACETAMINOPHEN

=> s aspirin

L2 0 ASPRIN

=> s aspirin

L3 50 ASPIRIN

=> e statin

E1 4 STATILINUS/BI

E2 1 STATIMO/BI

E3 1577 --> STATIN/BI

E4 2 STATINATE/BI

E5 25 STATINE/BI

E6 16 STATION/BI

E7 53 STATIONARY/BI

E8 11 STATIONIS/BI

E9 20 STATO/BI

E10 1 STATO21/BI

E11 1 STATOC/BI

E12 1 STATOCAL/BI

=> s e3

L4 1577 STATIN/BI

=> d 14 1577

L4 ANSWER 1577 OF 1577 REGISTRY COPYRIGHT 2002 ACS

RN 51-43-4 REGISTRY

CN 1,2-Benzenediol, 4-[(1R)-1-hydroxy-2-(methylamino)ethyl]- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 1,2-Benzenediol, 4-[1-hydroxy-2-(methylamino)ethyl]-, (R)-

CN Benzyl alcohol, 3,4-dihydroxy-.alpha.-[(methylamino)methyl]-, (-)- (8CI)

OTHER NAMES:

CN (-)-(R)-Epinephrine

CN (-)-3,4-Dihydroxy-.alpha.-[2-(methylamino)ethyl]benzyl alcohol

CN (-)-Adrenaline

CN (-)-Epinephrine

CN (R)-Adrenaline

CN (R)-Epinephrine

CN Adnephrine

CN Adrenal

CN Adrenalin

CN Adrenaline

CN Adrenine

CN Adrin

CN Ana-Kit

CN Bosmin

CN Chelafrin

CN Epifrin

CN Epinefrina

CN Epinephran

CN Epinephrine

CN Epipen

CN Epirenan

CN Exadrin

CN Hemisine

CN Hemostasin

CN **Hemostatin**

CN Hypernephrin

CN Isoptoepinal

CN 1-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol

CN 1-Adrenaline

CN L-Adrenaline

CN 1-Epinephrine

CN 1-Epirenamine

CN Levoepinephrine

CN Levorenin

CN Levorenine

CN Levoreninum

CN Lyodrin

CN Methylarterenol

CN Mucidrina

CN Nephridine

CN Nieraline

CN Paraneprhin

CN Primatene Mist

CN R-(-)-Epinephrine

CN Renaglandin

CN Renaleptine


CN Renalina

CN Renoform

ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for

DISPLAY
 FS STEREOSEARCH
 DR 51028-73-0
 MF C9 H13 N O3
 CI COM
 LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOBUSINESS,
 BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB,
 CEN, CHEMCATS, CHEMLIST, CIN, CSCHM, CSNB, DDFU, DIOGENES, DRUGU,
 EMBASE, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE,
 MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PDLCOM*, PHARMASEARCH, PIRA,
 PROMT, RTECS*, SPECINFO, TOXCENTER, USAN, USPAT2, USPATFULL
 (*File contains numerically searchable property data)
 Other Sources: DSL**, EINECS**, TSCA**, WHO
 (**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

29110 REFERENCES IN FILE CA (1962 TO DATE)
 209 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 29125 REFERENCES IN FILE CAPLUS (1962 TO DATE)
 356 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> s vitamin c
 1396 VITAMIN
 1686156 C
 L5 29 VITAMIN C
 (VITAMIN(W)C)

=> s vitamin e
 1396 VITAMIN
 588588 E
 L6 77 VITAMIN E
 (VITAMIN(W)E)


=> s atorvastatin
 L7 8 ATORVASTATIN

=> d 17 8

L7 ANSWER 8 OF 8 REGISTRY COPYRIGHT 2002 ACS
 RN 125995-03-1 REGISTRY
 CN 1H-Pyrrole-3-carboxamide, 5-(4-fluorophenyl)-2-(1-methylethyl)-N,4-
 diphenyl-1-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-
 (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN 1H-Pyrrole-3-carboxamide, 5-(4-fluorophenyl)-2-(1-methylethyl)-N,4-
 diphenyl-1-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-,
 (2R-trans)-
 OTHER NAMES:

CN Atorvastatin .delta.-lactone
 CN Atorvastatin lactone
 FS STEREOSEARCH
 DR 142062-65-5
 MF C33 H33 F N2 O4
 SR CA
 LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT, MRCK*, TOXCENTER, USPAT2,
 USPATFULL
 (*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

28 REFERENCES IN FILE CA (1962 TO DATE)
 28 REFERENCES IN FILE CAPLUS (1962 TO DATE)

=> e stanol

E1	1	STANOHL/BI
E2	1	STANOJELL/BI
E3	12 -->	STANOL/BI
E4	1	STANOLAN/BI
E5	1	STANOLAX/BI
E6	1	STANOLINE/BI
E7	4	STANOLONE/BI
E8	1	STANOMYCETIN/BI
E9	2	STANOSTAT/BI
E10	1	STANOV/BI
E11	1	STANOVAL/BI
E12	1	STANOX/BI

=> s e3

L8 12 STANOL/BI

=> d 18 12

L8 ANSWER 12 OF 12 REGISTRY COPYRIGHT 2002 ACS


RN 83-45-4 REGISTRY

CN Stigmastan-3-ol, (3.beta.,5.alpha.)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 5.alpha.-Stigmastan-3.beta.-ol (6CI, 7CI, 8CI)
 OTHER NAMES:
 CN .beta.-Sitostanol
 CN .beta.-Sitosterol, dihydro-
 CN 24.alpha.-Ethylcholestanol
 CN 5,6-Dihydro-.beta.-sitosterol
 CN Dihydro-.beta.-sitosterol
 CN Dihydrositosterin
 CN Dihydrositosterol
 CN **Fucostanol**
 CN Sitostanol
 CN Spinastanol
 FS STEREOSEARCH
 MF C29 H52 O
 CI COM
 LC STN Files: AGRICOLA, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA,
 CANCERLIT, CAOLD, CAPLUS, CASREACT, CEN, CHEMCATS, CHEMINFORMRX,
 CHEMLIST, CIN, DDFU, DRUGU, EMBASE, IPA, MEDLINE, MRCK*, MSDS-OHS,
 NAPRALERT, PIRA, PROMT, TOXCENTER, USPAT2, USPATFULL
 (*File contains numerically searchable property data)
 Other Sources: EINECS**
 (**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

650 REFERENCES IN FILE CA (1962 TO DATE)
 36 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 650 REFERENCES IN FILE CAPLUS (1962 TO DATE)
 21 REFERENCES IN FILE CAOLD (PRIOR TO 1967)


=> s tirofiban
 L9 3 TIROFIBAN

=> d 19 3

L9 ANSWER 3 OF 3 REGISTRY COPYRIGHT 2002 ACS
 RN 142373-60-2 REGISTRY
 CN L-Tyrosine, N-(butylsulfonyl)-O-[4-(4-piperidinyl)butyl]-,
 monohydrochloride (9CI) (CA INDEX NAME)
 OTHER NAMES:

CN Aggrastat
 CN L 700462
 CN MK 383
 CN N-(Butylsulfonyl)-O-[4-(4-piperidinyl)butyl]-L-tyrosine hydrochloride
 CN **Tirofiban hydrochloride**
 FS STEREOSEARCH
 MF C22 H36 N2 O5 S . Cl H
 SR CA
 LC STN Files: ADISNEWS, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAPLUS,
 CASREACT, CEN, CIN, DIOGENES, DRUGPAT, DRUGUPDATES, EMBASE, IPA, MRCK*,
 PHAR, PROMT, TOXCENTER, USAN, USPAT2, USPATFULL
 (*File contains numerically searchable property data)
 CRN (144494-65-5)

Absolute stereochemistry.



● HCl

58 REFERENCES IN FILE CA (1962 TO DATE)
 2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 58 REFERENCES IN FILE CAPLUS (1962 TO DATE)

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
56.02	56.23

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 15:25:14 ON 02 DEC 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 2 Dec 2002 VOL 137 ISS 23

FILE LAST UPDATED: 1 Dec 2002 (20021201/ED)

This file contains CAS Registry Numbers for easy and accurate

substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> e atherosclerosis

E1	1	ATHEROSCLEROSIA/BI
E2	4	ATHEROSCLEROSIC/BI
E3	33111	--> ATHEROSCLEROSIS/BI
E4	1	ATHEROSCLEROSIS8/BI
E5	1	ATHEROSCLEROSISARE/BI
E6	1	ATHEROSCLEROSISATHEROSCLEROSIS/BI
E7	1	ATHEROSCLEROSISHATHEROSCLEROSIS/BI
E8	1	ATHEROSCLEROSOIS/BI
E9	2	ATHEROSCLEROSOS/BI
E10	1	ATHEROSCLEROSS/BI
E11	1	ATHEROSCLEROSTIC/BI
E12	1	ATHEROSCLEROT/BI

=> s e3

L10 33111 ATHEROSCLEROSIS/BI

=> d his

(FILE 'HOME' ENTERED AT 15:16:16 ON 02 DEC 2002)

FILE 'REGISTRY' ENTERED AT 15:16:24 ON 02 DEC 2002

L1	122	S ACETAMINOPHEN
L2	0	S ASPRIN
L3	50	S ASPIRIN
		E STATIN
L4	1577	S E3
L5	29	S VITAMIN C
L6	77	S VITAMIN E
L7	8	S ATORVASTATIN
		E STANOL
L8	12	S E3
L9	3	S TIROFIBAN

FILE 'CAPLUS' ENTERED AT 15:25:14 ON 02 DEC 2002

E ATHEROSCLEROSIS
L10 33111 S E3

=> s l1

L11 10111 L1

=> s l11 and l10

L12 12 L11 AND L10

=> d l12 1-12

L12 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2002 ACS

AN 2002:777648 CAPLUS

DN 137:257659

TI Therapeutic combinations for cardiovascular and inflammatory indications

IN Seibert, Karen; Keller, Bradley T.; Isakson, Peter C.

PA Pharmacia Corporation, USA

SO PCT Int. Appl., 107 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002078625	A2	20021010	WO 2002-US9185	20020327
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRAI	US 2001-279239P	P	20010328		

L12 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2002 ACS

AN 2002:736715 CAPLUS

DN 137:253031

TI Pharmaceutical preparations of glutathione and methods of administration thereof

IN Demopoulos, Harry B.; Seligman, Myron L.

PA USA

SO U.S. Pat. Appl. Publ., 26 pp., Cont.-in-part of U.S. 6,350,467.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002136763	A1	20020926	US 2002-83327	20020225
	WO 9829101	A1	19980709	WO 1997-US23879	19971231
	W:	AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	US 6350467	B1	20020226	US 1999-331947	19990628
PRAI	US 1996-34101P	P	19961231		
	WO 1997-US23879	W	19971231		
	US 1999-331947	A2	19990628		

L12 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2002 ACS

AN 2002:717065 CAPLUS

DN 137:226613

TI Use of acetaminophen to prevent and treat arteriosclerosis

IN Nelson, Edward B.; Smith, Charles V.; Taylor, Addison A.

PA USA

SO U.S. Pat. Appl. Publ., 8 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002132855	A1	20020919	US 2001-887465	20010622
PRAI	US 2000-222781P	P	20000803		

L12 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2002 ACS

AN 2002:588980 CAPLUS
 DN 137:135080
 TI Modification of NSAIDs by sulfur-containing functional groups
 IN Lai, Ching-San; Wang, Tingmin
 PA Medinox, Inc., USA
 SO U.S., 27 pp., Cont.-in-part of U.S. Ser. No. 602,688.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6429223	B1	20020806	US 2000-715767	20001117
	US 6355666	B1	20020312	US 2000-602688	20000623
	WO 2002000167	A2	20020103	WO 2001-US19750	20010619
	WO 2002000167	A3	20020404		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
	GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				
	LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,				
	RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,				
	UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,				
	DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,				
	BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2001070010	A5	20020108	AU 2001-70010	20010619
PRAI	US 2000-602688	A2	20000623		
	US 2000-715767	A1	20001117		
	WO 2001-US19750	W	20010619		

RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2002 ACS
 AN 2002:406402 CAPLUS
 DN 137:320273
 TI Effect of acetaminophen on the myeloperoxidase-hydrogen peroxide-nitrite mediated oxidation of LDL
 AU Chou, Tien-min; Greenspan, Phillip
 CS Department of Pharmaceutical and Biomedical Sciences, University of Georgia, College of Pharmacy, Athens, GA, 30602-2356, USA
 SO Biochimica et Biophysica Acta (2002), 1581(1-2), 57-63
 CODEN: BBACAQ; ISSN: 0006-3002
 PB Elsevier Science B.V.
 DT Journal
 LA English

RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2002 ACS
 AN 2002:90556 CAPLUS
 DN 136:131255
 TI Methods for early diagnosis of kidney disease and treatment by drug intervention using lysosome activating compounds
 IN Comper, Wayne D.
 PA Austria
 SO U.S. Pat. Appl. Publ., 30 pp., Cont.-in-part of U.S. Ser. No. 415,217.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----

PI: US 2002012906 A1 20020131 US 2001-893346 20010628
 US 2002110799 A1 20020815 US 1999-415217 19991012
 US 6447989 B1 20020910
 WO 2000037944 A1 20000629 WO 1999-IB2029 19991220
 W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
 CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
 IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD,
 MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
 SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
 DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
 CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 PRAI AU 1998-7843 A 19981221
 US 1999-415217 A2 19991012
 WO 1999-IB2029 W 19991220

L12 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2002 ACS
 AN 2001:905774 CAPLUS
 DN 137:72333
 TI Effect of acetaminophen on **atherosclerosis**
 AU Chong, Pang H.; Kezele, Bob; Pontikes, Pamala J.
 CS Department of Pharmacy Practice, University of Illinois at Chicago,
 Chicago, IL, 60612-3736, USA
 SO Annals of Pharmacotherapy (2001), 35(11), 1476-1479
 CODEN: APHRER; ISSN: 1060-0280
 PB Harvey Whitney Books Co.
 DT Journal; General Review
 LA English
 RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2002 ACS
 AN 2001:380616 CAPLUS
 DN 135:10004
 TI Compositions and methods for counteracting effects of reactive oxygen
 species and free radicals
 IN Shashoua, Victor E.
 PA Ceremedix, Inc., USA
 SO PCT Int. Appl., 102 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001036454	A1	20010525	WO 2000-US31764	20001117
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,				
	HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,				
	LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,				
	SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,				
	ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,				
	DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,				
	BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP	1232174	A1	20020821	EP 2000-978811	20001117
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRAI	US 1999-166381P	P	19991118		
	WO 2000-US31764	W	20001117		
OS	MARPAT 135:10004				

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2002 ACS

AN 1999:783925 CAPLUS

DN 132:22753

TI Preparation of N-(arylsulfonylphenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide derivatives for the elevation of pyruvate dehydrogenase (PDH) activity

IN Butlin, Roger John; Nowak, Thorsten; Burrows, Jeremy Nicholas; Block, Michael Howard

PA Zeneca Limited, UK

SO PCT Int. Appl., 211 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9962506	A1	19991209	WO 1999-GB1669	19990526
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	CA 2331685	AA	19991209	CA 1999-2331685	19990526
	AU 9940524	A1	19991220	AU 1999-40524	19990526
	AU 740909	B2	20011115		
	BR 9910821	A	20010213	BR 1999-10821	19990526
	EP 1082110	A1	20010314	EP 1999-923767	19990526
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
	JP 2002516854	T2	20020611	JP 2000-551762	19990526
	NO 2000006010	A	20010126	NO 2000-6010	20001128
PRAI	GB 1998-11427	A	19980529		
	WO 1999-GB1669	W	19990526		

OS MARPAT 132:22753

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2002 ACS

AN 1999:593675 CAPLUS

DN 132:121896

TI Effect of methionine supplementation on endothelial function, plasma homocysteine, and lipid peroxidation

AU McAuley, Daniel F.; Hanratty, Colm G.; McGurk, Colm; Nugent, Ailish G.; Johnston, G. Dennis

CS The Queen's University of Belfast, Belfast, BT9 7BL, UK

SO Journal of Toxicology, Clinical Toxicology (1999), 37(4), 435-440

CODEN: JTCTDW; ISSN: 0731-3810

PB Marcel Dekker, Inc.

DT Journal

LA English

RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2002 ACS

AN 1998:484927 CAPLUS

DN 129:127177
 TI Pharmaceutical preparations of glutathione and methods of administration
 IN Demopoulos, Harry B.; Seligman, Myron L.
 PA Antioxidant Pharmaceuticals Corp., USA
 SO PCT Int. Appl., 52 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9829101	A1	19980709	WO 1997-US23879	19971231
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9856205	A1	19980731	AU 1998-56205	19971231
	EP 957901	A1	19991124	EP 1997-952640	19971231
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2001507696	T2	20010612	JP 1998-530206	19971231
	US 6350467	B1	20020226	US 1999-331947	19990628
	US 2002136763	A1	20020926	US 2002-83327	20020225
PRAI	US 1996-34101P	P	19961231		
	WO 1997-US23879	W	19971231		
	US 1999-331947	A2	19990628		

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2002 ACS

AN 1994:163728 CAPLUS
 DN 120:163728
 TI Amines (phenoxyalkylamines) as inhibitors of squalene synthase and their preparation and pharmaceutical compositions
 IN Brown, George Robert; Eakin, Murdoch Allan; Mallion, Keith Blakeney; Harrison, Peter John
 PA Harrison, Alison, UK; Zeneca Ltd.
 SO PCT Int. Appl., 68 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9320807	A1	19931028	WO 1993-GB742	19930408
	W: AT, AU, BB, BG, BR, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2093777	AA	19931010	CA 1993-2093777	19930408
	AU 9339005	A1	19931118	AU 1993-39005	19930408
	EP 589018	A1	19940330	EP 1993-908009	19930408
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 06511259	T2	19941215	JP 1993-518098	19930408
	US 5866611	A	19990202	US 1994-157204	19940519
PRAI	GB 1992-7855		19920409		
	WO 1993-GB742		19930408		

DT Journal; General Review
LA Serbo-Croatian

L20 ANSWER 765 OF 800 CAPLUS COPYRIGHT 2002 ACS
AN 1983:3813 CAPLUS
DN 98:3813
TI Effect of vitamin E on platelet aggregation and lipid pattern
AU Musca, Antonio; Cordova, Corrado; Violi, Francesco; Perrone, Alessandro;
Alessandri, Cesare; Salvadori, Flavio
CS IV Clin. Med., Univ. Roma, Rome, Italy
SO Clinica Terapeutica (Rome) (1982), 102(3), 273-6
CODEN: CLTEA4; ISSN: 0009-9074
DT Journal
LA Italian

L20 ANSWER 766 OF 800 CAPLUS COPYRIGHT 2002 ACS
AN 1982:597317 CAPLUS
DN 97:197317
TI **Atherosclerosis** in cholesterol-fed Japanese quail: evidence for
amelioration by dietary vitamin E
AU Donaldson, W. E.
CS Nutr. Prog., North Carolina State Univ., Raleigh, NC, 27650, USA
SO Poultry Science (1982), 61(10), 2097-102
CODEN: POSCAL; ISSN: 0032-5791
DT Journal
LA English

L20 ANSWER 767 OF 800 CAPLUS COPYRIGHT 2002 ACS
AN 1982:561428 CAPLUS
DN 97:161428
TI Vitamins E and A in vascular diseases
AU Butturini, U.
CS Ist. Clin. Med. Gen. Terapia Med., Univ. Studi Parma, Parma, 43100, Italy
SO Acta Vitaminologica et Enzymologica (1982), 4(1-2), 15-19
CODEN: AVEZA6; ISSN: 0300-8924
DT Journal
LA English

L20 ANSWER 768 OF 800 CAPLUS COPYRIGHT 2002 ACS
AN 1982:83583 CAPLUS
DN 96:83583
TI Studies on .alpha.-tocopherol (vitamin E) in **atherosclerosis**
AU Tochihiro, Toshihiko
CS Sch. Med., Nihon Univ., Tokyo, Japan
SO Nichidai Igaku Zasshi (1981), 40(12), 1287-96
CODEN: NICHAS; ISSN: 0029-0424
DT Journal
LA Japanese

L20 ANSWER 769 OF 800 CAPLUS COPYRIGHT 2002 ACS
AN 1982:67593 CAPLUS
DN 96:67593
TI Vitamin E in a rabbit model of endogeneous hypercholesterolemia and
atherosclerosis
AU Westrope, Kenneth L.; Miller, Rodney A.; Wilson, Robert B.
CS Dep. Vet. Microbiol. Pathol., Washington State Univ., Pullman, WA, 99164,
USA
SO Nutrition Reports International (1982), 25(1), 83-8
CODEN: NURIBL; ISSN: 0029-6635
DT Journal
LA English

L20 ANSWER 770 OF 800 CAPLUS COPYRIGHT 2002 ACS
 AN 1981:138210 CAPLUS
 DN 94:138210
 TI Effect of vitamin E deficiency and qualitatively different dietary fats on the structure of the aorta and cardiac and renal arteries
 AU Pozdnyakov, A. L.; Spirichev, V. B.; Levachev, M. M.; Blazhevich, N. V.; Lvovich, N. A.; Ponomareva, L. G.
 CS Inst. Pitan., Moscow, USSR
 SO Voprosy Pitaniya (1981), (1), 45-50
 CODEN: VPITAR; ISSN: 0042-8833
 DT Journal
 LA Russian

L20 ANSWER 771 OF 800 CAPLUS COPYRIGHT 2002 ACS
 AN 1981:41490 CAPLUS
 DN 94:41490
 TI Replacement of intramuscular oily injections of aevita by vitamin A and E suppositories for the treatment of **atherosclerosis**
 AU Yakimets, V. M.; Yakimets, O. M.; Vasilenko, Yu. K.; Tokarenko, L. F.; Kechatova, N. A.
 CS Pyatigorsk. Farm. Inst., Pyatigorsk, USSR
 SO Farmatsiya (Moscow, Russian Federation) (1980), 29(6), 9-12
 CODEN: FRMTAL; ISSN: 0367-3014
 DT Journal
 LA Russian

L20 ANSWER 772 OF 800 CAPLUS COPYRIGHT 2002 ACS
 AN 1979:455062 CAPLUS
 DN 91:55062
 TI Vascular wall lipid metabolism in tocopherol-deficient rats
 AU Saito, Yasushi; Matsuoka, Nobuo; Shirai, Kohji; Shinomiya, Masashige; Morisaki, Nobuhiro; Murano, Toshikazu; Sasaki, Norihiro; Yamamoto, Masamitsu; Kamagaya, Akira
 CS Fac. Med., Chiba Univ., Chiba, Japan
 SO Nippon Rinsho Taisha Gakkai Kiroku (1978), 15, 17-19
 CODEN: NRTKDI
 DT Journal
 LA Japanese

L20 ANSWER 773 OF 800 CAPLUS COPYRIGHT 2002 ACS
 AN 1979:449551 CAPLUS
 DN 91:49551
 TI Effect of "Aevita" administered in suppository form on the blood lipid composition in experimental hypercholesterolemia in rabbits
 AU Yakimets, O. M.; Yakimets, V. M.
 CS Pyatigorsk. Farm. Inst., Pyatigorsk, USSR
 SO Biol. Nauki (Moscow) (1979), (4), 63-5
 CODEN: BINKBT; ISSN: 0303-4119
 DT Journal
 LA Russian

L20 ANSWER 774 OF 800 CAPLUS COPYRIGHT 2002 ACS
 AN 1979:202626 CAPLUS
 DN 90:202626
 TI Polyunsaturated fatty acids, vitamin E, and the proliferation of aortic smooth muscle cells
 AU Cornwell, David G.; Huttner, James J.; Milo, George E.; Panganamala, R. V.; Sharma, H. M.; Geer, Jack C.
 CS Dep. Physiol. Chem., Ohio State Univ., Columbus, Ohio, USA
 SO Lipids (1979), 14(2), 194-207
 CODEN: LPDSAP; ISSN: 0024-4201
 DT Journal

LA English

L20 ANSWER 775 OF 800 CAPLUS COPYRIGHT 2002 ACS
 AN 1979:150606 CAPLUS
 DN 90:150606
 TI Cholesteremia in Japanese quail: response to a mixture of vitamins C and E and choline chloride
 AU Morrissey, R. B.; Donaldson, W. E.
 CS Dep. Poult. Sci., North Carolina State Univ., Raleigh, N. C., USA
 SO Artery (Fulton, Mich.) (1979), 5(2), 182-92
 CODEN: ARTEDR; ISSN: 0098-6127
 DT Journal
 LA English

L20 ANSWER 776 OF 800 CAPLUS COPYRIGHT 2002 ACS
 AN 1979:37884 CAPLUS
 DN 90:37884
 TI Vitamin E, antioxidants and lipid peroxidation in experimental **atherosclerosis** of rabbits
 AU Wilson, Robert B.; Middleton, Charles C.; Sun, Grace Y.
 CS Dep. Vet. Microbiol. Pathol., Washington State Univ., Pullman, Wash., USA
 SO J. Nutr. (1978), 108(11), 1858-67
 CODEN: JONUAI; ISSN: 0022-3166
 DT Journal
 LA English

L20 ANSWER 777 OF 800 CAPLUS COPYRIGHT 2002 ACS
 AN 1977:119706 CAPLUS
 DN 86:119706
 TI Effect of cholesterol feeding on tissue lipid peroxidation, glutathione peroxidase activity and liver microsomal functions in rats and guinea pigs
 AU Tsai, Alan C.; Thie, Geesje M.; Lin, C. R.-S.
 CS Sch. Public Health, Univ. Michigan, Ann Arbor, Mich., USA
 SO J. Nutr. (1977), 107(2), 310-19
 CODEN: JONUAI
 DT Journal
 LA English

L20 ANSWER 778 OF 800 CAPLUS COPYRIGHT 2002 ACS
 AN 1976:461802 CAPLUS
 DN 85:61802
 TI Vitamin E, cholesterol, and lipids during atherogenesis in rabbits
 AU Bitman, Joel; Weyant, Joan; Wood, D. L.; Wrenn, T. R.
 CS Anim. Physiol. Genet. Inst., ARS, Beltsville, Md., USA
 SO Lipids (1976), 11(6), 449-61
 CODEN: LPDSAP
 DT Journal
 LA English

L20 ANSWER 779 OF 800 CAPLUS COPYRIGHT 2002 ACS
 AN 1976:169685 CAPLUS
 DN 84:169685
 TI Hypolipemic tocopherol acetate compositions
 IN Giudicelli, Pierre R. L.; Najer, Henry
 PA Synthelabo S. A., Fr.
 SO Fr. Demande, 5 pp.
 CODEN: FRXXBL
 DT Patent
 LA French
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----

PI FR 2270862 A1 19751212 FR 1974-16994 19740516

L20 ANSWER 780 OF 800 CAPLUS COPYRIGHT 2002 ACS

AN 1975:562495 CAPLUS

DN 83:162495

TI Vitamin E deficiency in atherosclerotic rabbits

AU Awad, Atif B.; Gilbreath, Rex L.

CS Cook Coll., Rutgers State Univ., New Brunswick, N. J., USA

SO Nutr. Rep. Int. (1975), 11(4), 277-86

CODEN: NURIBL

DT Journal

LA English

L20 ANSWER 781 OF 800 CAPLUS COPYRIGHT 2002 ACS

AN 1975:512735 CAPLUS

DN 83:112735

TI Actions of vitamins A and E and some nicotinic acid derivatives on plasma lipids and on lipid infiltration of aorta in cholesterol-fed rabbits

AU Brattsand, Ralph

CS Res. Dep., AB Bofors Nobel-Pharma, Molndal, Swed.

SO Atherosclerosis (1975), 22(1), 47-61

CODEN: ATHSBL

DT Journal

LA English

L20 ANSWER 782 OF 800 CAPLUS COPYRIGHT 2002 ACS

AN 1975:441895 CAPLUS

DN 83:41895

TI Hypervitaminosis E in atherosclerotic rabbits

AU Awad, Atif B.; Gilbreath, Rex L.

CS Cook Coll., Rutgers State Univ., New Brunswick, N. J., USA

SO Nutr. Rep. Int. (1975), 11(5), 409-17

CODEN: NURIBL

DT Journal

LA English

L20 ANSWER 783 OF 800 CAPLUS COPYRIGHT 2002 ACS

AN 1973:123031 CAPLUS

DN 78:123031

TI Role of tocopherol (antioxidant) deficiency in the origin of **atherosclerosis**

AU Voskresenskii, O. N.

CS Dep. Pharmacol., N. I. Pirogov State Med. Sch., Odessa, USSR

SO Vop. Med. Khim. (1973), 19(1), 87-90

CODEN: VMDKAM

DT Journal

LA Russian

L20 ANSWER 784 OF 800 CAPLUS COPYRIGHT 2002 ACS

AN 1972:417296 CAPLUS

DN 77:17296

TI Problems of stabilization of thrombocytes and erythrocytes by flavanoids, ascorbic acid, and tocopherol

AU Zuern, H.

CS Bezirksinst. Blutspende-Transfusionswes., Dresden, E. Ger.

SO Bibl. Haematol. (Basel) (1971), No. 38(Pt. 2), 221-3

CODEN: BIHAA2

DT Journal

LA English

L20 ANSWER 785 OF 800 CAPLUS COPYRIGHT 2002 ACS

AN 1969:36405 CAPLUS

DN 70:36405
TI Plasma and muscle tocopherol contents during vitamin E therapy in arterial disease
AU Larsson, Hans; Haeger, Knut
CS Dep. Biochem., AB Ferrosan, Malmo, Swed.
SO Pharmacol. Clin. (1968), 1(2), 72-6
CODEN: PHCLAL
DT Journal
LA English

L20 ANSWER 786 OF 800 CAPLUS COPYRIGHT 2002 ACS
AN 1966:502528 CAPLUS
DN 65:102528
OREF 65:19179h,19180a-c
TI Effects of vitamin E upon lipid metabolism and experimental **atherosclerosis**
AU Fukumoto, Shinichi
CS Univ. Kumamoto, Japan
SO Kumamoto Daigaku Taishitsu Igaku Kenkyusho Hokoku (1965), 16(1), 1-45
DT Journal
LA Japanese

L20 ANSWER 787 OF 800 CAPLUS COPYRIGHT 2002 ACS
AN 1966:107759 CAPLUS
DN 64:107759
OREF 64:20358c-e
TI Peroxides as a factor of **atherosclerosis**
AU Iwakami, Minoru
CS School Med., Univ. Nagoya, Japan
SO Nagoya J. Med. Sci. (1965), 28(1), 50-66
DT Journal
LA English

L20 ANSWER 788 OF 800 CAPLUS COPYRIGHT 2002 ACS
AN 1966:6707 CAPLUS
DN 64:6707
OREF 64:1231b-c
TI The effect of vitamin E on the development of experimental **atherosclerosis** in rabbits
AU Vorob'eva, N. P.
CS 1st Med. Inst., Moscow
SO Vopr. Pitaniya (1965), 24(5), 42-5
DT Journal
LA Russian

L20 ANSWER 789 OF 800 CAPLUS COPYRIGHT 2002 ACS
AN 1965:449010 CAPLUS
DN 63:49010
OREF 63:8928c-f
TI Effect of thixotropic gel of iodinated poly(vinyl alcohol) on **atherosclerosis** in experimental conditions
AU Bogomolova, L. G.; Ushakov, S. N.; Izmailova, E. F.; Lavrent'eva, E. M.; Dekster, B. G.; Petrova, L. I.
CS Inst. Blood Transfusion, Leningrad
SO Patol. Fiziol. i Eksperim. Terapiya (1965), 9(2), 8-12
DT Journal
LA Russian

L20 ANSWER 790 OF 800 CAPLUS COPYRIGHT 2002 ACS
AN 1964:55588 CAPLUS
DN 60:55588
OREF 60:9807d-e

TI Effect of vitamin E on the total cholesterol level and blood lipoproteins
in **atherosclerosis**
AU Rugaja, A.
SO Sb. Nauchn. Rabot, 1-ya [Pervaya] Rizhsk. Gor. Klinich. Bol'nitsa (1962),
(2), 131-3
From: Ref. Zh., Biol. Khim. 1963, Abstr. No. 19F1211.
DT Journal
LA Unavailable

L20 ANSWER 791 OF 800 CAPLUS COPYRIGHT 2002 ACS

AN 1964:26277 CAPLUS

DN 60:26277

OREF 60:4673f-g

TI The therapeutic value of vitamin E in **atherosclerosis**

AU Nikitin, Yu. P.

SO Sb. Tr. Novokuznetskogo Inst. Usoversh. Vrachei (1962), 29, 130-5

From: Ref. Zh., Biol. Khim. 1963, Abstr. No. 8F1257.

DT Journal

LA Unavailable

L20 ANSWER 792 OF 800 CAPLUS COPYRIGHT 2002 ACS

AN 1964:11568 CAPLUS

DN 60:11568

OREF 60:2096c-d

TI Preventive action of vitamins A and E on the development of
cholesterol-induced **atherosclerosis**

AU Horn, Z.; Palkovits, M.; Scher, A.

CS Univ. Budapest, Hung.

SO Z. Vitamin-, Hormon-Fermentforsch. (1963), 13(1), 8-15

DT Journal

LA English

L20 ANSWER 793 OF 800 CAPLUS COPYRIGHT 2002 ACS

AN 1963:444019 CAPLUS

DN 59:44019

OREF 59:7979c-d

TI Nutrition and **atherosclerosis**. Influence of terpenes on
atherosclerosis

AU Lieber, Iris Ilona

SO Dia Med. (Cordoba, Rep. Arg.) (1963), 35, 236

DT Journal

LA Unavailable

L20 ANSWER 794 OF 800 CAPLUS COPYRIGHT 2002 ACS

AN 1963:438148 CAPLUS

DN 59:38148

OREF 59:6880h,6881a-c

TI Various drugs acting on the serum lipid pattern of **atherosclerosis**
. Therapeutic significance of an extractive heparinoid

AU Nicrosini, F.; Piccinelli, O.

CS Univ. Pavia, Italy

SO Drugs Affecting Lipid Metab., Proc. Symp., Milan (1961), Volume Date 1960
508-11

DT Journal

LA Unavailable

L20 ANSWER 795 OF 800 CAPLUS COPYRIGHT 2002 ACS

AN 1963:76136 CAPLUS

DN 58:76136

OREF 58:13040d-e

TI New views in the therapy of **atherosclerosis**

AU Giacobazzo, M.; Dal Fabbro, G.; Borso, M. T.; Garufi, L.

CS Univ. Rome
SO Rass. Fisiopatol. Clin. Terap. (Pisa) (1960), 32, 433-57
DT Journal
LA Unavailable

L20 ANSWER 796 OF 800 CAPLUS COPYRIGHT 2002 ACS
AN 1963:55091 CAPLUS
DN 58:55091
OREF 58:9457a-b
TI Influence of vitamin E on lipids and blood coagulability in patients with
atherosclerosis
AU Nikitin, Yu. P.
CS Post-Graduate Med. Inst., Novokuznetsk
SO Vopr. Pitaniya (1962), 21(No. 6), 22-7
DT Journal
LA Unavailable

L20 ANSWER 797 OF 800 CAPLUS COPYRIGHT 2002 ACS
AN 1962:486367 CAPLUS
DN 57:86367
OREF 57:17275a-c
TI Blood protein composition as an index of liver function in cardiac
atherosclerosis and the effect of vitamin E therapy
AU Shelygina, N. M.
SO Tr. Ukr. Nauchn.-Issled. Inst. Klin. Med. (1961), 7, 267-71
DT Journal
LA Unavailable

L20 ANSWER 798 OF 800 CAPLUS COPYRIGHT 2002 ACS
AN 1962:486358 CAPLUS
DN 57:86358
OREF 57:17273c
TI Cholesterol metabolism and **atherosclerosis** in the rat: effects
of linoleate and the vitamins A and E
AU Beeler, Donald Allen
CS Purdue Univ., Lafayette, IN
SO (1962) 85 pp. Avail.: Univ. Microfilms (Ann Arbor, Mich.), Order No.
62-3432
From: Dissertation Abstr. 23, 415-16
DT Dissertation
LA Unavailable

L20 ANSWER 799 OF 800 CAPLUS COPYRIGHT 2002 ACS
AN 1962:479153 CAPLUS
DN 57:79153
OREF 57:15752e-f
TI Parenteral application of essential phospholipids in the experimental
atherosclerosis of the rat
AU Konecki, J.; Pietkiewicz, W.; Samochowiec, L.
CS Military Hosp., Gliwice, Pol.
SO Arzneimittelforsch. (1962), 12, 831-5
DT Journal
LA Unavailable

L20 ANSWER 800 OF 800 CAPLUS COPYRIGHT 2002 ACS
AN 1962:451661 CAPLUS
DN 57:51661
OREF 57:10323d
TI Effects of vitamin E on the blood cholinesterase activity in
atherosclerosis patients
AU Anisimov, V. E.
SO Klinich. Meal. (1958), 36, 147-8

CS Peop. Rep. China
 SO Tianjin Yiyao (1985), 13(10), 615-17
 CODEN: TIYADG; ISSN: 0253-9896
 DT Journal
 LA Chinese

L20 ANSWER 755 OF 800 CAPLUS COPYRIGHT 2002 ACS
 AN 1985:595290 CAPLUS
 DN 103:195290
 TI Dietary supplementation with vitamin E in hyperlipoproteinemias: effects on plasma lipid peroxides, antioxidant activity, prostacyclin generation and platelet aggregability
 AU Szczeklik, A.; Gryglewski, R. J.; Domagala, B.; Dworski, R.; Basista, M.
 CS Dep. Intern. Med., Copernicus Acad. Med., Krakow, Pol.
 SO Thrombosis and Haemostasis (1985), 54(2), 425-30
 CODEN: THHADQ; ISSN: 0340-6245
 DT Journal
 LA English

L20 ANSWER 756 OF 800 CAPLUS COPYRIGHT 2002 ACS
 AN 1985:576605 CAPLUS
 DN 103:176605
 TI Familial apolipoprotein A-I and C-III deficiency, variant II
 AU Schaefer, Ernst J.; Ordovas, Jose M.; Law, Simon W.; Ghiselli, Giancarlo; Kashyap, Moti L.; Srivastava, Laxmi S.; Heaton, William H.; Albers, John J.; Connor, William E.; et al.
 CS Mol. Dis. Branch, Natl. Heart, Lung, Blood Inst., Bethesda, MD, 20205, USA
 SO Journal of Lipid Research (1985), 26(9), 1089-101
 CODEN: JLPRAW; ISSN: 0022-2275
 DT Journal
 LA English

L20 ANSWER 757 OF 800 CAPLUS COPYRIGHT 2002 ACS
 AN 1985:470218 CAPLUS
 DN 103:70218
 TI The effect of supplemental vitamin E on serum parameters in diabetics, post coronary and normal subjects
 AU Bierenbaum, Marvin L.; Noonan, Frank J.; Machlin, Lawrence J.; Machlin, Steven; Stier, Arleane; Watson, Portia B.; Naso, Ann Marie; Fleischman, Alan I.
 CS Vitam. Clin. Nutr. Dep., Hoffmann-La Roche Inc., Nutley, NJ, 07110, USA
 SO Nutrition Reports International (1985), 31(6), 1171-80
 CODEN: NURIBL; ISSN: 0029-6635
 DT Journal
 LA English

L20 ANSWER 758 OF 800 CAPLUS COPYRIGHT 2002 ACS
 AN 1985:184072 CAPLUS
 DN 102:184072
 TI Vitamin E in the split of opinions - what is guaranteed?
 AU Boehles, H.
 CS Universitaetskinderklin., Erlangen, D-8520, Fed. Rep. Ger.
 SO Deutsche Apotheker Zeitung (1985), 125(12), 598-600
 CODEN: DAZE2; ISSN: 0011-9857
 DT Journal; General Review
 LA German

L20 ANSWER 759 OF 800 CAPLUS COPYRIGHT 2002 ACS
 AN 1985:183321 CAPLUS
 DN 102:183321
 TI Prostacyclin and **atherosclerosis**
 AU Gryglewski, Ryszard J.

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 105 OF 143 CAPLUS COPYRIGHT 2003 ACS
 AN 2000:93323 CAPLUS
 DN 133:52
 TI The evolving role of statins in the management of **atherosclerosis**
 AU Vaughan, Carl J.; Gotto, Antonio M., Jr.; Basson, Craig T.
 CS Division of Cardiology, Department of Medicine, Weill Medical College of
 Cornell University, The New York Presbyterian Hospital, New York, NY,
 10021, USA
 SO Journal of the American College of Cardiology (2000), 35(1), 1-10
 CODEN: JACCDI; ISSN: 0735-1097
 PB Elsevier Science Inc.
 DT Journal; General Review
 LA English
 RE.CNT 88 THERE ARE 88 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 106 OF 143 CAPLUS COPYRIGHT 2003 ACS
 AN 2000:15355 CAPLUS
 DN 132:206346
 TI Diabetes enhances the uptake of cholesterol in low shear regions
 AU Liem, Timothy K.; Vouyouka, Angela; Dixon, Joseph; Shukla, Shivendra;
 Silver, Donald; Krause, Gary; Sturek, Michael S.
 CS Department of Surgery and the Dalton Cardiovascular Research Center,
 School of Medicine, University of Missouri, Columbia, MO, USA
 SO Surgical Forum (1999), 50, 429-432
 CODEN: SUFOAX; ISSN: 0071-8041
 PB American College of Surgeons
 DT Journal
 LA English
 RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 107 OF 143 CAPLUS COPYRIGHT 2003 ACS
 AN 2000:4636 CAPLUS
 DN 132:30628
 TI Efficacy of vitamin E compared with either simvastatin or atorvastatin in
 preventing the progression of **atherosclerosis** in homozygous
 familial hypercholesterolemia
 AU Raal, Frederick J.; Pilcher, Gillian J.; Veller, Martin G.; Kotze, Maritha
 J.; Joffe, Barry I.
 CS The Carbohydrate and Lipid Metabolism Research Group, Department of
 Medicine, and The Vascular Unit, Department of Surgery, University of the
 Witwatersrand, Johannesburg, 2193, S. Afr.
 SO American Journal of Cardiology (1999), 84(11), 1344-1346
 CODEN: AJCDAG; ISSN: 0002-9149
 PB Excerpta Medica, Inc.
 DT Journal
 LA English
 RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 108 OF 143 CAPLUS COPYRIGHT 2003 ACS
 AN 1999:812038 CAPLUS
 DN 132:235449
 TI Statin-sensitive dysregulated AT1 receptor function and density in
 hypercholesterolemic men
 AU Nickenig, Georg; Baumer, Anselm T.; Temur, Yavuz; Kebben, Daniela;
 Jockenhovel, Friedrich; Bohm, Michael
 CS Klinik III fur Innere Medizin and Klinik II fur Innere Medizin,
 Universitat Koln, Koln, 50924, Germany

SO Circulation (1999), 100(21), 2131-2134
 CODEN: CIRCAZ; ISSN: 0009-7322
 PB Lippincott Williams & Wilkins
 DT Journal
 LA English
 RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 109 OF 143 CAPLUS COPYRIGHT 2003 ACS
 AN 1999:795649 CAPLUS
 DN 132:35554
 TI Preparation of multibinding multimeric inhibitors of HMG-CoA reductase
 IN Griffin, John H.; Leadbetter, Michael R.; Schmidt, Donald E, Jr.
 PA Advanced Medicine, Inc., USA
 SO PCT Int. Appl., 188 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 25

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9963994	A1	19991216	WO 1999-US11787	19990604
	W:				
	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2319761	AA	19991216	CA 1999-2319761	19990604
	AU 9945436	A1	19991230	AU 1999-45436	19990604
	EP 1083894	A1	20010321	EP 1999-928345	19990604
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	US. 6355810	B1	20020312	US 1999-325663	19990604
	ZA 2000004559	A	20020402	ZA 2000-4559	20000831
	US 2002028943	A1	20020307	US 2001-760827	20010117
PRAI	US 1998-88448P	P	19980608		
	US 1998-93072P	P	19980716		
	US 1998-114083P	P	19981228		
	US 1999-325662	A3	19990604		
	WO 1999-US11787	W	19990604		
OS	MARPAT 132:35554				

RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 110 OF 143 CAPLUS COPYRIGHT 2003 ACS
 AN 1999:785577 CAPLUS
 DN 132:301
 TI An assessment of the efficacy of atorvastatin in treating patients with dyslipidemia to target LDL-cholesterol goals: the atorvastatin matrix study
 AU McVey, D.; Patel, H.; Emlinton, Z.; Maton, S.
 CS Parke-Davis Medical Division, Hants, S053 3ZQ, UK
 SO International Journal of Clinical Practice (1999), 53(7), 509-513
 CODEN: IJCPF9; ISSN: 1368-5031
 PB Medicom International
 DT Journal
 LA English
 RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 111 OF 143 CAPLUS COPYRIGHT 2003 ACS
 AN 1999:736664 CAPLUS
 DN 131:346502
 TI Combinations of protein farnesyltransferase inhibitors and HMG-CoA
 reductase inhibitors and their use to treat cancer and other diseases
 IN Leopold, Judith; Newton, Roger Schofield
 PA Warner-Lambert Company, USA
 SO PCT Int. Appl., 66 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9958505	A2	19991118	WO 1999-US10188	19990510
	WO 9958505	A3	20000106		
	W:	AE, AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	CA 2331295	AA	19991118	CA 1999-2331295	19990510
	AU 9939792	A1	19991129	AU 1999-39792	19990510
	EP 1077949	A2	20010228	EP 1999-922898	19990510
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
	BR 9911785	A	20010403	BR 1999-11785	19990510
	JP 2002514628	T2	20020521	JP 2000-548309	19990510
	US 6492410	B1	20021210	US 2000-674818	20001106
	NO 2000005680	A	20010110	NO 2000-5680	20001110
PRAI	US 1998-85202P	P	19980512		
	US 1998-92253P	P	19980710		
	WO 1999-US10188	W	19990510		
OS	MARPAT 131:346502				

L11 ANSWER 112 OF 143 CAPLUS COPYRIGHT 2003 ACS
 AN 1999:613662 CAPLUS
 DN 131:248237
 TI Statin-matrix metalloproteinase inhibitor combinations
 IN Newton, Roger Schofield; Roth, Bruce David
 PA Warner-Lambert Company, USA
 SO PCT Int. Appl., 153 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9947138	A1	19990923	WO 1998-US24681	19981120
	W:	AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HR, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	CA 2309588	AA	19990923	CA 1998-2309588	19981120
	AU 9915916	A1	19991011	AU 1999-15916	19981120

BR 9815745	A	20001114	BR 1998-15745	19981120
EP 1063991	A1	20010103	EP 1998-960279	19981120
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002506818	T2	20020305	JP 2000-536378	19981120
ZA 9902106	A	19990930	ZA 1999-2106	19990316
US 2002049237	A1	20020425	US 2001-977162	20011012
PRAI US 1998-78265P	P	19980317		
WO 1998-US24681	W	19981120		
US 1999-297592	B1	19990503		
OS	MARPAT 131:248237			
RE.CNT	9	THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT		

L11 ANSWER 113 OF 143 CAPLUS COPYRIGHT 2003 ACS
AN 1999:609873 CAPLUS
DN 131:223312
TI Efficacy and safety of atorvastatin and pravastatin in patients with hypercholesterolemia
AU Assmann, G.; Huwel, D.; Schussman, K.-M.; Smilde, J. G.; Kosling, M.; Withagen, A. J. A. M.; Wunderlich, J.; Stoel, I.; Van Dormaal, J. J.; Neuss, J.; Oldenbroek, C.; Cuppers, M. C.; Von Eckardstein, A.; Schulte, H.; Wagner, B.; McLain, R.; Black, D. M.
CS Institut fur Klinische Chemie und Laboratoriumsmedizin, Zentrallaboratorium, Munster, 48149, Germany
SO European Journal of Internal Medicine (1999), 10(1), 33-39
CODEN: EJIMEJ; ISSN: 0953-6205
PB Elsevier Science Ireland Ltd.
DT Journal
LA English
RE.CNT 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 114 OF 143 CAPLUS COPYRIGHT 2003 ACS
AN 1999:538570 CAPLUS
DN 131:295415
TI Hypocholesterolemic effects of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in the guinea pig. Atorvastatin versus simvastatin
AU Conde, K.; Pineda, G.; Newton, R. S.; Fernandez, M. L.
CS Department of Nutritional Sciences, Lipid Metabolism Laboratory, University of Connecticut, Storrs, CT, USA
SO Biochemical Pharmacology (1999), 58(7), 1209-1219
CODEN: BCPA6; ISSN: 0006-2952
PB Elsevier Science Inc.
DT Journal
LA English
RE.CNT 62 THERE ARE 62 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 115 OF 143 CAPLUS COPYRIGHT 2003 ACS
AN 1999:501721 CAPLUS
DN 131:153629
TI Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders
AU Murdock, David K.; Murdock, Anthony K.; Murdock, Robert W.; Olson, Karen J.; Frane, Arlyne M.; Kersten, Mary E.; Joyce, Diane M.; Gantner, Sue E.
CS The Lipid Clinic of Cardiovascular Associates of Northern Wisconsin and The CARE Foundation, Wausau, WI, USA
SO American Heart Journal (1999), 138(1, Pt. 1), 151-155
CODEN: AHJOA2; ISSN: 0002-8703
PB Mosby, Inc.

DT Journal
LA English
RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 116 OF 143 CAPLUS COPYRIGHT 2003 ACS
AN 1999:489710 CAPLUS
DN 131:331943
TI Platelet deposition on eroded vessel walls at a stenotic shear rate is inhibited by lipid-lowering treatment with atorvastatin
AU Alfon, Jose; Royo, Teresa; Garcia-Moll, Xavier; Badimon, Lina
CS Cardiovascular Research Center, CSIC-HSCSP-UAB, Barcelona, Spain
SO Arteriosclerosis, Thrombosis, and Vascular Biology (1999), 19(7), 1812-1817
CODEN: ATVBFA; ISSN: 1079-5642
PB Lippincott Williams & Wilkins
DT Journal
LA English
RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 117 OF 143 CAPLUS COPYRIGHT 2003 ACS
AN 1999:464665 CAPLUS
DN 131:295408
TI Nitric oxide synthase II (NOS II) gene expression correlates with atherosclerotic intimal thickening. Preventive effects of HMG-CoA reductase inhibitors
AU Alfon, Jose; Guasch, Joan F.; Berrozpe, Maria; Badimon, Lina
CS CSIC-HSCSP-UAB, Cardiovascular Research Center, Barcelona, 08034, Spain
SO Atherosclerosis (Shannon, Ireland) (1999), 145(2), 325-331
CODEN: ATHSBL; ISSN: 0021-9150
PB Elsevier Science Ireland Ltd.
DT Journal
LA English
RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 118 OF 143 CAPLUS COPYRIGHT 2003 ACS
AN 1999:442143 CAPLUS
DN 131:306908
TI Lipophilic statins induce apoptosis of human vascular smooth muscle cells
AU Guijarro, Carlos; Blanco-Colio, Luis Miguel; Massy, Ziad A.; O'Donnell, Michael P.; Kasiske, Bertram L.; Keane, William F.; Egido, Jesus
CS Research Laboratories, Instituto de Investigacion Medica, Fundacion Jimenez Diaz, Universidad Autonoma de Madrid, Madrid, Spain
SO Kidney International, Supplement (1999), 71, S88-S91
CODEN: KISUDF; ISSN: 0098-6577
PB Blackwell Science, Inc.
DT Journal
LA English
RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 119 OF 143 CAPLUS COPYRIGHT 2003 ACS
AN 1999:282039 CAPLUS
DN 130:306593
TI Combination therapy using a HMG-CoA reductase inhibitor and a cyclooxygenase-2 (COX-2) inhibitor for reducing the risks associated with cardio- and cerebrovascular disease
IN Winokur, Melvin
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 55 pp.

CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9920110	A1	19990429	WO 1998-US21901	19981016
	W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2306646	AA	19990429	CA 1998-2306646	19981016
	AU 9913612	A1	19990510	AU 1999-13612	19981016
	AU 753657	B2	20021024		
	EP 1024696	A1	20000809	EP 1998-957328	19981016
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
	JP 2001520174	T2	20011030	JP 2000-516533	19981016
	US 6245797	B1	20010612	US 1998-179349	19981020
PRAI	US 1997-62691P	P	19971022		
	GB 1998-6688	A	19980327		
	WO 1998-US21901	W	19981016		
RE.CNT 1	THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT				

L11 ANSWER 120 OF 143 CAPLUS COPYRIGHT 2003 ACS

AN 1999:193844 CAPLUS

DN 130:227739

TI Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug

IN Gregg, Richard E.; Pouleur, Hubert G.; Wetterau, John R., II

PA Bristol-Myers Squibb Company, USA

SO U.S., 22 pp.

CODEN: USXXAM

DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5883109	A	19990316	US 1997-854311	19970512
PRAI	US 1997-854311		19970512		
OS	MARPAT 130:227739				
RE.CNT 42	THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT				

L11 ANSWER 121 OF 143 CAPLUS COPYRIGHT 2003 ACS

AN 1999:184130 CAPLUS

DN 130:205139

TI Combination therapy comprising atorvastatin and an antihypertensive agent

IN Scott, Robert Andrew Donald

PA Pfizer Inc., USA

SO PCT Int. Appl., 51 pp.

CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9911260	A1	19990311	WO 1998-IB1230	19980811

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9884589 A1 19990322 AU 1998-84589 19980811

AU 740424 B2 20011101

EP 1009400 A1 20000621 EP 1998-935250 19980811

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO

BR 9811556 A 20000822 BR 1998-11556 19980811

JP 2001514223 T2 20010911 JP 2000-508363 19980811

ZA 9807839 A 20000228 ZA 1998-7839 19980828

NO 2000000996 A 20000427 NO 2000-996 20000228

US 2002099046 A1 20020725 US 2001-45329 20011023

PRAI US 1997-57276P P 19970829

WO 1998-IB1230 W 19980811

US 2000-513887 B1 20000225

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 122 OF 143 CAPLUS COPYRIGHT 2003 ACS

AN 1999:184129 CAPLUS

DN 130:205138

TI Therapeutic combinations comprising amlodipine and atorvastatin

IN Buch, Jan; Scott, Robert Andrew Donald

PA Pfizer Inc., USA

SO PCT Int. Appl., 50 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9911259	A1	19990311	WO 1998-IB1225	19980811
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2301732	AA	19990311	CA 1998-2301732	19980811
	AU 9885548	A1	19990322	AU 1998-85548	19980811
	EP 1003503	A1	20000531	EP 1998-936587	19980811
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
	BR 9812030	A	20000926	BR 1998-12030	19980811
	JP 2001514222	T2	20010911	JP 2000-508362	19980811
	ZA 9807844	A	20000228	ZA 1998-7844	19980828
	US 6455574	B1	20020924	US 2000-512914	20000225
	NO 2000000998	A	20000228	NO 2000-998	20000228
	US 2003008904	A1	20030109	US 2002-214058	20020807
PRAI	US 1997-57275P	P	19970829		
	WO 1998-IB1225	W	19980811		
	US 2000-512914	A3	20000225		
RE.CNT	2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT				

L11 ANSWER 123 OF 143 CAPLUS COPYRIGHT 2003 ACS
 AN 1999:159872 CAPLUS
 DN 130:246722
 TI Clinical positioning of HMG-CoA reductase inhibitors in lipid management protocols
 AU Cziraky, Mark
 CS Health Core, Newark, DE, USA
 SO PharmacoEconomics (1998), 14(Suppl. 3), 29-38
 CODEN: PARMEK; ISSN: 1170-7690
 PB Adis International Ltd.
 DT Journal
 LA English
 RE.CNT 82 THERE ARE 82 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 124 OF 143 CAPLUS COPYRIGHT 2003 ACS
 AN 1999:113552 CAPLUS
 DN 130:173009
 TI Combinations of HMG-CoA reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia
 IN Bova, David J.; Dunne, Josephine
 PA Kos Pharmaceuticals, Inc., USA
 SO PCT Int. Appl., 86 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	WO 9906046	A1	19990211	WO 1998-US15989	19980731
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 2001006644	A1	20010705	US 1997-903871	19970731
	AU 9886800	A1	19990222	AU 1998-86800	19980731
	EP 1003515	A1	20000531	EP 1998-938227	19980731
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	NO 2000000407	A	20000316	NO 2000-407	20000127
PRAI	US 1997-903871	A	19970731		
	WO 1998-US15989	W	19980731		

RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 125 OF 143 CAPLUS COPYRIGHT 2003 ACS
 AN 1999:113543 CAPLUS
 DN 130:187186
 TI Pharmaceutical composition containing combinations of HMG-CoA reductase inhibitors and nicotinic acid compounds for treating hyperlipidemia once a day at night
 IN Bova, David J.; Dunne, Josephine
 PA Kos Pharmaceuticals, Inc., USA
 SO PCT Int. Appl., 80 pp.
 CODEN: PIXXD2
 DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9906035	A2	19990211	WO 1998-US15990	19980731
	WO 9906035	A3	19990422		
	W:		AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
	RW:		GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
	AU 9886801	A1	19990222	AU 1998-86801	19980731
	AU 752673	B2	20020926		
	EP 1017390	A2	20000712	EP 1998-938228	19980731
	R:		AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI		
	BR 9815548	A	20001107	BR 1998-15548	19980731
	JP 2001511444	T2	20010814	JP 2000-504849	19980731
	NO 2000000439	A	20000322	NO 2000-439	20000127
PRAI	US 1997-903752	A	19970731		
	WO 1998-US15990	W	19980731		

L11 ANSWER 126 OF 143 CAPLUS COPYRIGHT 2003 ACS

AN 1999:1203 CAPLUS

DN 130:218023

TI HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of **atherosclerosis**

AU Bustos, Carmen; Hernandez-Presa, Miguel A.; Ortego, Monica; Tunon, Jose; Ortega, Luis; Perez, Fernando; Diaz, Cristina; Hernandez, Gonzalo; Egido, Jesus

CS Fundacion Jimenez Diaz, Universidad Autonoma, Madrid, 28040, Spain

SO Journal of the American College of Cardiology (1998), 32(7), 2057-2064
CODEN: JACCDI; ISSN: 0735-1097

PB Elsevier Science Inc.

DT Journal

LA English

RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 127 OF 143 CAPLUS COPYRIGHT 2003 ACS

AN 1998:744939 CAPLUS

DN 130:17236

TI MTP inhibitors and fat soluble vitamin therapeutic combinations to lower serum lipid levels

IN Gregg, Richard E.; Wetterau, John R., II

PA Bristol-Myers Squibb Co., USA

SO PCT Int. Appl., 59 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9850028	A1	19981112	WO 1998-US8269	19980423
	W:		AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
	RW:		GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,		

FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
CM, GA, GN, ML, MR, NE, SN, TD, TG

AU 9871559 A1 19981127 AU 1998-71559 19980423
AU 748608 B2 20020606
EP 1024804 A1 20000809 EP 1998-918680 19980423
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, FI

JP 2001527551 T2 20011225 JP 1998-548138 19980423

PRAI US 1997-45405P P 19970501
WO 1998-US8269 W 19980423

OS MARPAT 130:17236

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 128 OF 143 CAPLUS COPYRIGHT 2003 ACS
AN 1998:625982 CAPLUS
DN 130:20459
TI Treating patients with documented **atherosclerosis** to national
cholesterol education program-recommended low-density-lipoprotein
cholesterol goals with atorvastatin, fluvastatin, lovastatin and
simvastatin

AU Brown, Alan S.; Bakker-Arkema, Rebecca G.; Yellen, Laurence; Henley,
Robert W., Jr.; Guthrie, Richard; Campbell, Cam F.; Koren, Michael; Woo,
William; McLain, Richard; Black, Donald M.

CS Midwest Heart Research Foundation, Naperville, IL, USA
SO Journal of the American College of Cardiology (1998), 32(3), 665-672
CODEN: JACCDI; ISSN: 0735-1097

PB Elsevier Science Inc.
DT Journal
LA English

RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 129 OF 143 CAPLUS COPYRIGHT 2003 ACS
AN 1998:509102 CAPLUS
DN 129:153237
TI Method for treating **atherosclerosis** with an MPT inhibitor and
cholesterol-lowering drugs

IN Behounek, Bruce D.; McGovern, Mark E.; Belder, Rene
PA Bristol-Myers Squibb Co., USA
SO PCT Int. Appl., 70 pp.
CODEN: PIXXD2

DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9831366	A1	19980723	WO 1998-US524	19980112
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9862397	A1	19980807	AU 1998-62397	19980112
	AU 727895	B2	20010104		
	EP 989852	A1	20000405	EP 1998-904548	19980112
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2001508795	T2	20010703	JP 1998-534460	19980112

PRAI US 1997-35592P P 19970117

WO 1998-US524 W 19980112

OS MARPAT 129:153237

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 130 OF 143 CAPLUS COPYRIGHT 2003 ACS

AN 1998:478194 CAPLUS

DN 129:225548

TI LPS-induced cytokine production and expression of LPS-receptors by
peripheral blood mononuclear cells of patients with familial
hypercholesterolemia and the effect of HMG-CoA reductase inhibitors

AU de Bont, Natasja; Netea, Mihai G.; Rovers, Chantal; Smilde, Tineke;
Demacker, Pierre N. M.; van der Meer, Jos W. M.; Stalenhoef, Anton F. H.

CS Department of Medicine, Division of General Internal Medicine, University
Hospital Nijmegen, Nijmegen, 6500 HB, Neth.

SO Atherosclerosis (Shannon, Ireland) (1998), 139(1), 147-152

CODEN: ATHSBL; ISSN: 0021-9150

PB Elsevier Science Ireland Ltd.

DT Journal

LA English

RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 131 OF 143 CAPLUS COPYRIGHT 2003 ACS

AN 1998:478160 CAPLUS

DN 129:225547

TI HMG-CoA reductase and ACAT inhibitors act synergistically to lower plasma
cholesterol and limit atherosclerotic lesion development in the
cholesterol-fed rabbit

AU Bocan, Thomas M. A.; Bak Mueller, Sandra; Quenby Brown, Edie; Lee, Peter;
Bocan, Michelle J.; Rea, Thomas; Pape, Michael E.

CS Parke-Davis Pharmaceutical Research, Department of Vascular and Cardiac
Diseases, Division of Warner Lambert Company, Ann Arbor, MI, 48105, USA

SO Atherosclerosis (Shannon, Ireland) (1998), 139(1), 21-30

CODEN: ATHSBL; ISSN: 0021-9150

PB Elsevier Science Ireland Ltd.

DT Journal

LA English

RE.CNT 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 132 OF 143 CAPLUS COPYRIGHT 2003 ACS

AN 1998:458053 CAPLUS

DN 129:184104

TI Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are
potent antioxidants against lipoprotein oxidation

AU Aviram, Michael; Rosenblat, Mira; Bisgaier, Charles L.; Newton, Roger S.

CS Technion Faculty of Medicine, Rappaport Family Institute for Research in
the Medical Sciences and Rambam Medical Center, Haifa, 31096, Israel

SO Atherosclerosis (Shannon, Ireland) (1998), 138(2), 271-280

CODEN: ATHSBL; ISSN: 0021-9150

PB Elsevier Science Ireland Ltd.

DT Journal

LA English

L11 ANSWER 133 OF 143 CAPLUS COPYRIGHT 2003 ACS

AN 1998:404579 CAPLUS

DN 129:130773

TI Advances in drug treatment of dyslipidemia: focus on atorvastatin

AU Davignon, Jean

CS Hyperlipidemia and Atherosclerosis Research Group, Clinical Research

SO Institute of Montreal, Montreal, QC, H2W 1R7, Can.
 Canadian Journal of Cardiology (1998), 14(Suppl. B), 28B-38B
 CODEN: CJCAEX; ISSN: 0828-282X
 PB Pulsus Group
 DT Journal; General Review
 LA English

L11 ANSWER 134 OF 143 CAPLUS COPYRIGHT 2003 ACS
 AN 1998:400182 CAPLUS
 DN 129:131131
 TI Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors,
 atorvastatin and simvastatin, on the expression of endothelin-1 and
 endothelial nitric oxide synthase in vascular endothelial cells
 AU Hernandez-Perera, Octavio; Perez-Sala, Dolores; Navarro-Antolin, Javier;
 Sanchez-Pascuala, Rafael; Hernandez, Gonzalo; Diaz, Cristina; Lamas,
 Santiago
 CS Centro de Investigaciones Biologicas, Instituto Reina Sofia de
 Investigaciones Nefrologicas, Consejo Superior de Investigaciones
 Cientificas, Madrid, 28006, Spain
 SO Journal of Clinical Investigation (1998), 101(12), 2711-2719
 CODEN: JCINAO; ISSN: 0021-9738
 PB Rockefeller University Press
 DT Journal
 LA English
 RE.CNT 59 THERE ARE 59 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 135 OF 143 CAPLUS COPYRIGHT 2003 ACS
 AN 1998:388501 CAPLUS
 DN 129:54297
 TI Apo B-secretion/MTP inhibitory 4'-(trifluoromethyl)biphenyl-2-carboxylic
 acid (1,2,3,4-tetrahydroisoquinolin-6-yl)amides and their preparation,
 pharmaceutical compositions, and use
 IN Chang, George; Quallich, George Joseph
 PA Pfizer Inc., USA; Chang, George; Quallich, George Joseph
 SO PCT Int. Appl., 105 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9823593	A1	19980604	WO 1997-IB1368	19971103
	W:				
	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,				
	DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC,				
	LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT,				
	RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN,				
	YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR,				
	GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,				
	GN, ML, MR, NE, SN, TD, TG				
	AU 9746347	A1	19980622	AU 1997-46347	19971103
	AU 716151	B2	20000217		
	EP 944602	A1	19990929	EP 1997-945048	19971103
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,				
	SI, LT, LV, FI, RO				
	CN 1238764	A	19991215	CN 1997-180033	19971103
	BR 9714364	A	20000321	BR 1997-14364	19971103
	JP 2000505810	T2	20000516	JP 1998-524464	19971103
	JP 3270764	B2	20020402		
	ZA 9710641	A	19990526	ZA 1997-10641	19971126
	US 6121283	A	20000919	US 1999-284466	19990420

NO 9902525 A 19990526 NO 1999-2525 19990526
 KR 2000057269 A 20000915 KR 1999-704662 19990526
 CN 1380289 A 20021120 CN 2002-105189 20020219
 PRAI US 1996-32307P P 19961127
 WO 1997-IB1368 W 19971103
 OS CASREACT 129:54297; MARPAT 129:54297
 RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 136 OF 143 CAPLUS COPYRIGHT 2003 ACS

AN 1998:87580 CAPLUS

DN 128:162883

TI Method for lowering serum lipid levels employing a microsomal
 triglyceride-transfer protein (MTP) inhibitor in combination with another
 cholesterol-lowering drug

IN Gregg, Richard E.; Pouleur, Hubert G.; Wetterau, John R., II

PA Bristol-Myers Squibb Co., USA

SO PCT Int. Appl., 60 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9803069	A1	19980129	WO 1997-US12229	19970714
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	ZA 9705950	A	19990104	ZA 1997-5950	19970703
	AU 9736624	A1	19980210	AU 1997-36624	19970714
	AU 716145	B2	20000217		
	EP 1014791	A1	20000705	EP 1997-933435	19970714
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2000515526	T2	20001121	JP 1998-507023	19970714
PRAI	US 1996-22866P	P	19960724		
	WO 1997-US12229	W	19970714		
OS	MARPAT 128:162883				

L11 ANSWER 137 OF 143 CAPLUS COPYRIGHT 2003 ACS

AN 1997:778860 CAPLUS

DN 128:70496

TI Proapoptotic effect of atorvastatin on stimulated rabbit smooth muscle cells

AU Baetta, Roberta; Donetti, Elena; Comparato, Carmen; Calore, Monica; Rossi, Alessandra; Teruzzi, Chiara; Paoletti, Rodolfo; Fumagalli, Remo; Soma, Maurizio R.

CS Institute of Pharmacological Sciences, University of Milan, Milan, 20133, Italy

SO Pharmacological Research (1997), 36(2), 115-121

CODEN: PHMREP; ISSN: 1043-6618

PB Academic Press Ltd.

DT Journal

LA English

L11 ANSWER 138 OF 143 CAPLUS COPYRIGHT 2003 ACS

AN 1997:696637 CAPLUS

DN 127:351217
 TI Combination therapy containing HMG-CoA reductase inhibitors for reducing the risks associated with cardiovascular disease
 IN Tobert, Jonathan A.
 PA Merck & Co., Inc., USA; Tobert, Jonathan A.
 SO PCT Int. Appl., 24 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9738694	A1	19971023	WO 1997-US6127	19970414
	W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2251972	AA	19971023	CA 1997-2251972	19970414
	AU 9726665	A1	19971107	AU 1997-26665	19970414
	AU 732465	B2	20010426		
	EP 904082	A1	19990331	EP 1997-918595	19970414
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
	JP 2000508659	T2	20000711	JP 1997-537264	19970414
PRAI	US 1996-15689P	P	19960417		
	GB 1996-12082	A	19960610		
	US 1996-20977P	P	19960624		
	GB 1996-16804	A	19960809		
	WO 1997-US6127	W	19970414		

L11 ANSWER 139 OF 143 CAPLUS COPYRIGHT 2003 ACS
 AN 1997:576602 CAPLUS
 DN 127:243263
 TI Combination of a cholesterol biosynthesis inhibitor and a .beta.-lactam cholesterol absorption inhibitor as antihypercholesterolemic
 IN Davis, Harry R.
 PA Schering Corporation, USA
 SO U.S., 7 pp., Cont.-in-part of U.S. Ser. No. 995,488, abandoned.
 CODEN: USXXAM

DT Patent
 LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5661145	A	19970826	US 1995-454348	19950620
	WO 9414433	A1	19940707	WO 1993-US12291	19931221
	W: AU, BB, BG, BR, BY, CA, CZ, FI, HU, JP, KR, KZ, LK, LV, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US, UZ, VN				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
PRAI	US 1992-995488	B2	19921223		
	WO 1993-US12291	W	19931221		
OS	MARPAT 127:243263				

L11 ANSWER 140 OF 143 CAPLUS COPYRIGHT 2003 ACS
 AN 1997:356461 CAPLUS
 DN 126:330797
 TI Preparation of steroidal glycosides for treatment of hypercholesterolemia and related disorders
 IN Kim, Dooseop

PA Merck and Co., Inc., USA
SO Brit. UK Pat. Appl., 78 pp.
CODEN: BAXXDU

DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 2304106	A1	19970312	GB 1996-16443	19960805
PRAI	US 1995-2039P	P	19950808		
OS	MARPAT 126:330797				

L11 ANSWER 141 OF 143 CAPLUS COPYRIGHT 2003 ACS

AN 1997:280110 CAPLUS

DN 126:325296

TI Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia

AU Bertolini, Stefano; Bittolo Bon, Gabriele; Campbell, L. Malcolm; Farnier, Michel; Langan, John; Mahla, Gerhard; Pauciullo, Paolo; Sirtori, Cesare; Egros, Fabrice; Fayyad, Rana; Nawrocki, James W.

CS Dipartimento di Medicina Interna, Genoa, Italy

SO Atherosclerosis (Shannon, Ireland) (1997), 130(1,2), 191-197

CODEN: ATHSBL; ISSN: 0021-9150

PB Elsevier

DT Journal

LA English

L11 ANSWER 142 OF 143 CAPLUS COPYRIGHT 2003 ACS

AN 1997:178769 CAPLUS

DN 126:176899

TI Synergistic combination comprising an insulin sensitizer and a HMG-CoA reductase inhibitor for treating **arteriosclerosis**

IN Tsujita, Yoshio; Horikoshi, Hiroyoshi; Shiomi, Masashi; Ito, Takashi

PA Sankyo Co., Ltd., Japan

SO Eur. Pat. Appl., 24 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 753298	A1	19970115	EP 1996-304924	19960703
	EP 753298	B1	20011121		
	R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	CA 2180296	AA	19970104	CA 1996-2180296	19960702
	NO 9602784	A	19970106	NO 1996-2784	19960702
	AU 9656261	A1	19970116	AU 1996-56261	19960702
	AU 706628	B2	19990617		
	JP 09071540	A2	19970318	JP 1996-172137	19960702
	US 5798375	A	19980825	US 1996-676090	19960702
	IL 118778	A1	19990714	IL 1996-118778	19960702
	RU 2158607	C2	20001110	RU 1996-112769	19960702
	TW 474809	B	20020201	TW 1996-85107984	19960702
	ZA 9605650	A	19970127	ZA 1996-5650	19960703
	CN 1148492	A	19970430	CN 1996-112170	19960703
	CN 1089584	B	20020828		
	CZ 286832	B6	20000712	CZ 1996-1982	19960703
	AT 209046	E	20011215	AT 1996-304924	19960703
	ES 2165474	T3	20020316	ES 1996-304924	19960703
	US 6159997	A	20001212	US 1998-61446	19980416
PRAI	JP 1995-167291	A	19950703		

L11 ANSWER 143 OF 143 CAPLUS COPYRIGHT 2003 ACS

AN 1996:431460 CAPLUS

DN 125:76399

TI Combination of a cholesterol absorption inhibitor and a cholesterol synthesis inhibitor for treatment of hypercholesterolemia and **atherosclerosis**

IN Morehouse, Lee A.

PA Morehouse, Lee, A., USA

SO PCT Int. Appl., 78 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9609827	A2	19960404	WO 1995-IB447	19950607
	WO 9609827	A3	19960523		
	W: AU, CA, CN, CZ, FI, HU, JP, KR, MX, NO, NZ, PL, RU, SI, SK, UA, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2200436	AA	19960404	CA 1995-2200436	19950607
	AU 9524532	A1	19960419	AU 1995-24532	19950607
	EP 782451	A1	19970709	EP 1995-918721	19950607
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	JP 09511753	T2	19971125	JP 1995-511549	19950607
	BR 9504072	A	19960730	BR 1995-4072	19950919
	ZA 9507879	A	19970319	ZA 1995-7879	19950919
	US 5807834	A	19980915	US 1997-793802	19970318
	FI 9701151	A	19970319	FI 1997-1151	19970319
PRAI	US 1994-308908	A	19940920		
	WO 1995-IB447	W	19950607		
OS	MARPAT 125:76399				

=> d 104:147555 all

ANSWER 1 CAPLUS COPYRIGHT 2003 ACS

AN 1986:147555 CAPLUS

DN 104:147555

TI Effects of vitamin C and E, trace element selenium and brown sugar in guinea pig arteriosclerosis

AU Sun, Yuming; Lu, Tianluan; Gao, Jianzhong; Dou, Shulan; Wang, Hong; Sun, Shuqin; Li, Tianyang; Sun, Rui

CS Peop. Rep. China

SO Tianjin Yiyao (1985), 13(10), 615-17

CODEN: TIYADG; ISSN: 0253-9896

DT Journal

LA Chinese

CC 18-1 (Animal Nutrition)

AB Dietary vitamin C [50-81-7] and E [1406-18-4], Se, and brown sugar decreased the incidence of arteriosclerosis induced by cholesterol (0.1 g/day) in guinea pig. In the exptl. animal diets, the supplementary amts. were 1.5 mg vitamin C, 1.5 mg vitamin E, 35 .mu.g Na2SeO3, and 2 g brown sugar/day/animal. Vitamin C showed the strongest effect on inhibition of arteriosclerosis. The extents of fatty liver and peroxy fatty acids were also decreased by the inhibitory agents.

ST atherosclerosis vitamin selenium sugar diet; liver lipid atherosclerosis inhibitor diet

IT Lipids, biological studies

RL: BIOL (Biological study)

(dietary atherosclerosis inhibitors effect on, of liver)

IT Atherosclerosis
 (inhibition of, dietary vitamin C and E and brown sugar in)
 IT Liver, composition
 (lipids and peroxy fatty acids of, dietary atherosclerosis inhibitors
 effect on)
 IT Fatty acids, biological studies
 RL: BIOL (Biological study)
 (peroxy, dietary atherosclerosis inhibitors effect on, of liver)
 IT 50-81-7, biological studies 1406-18-4 7782-49-2, biological studies
 RL: BIOL (Biological study)
 (atherosclerosis inhibition by dietary)
 IT 57-50-1, biological studies
 RL: BIOL (Biological study)
 (brown, atherosclerosis inhibition by dietary)

=> d 79:100515 all

ANSWER 1 CAPLUS COPYRIGHT 2003 ACS

AN 1973:500515 CAPLUS

DN 79:100515

TI Antiinflammatory drugs in experimental atherosclerosis. 1. Relative
 potencies for inhibiting plaque formation

AU Bailey, J. Martyn; Butler, Jean

CS Sch. Med., George Washington Univ., Washington, DC, USA

SO Atherosclerosis (Shannon, Ireland) (1973), 17(3), 515-22

CODEN: ATHSBL; ISSN: 0021-9150

DT Journal

LA English

CC 1-5 (Pharmacodynamics)

AB Orally administered 9.alpha.-fluorohydrocortisone (I) [127-31-1] (30
 .mu.g/day) was effective in decreasing plaque formation in cholesterol-fed
 rabbits. Dexamethasone [50-02-2], methylprednisolone [83-43-2],
 triamcinolone [124-94-7], prednisone [53-03-2], and cortisone acetate
 [50-04-4] were also effective at higher dose levels. All of the steroids
 tested decreased plaque formation by 55 to 95%. These protective effects
 were partially duplicated by a number of nonsteroidal inflammation
 inhibitors including flufenamic acid [530-78-9], phenylbutazone [50-33-9],
 oxyphenylbutazone [129-20-4], and mefenamic acid [61-68-7]. Aminopyrine
 [58-15-1] and aspirin [50-78-2] were inactive. By means of dose-response
 curves, it was possible to demonstrate dissociation of the hyperlipemic
 effects of the steroids from their protective effects. The relative
 potencies of these drugs in inhibiting atherosclerosis in the rabbit,
 paralleled closely their effectiveness in treatment of inflammatory
 disorders in humans.

ST atherosclerosis inflammation inhibitor; fluorohydrocortisone
 atherosclerosis dexamethasone prednisone; phenylbutazone atherosclerosis
 oxyphenbutazone mefenamate

IT Inflammation inhibitors

(atherosclerosis prevention by)

IT Atherosclerosis

(inflammation inhibitors effect on)

IT 530-78-9

RL: BIOL (Biological study)

(atherosclerosis prevention by)

IT 50-02-2 50-04-4 50-33-9 53-03-2 61-68-7 83-43-2 127-31-1
 129-20-4

RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
 (Uses)

(atherosclerosis prevention by)

IT 50-78-2 58-15-1

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(atherosclerosis prevention in relation to)

=> d 66:9364 all

ANSWER 1 CAPLUS COPYRIGHT 2003 ACS

AN 1967:9364 CAPLUS

DN 66:9364

TI Influence of antiinflammatory agents on experimental atherosclerosis

AU Bailey, John Martyn; Butler, Jean

CS Sch. of Med., George Washington Univ., Washington, DC, USA

SO Nature (London, United Kingdom) (1966), 212(5063), 731-2

CODEN: NATUAS; ISSN: 0028-0836

DT Journal

LA English

CC 12 (Mammalian Pathological Biochemistry)

AB Daily supplements of cholesterol (1 g.) in rabbit diets increased plasma lipid concns. 10-20-fold and induced atherosclerotic plaques in the thoracic aortas within 12 weeks. The addn. of 1 or 5 mg. of cortisone acetate (I) to rabbit diets contg. cholesterol increased plasma lipids, but reduced the development of atherosclerotic plaques by about 75%. Phenylbutazone (100 mg. daily) decreased plaque formation; 44% of the animals developed no plaques at all. The phenylbutazone-induced decreased plaque formations did not alter serum lipid patterns. The severity of atherosclerosis in animals treated with 100 mg. of aminopyrine was slightly less than in the controls; plasma cholesterol was considerably lower. Vitamin C (100 mg.) produced no decrease in the no. of plaques, and acetyl salicylate increased the incidence of atherosclerosis 17.1%. Rabbits fed a diet contg. 1% cholesterol for 12 weeks produced extensive plaques which did not regress during the following 12 weeks on a cholesterol-free diet, with or without daily supplementation with 5 mg. of I, indicating that I acts in the early stages of plaque formation through its antiinflammatory properties rather than through its lipemic effects.

ST LIPIDS ATHEROSCLEROSIS; ANTIINFLAMMATORIES ATHEROSCLEROSIS; CORTISONE ATHEROSCLEROSIS; ATHEROSCLEROSIS CORTISONE; STEROIDS ATHEROSCLEROSIS; CORTISONE ATHEROSCLEROSIS; ATHEROSCLEROSIS CORTISONE; LIPIDS ATHEROSCLEROSIS; ANTIINFLAMMATORIES ATHEROSCLEROSIS; STEROIDS ATHEROSCLEROSIS

IT Lipids

RL: BIOL (Biological study)

(in blood plasma, inflammation inhibitor effect on)

IT Atherosclerosis

(inflammation inhibitor effect on)

IT 50-78-2, biological studies

RL: BIOL (Biological study)

(atherosclerosis in response to)

IT 50-04-4 50-33-9 58-15-1

RL: BIOL (Biological study)

(atherosclerosis in response to)

=> d 17 201 100 198 195 194 193 all

L7 ANSWER 201 OF 202 CAPLUS COPYRIGHT 2003 ACS

AN 1967:9364 CAPLUS

DN 66:9364

TI Influence of antiinflammatory agents on experimental
atherosclerosis

AU Bailey, John Martyn; Butler, Jean

CS Sch. of Med., George Washington Univ., Washington, DC, USA

SO Nature (London, United Kingdom) (1966), 212(5063), 731-2

CODEN: NATUAS; ISSN: 0028-0836

DT Journal
LA English
CC 12 (Mammalian Pathological Biochemistry)
AB Daily supplements of cholesterol (1 g.) in rabbit diets increased plasma lipid concns. 10-20-fold and induced atherosclerotic plaques in the thoracic aortas within 12 weeks. The addn. of 1 or 5 mg. of cortisone acetate (I) to rabbit diets contg. cholesterol increased plasma lipids, but reduced the development of atherosclerotic plaques by about 75%. Phenylbutazone (100 mg. daily) decreased plaque formation; 44% of the animals developed no plaques at all. The phenylbutazone-induced decreased plaque formations did not alter serum lipid patterns. The severity of **atherosclerosis** in animals treated with 100 mg. of aminopyrine was slightly less than in the controls; plasma cholesterol was considerably lower. Vitamin C (100 mg.) produced no decrease in the no. of plaques, and acetyl salicylate increased the incidence of **atherosclerosis** 17.1%. Rabbits fed a diet contg. 1% cholesterol for 12 weeks produced extensive plaques which did not regress during the following 12 weeks on a cholesterol-free diet, with or without daily supplementation with 5 mg. of I, indicating that I acts in the early stages of plaque formation through its antiinflammatory properties rather than through its lipemic effects.

ST LIPIDS **ATHEROSCLEROSIS**; ANTIINFLAMMATORIES
ATHEROSCLEROSIS; CORTISONE **ATHEROSCLEROSIS**;
ATHEROSCLEROSIS CORTISONE; STEROIDS **ATHEROSCLEROSIS**;
CORTISONE **ATHEROSCLEROSIS**; **ATHEROSCLEROSIS** CORTISONE;
LIPIDS **ATHEROSCLEROSIS**; ANTIINFLAMMATORIES
ATHEROSCLEROSIS; STEROIDS **ATHEROSCLEROSIS**

IT Lipids
RL: BIOL (Biological study)
(in blood plasma, inflammation inhibitor effect on)

IT **Atherosclerosis**
(inflammation inhibitor effect on)

IT 50-78-2, biological studies
RL: BIOL (Biological study)
(atherosclerosis in response to)

IT 50-04-4 50-33-9 58-15-1
RL: BIOL (Biological study)
(**atherosclerosis** in response to)

L7 ANSWER 100 OF 202 CAPLUS COPYRIGHT 2003 ACS
AN 1999:317391 CAPLUS
DN 130:346750
TI Antithrombotic drugs in the primary medical management of intermittent claudication. A meta-analysis
AU Girolami, Bruno; Bernardi, Enrico; Prins, Martin H.; Ten Cate, Jan Wouter; Prandoni, Paolo; Hettiarachchi, Rohan; Marras, Elena; Stefani, Piero Maria; Girolami, Antonio; Buller, Harry R.
CS Institute Medical Semeiotics, University Padua, Padua, I-35100, Italy
SO Thrombosis and Haemostasis (1999), 81(5), 715-722
CODEN: THHADQ; ISSN: 0340-6245
PB F. K. Schattauer Verlagsgesellschaft mbH
DT Journal; General Review
LA English
CC 1-0 (Pharmacology)
AB A review with 78 refs. is given on the efficacy of antithrombotic drugs available for patients with intermittent claudication. A Medline and manual search was used to identify relevant publications. Uncontrolled or retrospective studies, double reports or trials without clin. outcomes were excluded. Included studies were graded as level 1 (randomized and double- or assessor-blind), level 2 (open randomized), or level 3 (non-randomized comparative). Mortality, cerebro- or cardiovascular events, amputations, arterial occlusions or no. of revascularization

procedures performed in the lower limbs, pain-free and total walking distance, ankle brachial index and calf blood flow, were the main outcomes considered. When feasible, end of treatment results, either continuous or binary, were combined with appropriate statistical methods. Mortality was decreased by ticlopidine compared to placebo (common odds ratio 0.68, 95% C.I., 0.49-0.95); clopidogrel decreased vascular events in comparison to aspirin (odds ratio 0.76, 95% C.I., 0.63-0.92) in level 1 studies.

Arterial occlusions and the no. of revascularization procedures performed were decreased by aspirin and ticlopidine, resp. A small improvement in pain-free walking distance was detd. by picotamide, indobufen, low mol. wt. heparins, sulodexide, and defibrotide, in small studies. Clopidogrel and ticlopidine do reduce clin. important events in patients with intermittent claudication and could be added to the primary medical treatment of these patients. The use of aspirin in these patients cannot be based on direct evidence, but only on analogy with coronary and cerebral **atherosclerosis**, where it has documented efficacy. Other antithrombotic drugs were not properly evaluated in patients with intermittent claudication.

ST review antithrombotic intermittent claudication

IT Anticoagulants

(antithrombotic drugs in the primary medical management of intermittent claudication)

IT Artery, disease

(intermittent claudication; antithrombotic drugs in the primary medical management of intermittent claudication)

IT 50-78-2, Aspirin 32828-81-2, Picotamide 55142-85-3,
Ticlopidine 57821-29-1, Sulodexide 63610-08-2, Indobufen 83712-60-1,
Defibrotide 113665-84-2, Clopidogrel

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antithrombotic drugs in the primary medical management of intermittent claudication)

IT 9005-49-6, Heparin, biological studies

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(low mol. wt.; antithrombotic drugs in the primary medical management of intermittent claudication)

RE.CNT 78 THERE ARE 78 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Adriaensen, H; Curr Med Res Opin 1976, V4, P395 MEDLINE
- (2) Allegra, C; Int J Clin Pharmacol Ther 1994, V12, P646
- (3) Andreozzi, G; Angiology 1993, V44, P307 MEDLINE
- (4) Antiplatelet Trialists' Collaboration; BMJ 1994, V308, P159
- (5) Antiplatelet Trialists' Collaboration; BMJ 1994, V308, P81
- (6) Arcan, J; Angiology 1988, V39, P802 MEDLINE
- (7) Arcan, J; Thromb Res 1986, VSuppl VI, P159
- (8) Ariyoshi, K; Am J Hematol 1997, V54, P175 MEDLINE
- (9) Aukland, A; J Clin Pathol 1982, V35, P740 MEDLINE
- (10) Auteri, A; Int J Clin Pharmacol Res 1995, V15, P57 CAPLUS
- (11) Balkau, B; J Cardiovasc Pharmacol 1994, V23(Suppl 3), PS8
- (12) Balsano, F; Circulation 1993, V87, P1563 MEDLINE
- (13) Balsano, F; J Lab Clin Med 1989, V114, P84 MEDLINE
- (14) Belcaro, G; Angiology 1991, V42, P8 MEDLINE
- (15) Belcaro, G; Curr Ther Res 1990, V48, P667
- (16) Berqvist, D; Eur J Vasc Endovasc Surg 1995, V10, P69
- (17) Blanchard, J; Nouv Rev Fr Hematol 1993, V35, P523
- (18) Bonalumi, F; Eur Rev Med Pharmacol Sci 1986, VVIII, P123
- (19) CAPRIE Steering Committee; Lancet 1996, V348, P1329
- (20) Calabro, A; Angiology 1993, V44, P188 MEDLINE
- (21) Caramelli, L; Eur Rev Med Pharmacol Sci 1988, V10, P55 MEDLINE

- (22) Castelluccio, A; Curr Med Res Opin 1991, V12, P325 MEDLINE
- (23) Catania, G; Eur Rev Med Farmacol Sci 1992, V14, P149 MEDLINE
- (24) Centurioni, R; Haematologica 1993, V78, P196 MEDLINE
- (25) Ciocon, J; Angiology 1997, V48, P237 MEDLINE
- (26) Clagett, G; Chest 1995, V108(Suppl), P431S
- (27) Cloarec, M; Thromb Res 1985, VSuppl VI, P160
- (28) Corsi, C; J Int Med Res 1985, V13, P40 MEDLINE
- (29) Coto, V; Angiology 1989, V40, P880 MEDLINE
- (30) Craveri, A; Int Angiol 1990, V9, P274 MEDLINE
- (31) Crepaldi, G; Atherosclerosis 1990, V81, P233 MEDLINE
- (32) de Smit, P; Acta Chir Austriaca 1992, V24, P5
- (33) Dettori, A; Angiology 1989, V40, P237 MEDLINE
- (34) Di Stefano, F; Curr Ther Res 1988, V44, P1
- (35) Di Stefano, F; Eur Rev Med Pharmacol Sci 1984, VVI, P525
- (36) Dormandy, J; J Cardiovasc Surg (Torino) 1989, V30, P50 MEDLINE
- (37) Fagher, B; Angiology 1993, V44, P300 MEDLINE
- (38) Fagher, B; Angiology 1994, V45, P777 MEDLINE
- (39) Fontaine, V; Helv Chir Acta 1954, V5/6, P499
- (40) Giansante, C; J Int Med Res 1990, V18, P400 MEDLINE
- (41) Gillot, P; Curr Ther Res Clin Exp 1976, V20, P637 MEDLINE
- (42) Girolami, B; Arch Intern Med 1999, V159, P337 MEDLINE
- (43) Girolami, B; Thromb Haemost 1995, V6, P1386
- (44) Gregorie, G; J Clin Epidemiol 1995, V48, P159
- (45) Hess, H; Lancet 1985, V23, P415
- (46) Holm, J; Vasa 1984, V13, P175 MEDLINE
- (47) Housley, E; BMJ 1988, V296, P1483 MEDLINE
- (48) Janzon, L; J Intern Med 1990, V227, P301 MEDLINE
- (49) Jones, N; Br J Surg 1982, V69, P38 MEDLINE
- (50) Kannel, W; Circulation 1970, V41, P875 MEDLINE
- (51) Kirtstein, P; Atherosclerosis 1980, V36, P471
- (52) Kovacs, M; Ann Pharmacother 1993, V27, P1060 MEDLINE
- (53) Laurora, G; PanMinerva Med 1994, V36, P83 MEDLINE
- (54) Libretti, A; Int J Clin Pharmacol Res 1986, V6, P59 MEDLINE
- (55) Libretti, A; Monogr Atheroscl 1986, V14, P207 MEDLINE
- (56) Mannarino, E; Angiology 1991, V42, P1 MEDLINE
- (57) Mannarino, E; Angiology 1991, V42, P513 MEDLINE
- (58) Mantel, N; J Natl Cancer Inst 1959, V22, P719 MEDLINE
- (59) Marelli, C; Curr Ther Res 1990, V47, P459
- (60) Moloney, B; Ticlopidine, platelets and vascular disease 1993, P99
- (61) Money, S; J Vasc Surg 1998, V27, P267 MEDLINE
- (62) Neirotti, M; Angiology 1994, V45, P137 MEDLINE
- (63) Palmieri, G; Curr Ther Res 1987, V41, P998
- (64) Palmieri, G; Int Angiol 1988, V7(Suppl 3), P41
- (65) Palmieri, J; Clin Trials J 1984, V21, P411
- (66) Panchenko, E; Angiology 1997, V48, P247 MEDLINE
- (67) Rao, C; Linear statistical inference and its applications 1973, P389
- (68) Roztocil, K; Cor Vasa 1989, V31, P128 MEDLINE
- (69) Sabba, C; Int J Clin Pharmacol Ther Toxicol 1988, V26, P249 MEDLINE
- (70) Schoop, W; Thromb Haemost 1983, V50, P137
- (71) Shustov, S; Curr Med Res Opin 1997, V13, P573 CAPLUS
- (72) Signorini, G; Angiology 1988, V39, P742 MEDLINE
- (73) Strano, A; Drugs Exp Clin Res 1990, V16, P543 MEDLINE
- (74) Strano, A; Semin Thromb Hemost 1991, V17, P228
- (75) Tesi, M; J Drug Dev 1989, V2, P73
- (76) Tonnesen, K; Int Angiol 1993, V12, P371 MEDLINE
- (77) Verhaeghe, R; J Cardiovasc Pharmacol 1981, V3, P279 MEDLINE
- (78) Verstraete, M; Drugs 1982, V24, P240 MEDLINE

L7 ANSWER 198 OF 202 CAPLUS COPYRIGHT 2003 ACS

AN 1975:93102 CAPLUS

DN 82:93102

TI Suppression of atheromatous fibrous plaque formation by antiproliferative

and antiinflammatory drugs

AU Hollander, William; Kramsch, Dieter M.; Franzblau, Carl; Paddock, John; Colombo, Marilyn A.

CS Med. Cent., Boston Univ., Boston, MA, USA

SO Circulation Research, Supplement (1974), 34(5, Suppl. 1), 131-41
CODEN: CIRSAF; ISSN: 0069-4185

DT Journal

LA English

CC 1-5 (Pharmacodynamics)

AB In rabbits fed an atherogenic diet plus colchicine (I) [64-86-8] or cortisone acetate [50-04-4], the aorta had fewer gross visual lesions and contained significantly less free and ester cholesterol as well as collagen and elastin than the aorta of rabbits fed the atherogenic diet alone. In contrast to I and cortisone, penicillamine [52-67-5] and aspirin [50-78-2] did not alter the extent of **atherosclerosis** or the deposition of cholesterol in the lesions, but they did inhibit the connective tissue proliferation in the lesion. On the other hand, chlorpheniramine [132-22-9] did not prevent fibrous protein deposition in the plaque but did partially prevent cellular proliferation and lipid deposition. As opposed to all the other drugs, butazolidin [50-33-9] augmented lipid infiltration into the aorta while it appeared to protect against collagen deposition. The present studies suggest that certain antiproliferative and anti-inflammatory drugs which have specific inhibitory effects on the atherosclerotic process could prove to be useful in the control of **atherosclerosis** and its sequelae.

ST colchicine atheromatous plaque formation; cortisone atheromatous plaque formation; penicillamine atheromatous plaque formation; antiinflammatory atheromatous plaque formation

IT **Atherosclerosis**
(antiinflammatory and antiproliferative drugs in treatment of)

IT Collagens, biological studies
Elastins
RL: BIOL (Biological study)
(of aorta, antiinflammatory and antiproliferative drugs effect on, in **atherosclerosis**)

IT 50-04-4 64-86-8
RL: BIOL (Biological study)
(atheromatous fibrous plaque formation suppression by, in aorta)

IT 50-33-9 50-78-2 52-67-5 132-22-9
RL: BIOL (Biological study)
(**atherosclerosis** response to, in aorta)

IT 57-88-5, biological studies
RL: BIOL (Biological study)
(of aorta, antiinflammatory and antiproliferative drugs effect on, in **atherosclerosis**)

L7 ANSWER 195 OF 202 CAPLUS COPYRIGHT 2003 ACS

AN 1979:145804 CAPLUS

DN 90:145804

TI Anti-inflammatory drugs in experimental **atherosclerosis**. Part 4. Inhibition of **atherosclerosis** in vivo and thromboxane synthesis and platelet aggregation in vitro

AU Bailey, J. Martyn; Makheja, A. N.; Butler, Jean; Salata, K.

CS Sch. Med. Health Sci., George Washington Univ., Washington, DC, USA

SO Atherosclerosis (Shannon, Ireland) (1979), 32(2), 195-203
CODEN: ATHSBL; ISSN: 0021-9150

DT Journal

LA English

CC 1-5 (Pharmacodynamics)


Section cross-reference(s): 14

AB Groups of New Zealand white male rabbits were fed atherogenic diets

contg. 1% cholesterol. The diets of exptl. groups were supplemented addnl. with either aspirin [50-78-2], phenylbutazone [50-33-9], mefenamic acid [61-68-7], flufenamic acid [530-78-9], oxyphenylbutazone [129-20-4] or aminopyrine [58-15-1]. Blood cholesterol and phospholipids were measured at 3-4 wk intervals. After 12 wk the animals were sacrificed and the severity of **atherosclerosis** in the thoracic aorta was measured. In sep. expts., rabbit platelets were incubated with each of the drugs individually and conversion of [14C]arachidonic acid to thromboxanes and related compds. was assayed. Inhibition of collagen and arachidonic acid-induced platelet aggregation by each drug was also measured. All drugs inhibited thromboxane synthesis and platelet aggregation in varying degrees with flufenamate and aspirin being most and aminopyrine least effective. The pattern of metabolite formation from [14C]arachidonate was consistent with a block in the cyclooxygenase reaction. Phenylbutazone, flufenamic acid, and oxyphenylbutazone produced significant redns. in atherosclerotic plaque formation without major changes in blood cholesterol levels or blood cholesterol-phospholipid ratios. Aspirin and aminopyrine were ineffective. The effectiveness of antiinflammatory drugs as inhibitors of thromboxane synthesis and platelet aggregation in vitro does not appear to afford a sufficient predictive index of their antiatherogenicity in vivo. The significance of these findings is discussed in terms of the possible involvement of cyclooxygenase derivs. in atherogenesis.

- ST inflammation inhibitor **atherosclerosis** thromboxane; blood platelet antiinflammatory drug
- IT Blood platelet
 - (aggregation of, inflammation inhibitors inhibition of, antiatherogenicity in relation to)
- IT Thromboxanes
 - RL: FORM (Formation, nonpreparative)
 - (formation of, inflammation inhibitors inhibition of, antiatherogenicity in relation to)
- IT **Atherosclerosis**
 - (inflammation inhibitors effect on, platelet aggregation and thromboxane formation inhibition in relation to)
- IT Inflammation inhibitors
 - (platelet aggregation and thromboxane formation inhibition by, antiatherogenicity in relation to)
- IT 50-33-9, biological studies **50-78-2** 58-15-1 61-68-7
129-20-4 530-78-9
RL: BIOL (Biological study)
 - (platelet aggregation and thromboxane formation inhibition by, antiatherogenicity in relation to)

L7 ANSWER 194 OF 202 CAPLUS COPYRIGHT 2003 ACS
 AN 1979:180165 CAPLUS
 DN 90:180165
 TI Studies on the progression and regression of coronary and peripheral **atherosclerosis** in the cynomolgus monkey. I. Effects of dipyridamole and aspirin
 AU Hollander, William; Kirkpatrick, Barbara; Paddock, John; Colombo, Marilyn; Nagraj, Siva; Prusty, Somnath
 CS Med. Cent., Boston Univ., Boston, MA, USA
 SO Experimental and Molecular Pathology (1979), 30(1), 55-73
 CODEN: EXMPA6; ISSN: 0014-4800
 DT Journal
 LA English
 CC 1-5 (Pharmacodynamics)
 Section cross-reference(s): 14
 GI



AB The morphol. and biochem. changes in the arteries of the cynomolgus monkey were investigated during the induction and regression of **atherosclerosis**. During the feeding of an atherogenic diet contg. 2% cholesterol and 10% butter for 5 mo, the animals developed fibro-fatty plaques which involved the coronary and peripheral arteries and caused significant luminal narrowing of these vessels. The induced aortic lesions contained increased amts. of free and esterified cholesterol [57-88-5], collagen, elastin, and Ca. These changes were assocd. with an elevation of plasma cholesterol and an increased net influx of plasma cholesterol and low d. lipoproteins (LDL) into the aorta. Dipyridamole (I) [58-32-2] (10 mg/kg) and aspirin (II) [50-78-2] (50 mg/kg) had no effect on the arterial uptake of plasma LDL and cholesterol and did not protect against **atherosclerosis** in any of the vessels examd. During the regression period (low cholesterol diet) of 12 mo duration, the induced lesions became more fibrotic and calcified while the cellularity and lipid content of the same lesions decreased. As a result of these changes there were no significant decreases in the atherosclerotic narrowing of the coronary and peripheral vessels. The net influx of plasma LDL and cholesterol into the aorta returned to normal during the regression period. This finding together with the slow rate of aortic cholesterol equilibration suggests that the retention of cholesterol in the regressed aortic lesions is due to a defect in cholesterol transport rather than to an abnormality in intimal permeability. The addn. of I and II to the regression diet did not alter the course of the **atherosclerosis**.

ST dipyridamole aspirin **atherosclerosis**

IT Collagens, biological studies

Elastins

RL: BIOL (Biological study)

(of aorta, in **atherosclerosis**, aspirin and dipyridamole effect on)

IT **Atherosclerosis**

(progression and regression of, aspirin and dipyridamole effect)

IT Lipoproteins

RL: BIOL (Biological study)

(low-d., of blood plasma, in **atherosclerosis**, aspirin and dipyridamole effect on)

IT 50-78-2 58-32-2

RL: BIOL (Biological study)

(**atherosclerosis** response to)

IT 7440-70-2, biological studies

RL: BIOL (Biological study)

(of aorta, in **atherosclerosis**, aspirin and dipyridamole effect on)

IT 57-88-5, biological studies

FILE 'REGISTRY' ENTERED AT 15:16:24 ON 02 DEC 2002

L1 122 S ACETAMINOPHEN
L2 0 S ASPRIN
L3 50 S ASPIRIN
E STATIN
L4 1577 S E3
L5 29 S VITAMIN C
L6 77 S VITAMIN E
L7 8 S ATORVASTATIN
E STANOL
L8 12 S E3
L9 3 S TIROFIBAN

FILE 'CAPLUS' ENTERED AT 15:25:14 ON 02 DEC 2002

E ATHEROSCLEROSIS
L10 33111 S E3
L11 10111 S L1
L12 12 S L11 AND L10.

=>

L20, 726, 724, 754

L18 - 415

L20 ANSWER 796 OF 800 CAPLUS COPYRIGHT 2002 ACS

AN 1963:55091 CAPLUS

DN 58:55091

OREF 58:9457a-b

TI Influence of vitamin E on lipids and blood coagulability in patients with **atherosclerosis**

AU Nikitin, Yu. P.

CS Post-Graduate Med. Inst., Novokuznetsk

SO Vopr. Pitaniya (1962), 21(No. 6), 22-7

DT Journal

LA Unavailable

CC 64 (Animal Nutrition)

AB Some biochem. indexes in atherosclerotic patients were examd. after administration of vitamin E (I). The serum cholesterol (II) level, lecithin (III), and ketone bodies (IV) were detd. Before administration of I the serum levels of II and III were 277 mg.%, range 193-420 and 366 mg.%, range 207-456 resp. The ratio of III/II was 1.31. After the treatment of I for 7-35 days at the rate of 50-90 mg./24 hrs., II level diminished in most cases by 10-25%, III changes varied, and the ratio III/II was 1.60. The changes in IV were not specific, nor were the changes of the recalcification time of the oxalated plasma and the changes of the tolerance of plasma to heparin II. 44 references.

IT Blood coagulation

(A, vitamin E effect on)

IT **Atherosclerosis**

(blood coagulation and lipids in blood in, vitamin E effect on)

IT Lipids

(in blood, in **atherosclerosis**, vitamin E effect on)

IT **1406-18-4, Vitamin E**

(blood coagulation and lipids in blood in **atherosclerosis** in relation to)

IT 57-88-5, Cholesterol

(in blood in **atherosclerosis**, vitamin E effect on)

L20 ANSWER 794 OF 800 CAPLUS COPYRIGHT 2002 ACS

AN 1963:438148 CAPLUS

DN 59:38148

OREF 59:6880h,6881a-c

TI Various drugs acting on the serum lipid pattern of **atherosclerosis**. Therapeutic significance of an extractive heparinoid

AU Nicrosini, F.; Piccinelli, O.

CS Univ. Pavia, Italy

SO Drugs Affecting Lipid Metab., Proc. Symp., Milan (1961), Volume Date 1960 508-11

DT Journal

LA Unavailable

CC 68 (Pharmacodynamics)

AB The serum lipid pattern of **atherosclerosis** shows a marked increase of total lipids, an abs. and relative increase of glycerides equal to that of total steroids, a relative decrease of phospholipids which is often abs., and an abs. and relative increase of total steroids about 67% due to the increase of steroids which do not ppt. with digitonin and which give the Lieberman-Burchard reaction (fraction A), and about 33% due to the increase of steroids which do not give this reaction and which do not ppt. with digitonin (satd. .beta.-steroids or B2 fraction, probably represented by dihydrocholesterol). Steroids pptg. with digitonin and giving at the same time the Lieberman-Burchard reaction (unsatd. .beta.-steroids or B1 fraction), i.e., cholesterol itself, appear within almost normal limits, thus presenting a relatively marked decrease. .beta.-Steroid esterification is significantly increased. At the onset of atheroma, changes in the lipids of the arterial wall show a higher concn. of total glycerides and steroids, a lower concn. of phospholipids, a

AN 1973:500515 CAPLUS
 DN 79:100515
 TI Antiinflammatory drugs in experimental atherosclerosis. 1. Relative
 potencies for inhibiting plaque formation
 AU Bailey, J. Martyn; Butler, Jean
 CS Sch. Med., George Washington Univ., Washington, DC, USA
 SO Atherosclerosis (Shannon, Ireland) (1973), 17(3), 515-22
 CODEN: ATHSBL; ISSN: 0021-9150
 DT Journal
 LA English
 CC 1-5 (Pharmacodynamics)
 AB Orally administered 9.alpha.-fluorohydrocortisone (I) [127-31-1] (30
 .mu.g/day) was effective in decreasing plaque formation in cholesterol-fed
 rabbits. Dexamethasone [50-02-2], methylprednisolone [83-43-2],
 triamcinolone [124-94-7], prednisone [53-03-2], and cortisone acetate
 [50-04-4] were also effective at higher dose levels. All of the steroids
 tested decreased plaque formation by 55 to 95%. These protective effects
 were partially duplicated by a number of nonsteroidal inflammation
 inhibitors including flufenamic acid [530-78-9], phenylbutazone [50-33-9],
 oxyphenylbutazone [129-20-4], and mefenamic acid [61-68-7]. Aminopyrine
 [58-15-1] and aspirin [50-78-2] were inactive. By means of dose-response
 curves, it was possible to demonstrate dissociation of the hyperlipemic
 effects of the steroids from their protective effects. The relative
 potencies of these drugs in inhibiting atherosclerosis in the rabbit,
 paralleled closely their effectiveness in treatment of inflammatory
 disorders in humans.
 ST atherosclerosis inflammation inhibitor; fluorohydrocortisone
 atherosclerosis dexamethasone prednisone; phenylbutazone atherosclerosis
 oxyphenbutazone mefenamate
 IT Inflammation inhibitors
 (atherosclerosis prevention by)
 IT Atherosclerosis
 (inflammation inhibitors effect on)
 IT 530-78-9
 RL: BIOL (Biological study)
 (atherosclerosis prevention by)
 IT 50-02-2 50-04-4 50-33-9 53-03-2 61-68-7 83-43-2 127-31-1
 129-20-4
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
 (Uses)
 (atherosclerosis prevention by)
 IT 50-78-2 58-15-1
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (atherosclerosis prevention in relation to)

=>

AN 1973:500515 CAPLUS
 DN 79:100515
 TI Antiinflammatory drugs in experimental atherosclerosis. 1. Relative
 potencies for inhibiting plaque formation
 AU Bailey, J. Martyn; Butler, Jean
 CS Sch. Med., George Washington Univ., Washington, DC, USA
 SO Atherosclerosis (Shannon, Ireland) (1973), 17(3), 515-22
 CODEN: ATHSBL; ISSN: 0021-9150
 DT Journal
 LA English
 CC 1-5 (Pharmacodynamics)
 AB Orally administered 9.alpha.-fluorohydrocortisone (I) [127-31-1] (30
 .mu.g/day) was effective in decreasing plaque formation in cholesterol-fed
 rabbits. Dexamethasone [50-02-2], methylprednisolone [83-43-2],
 triamcinolone [124-94-7], prednisone [53-03-2], and cortisone acetate
 [50-04-4] were also effective at higher dose levels. All of the steroids
 tested decreased plaque formation by 55 to 95%. These protective effects
 were partially duplicated by a number of nonsteroidal inflammation
 inhibitors including flufenamic acid [530-78-9], phenylbutazone [50-33-9],
 oxyphenylbutazone [129-20-4], and mefenamic acid [61-68-7]. Aminopyrine
 [58-15-1] and aspirin [50-78-2] were inactive. By means of dose-response
 curves, it was possible to demonstrate dissociation of the hyperlipemic
 effects of the steroids from their protective effects. The relative
 potencies of these drugs in inhibiting atherosclerosis in the rabbit,
 paralleled closely their effectiveness in treatment of inflammatory
 disorders in humans.
 ST atherosclerosis inflammation inhibitor; fluorohydrocortisone
 atherosclerosis dexamethasone prednisone; phenylbutazone atherosclerosis
 oxyphenbutazone mefenamate
 IT Inflammation inhibitors
 (atherosclerosis prevention by)
 IT Atherosclerosis
 (inflammation inhibitors effect on)
 IT 530-78-9
 RL: BIOL (Biological study)
 (atherosclerosis prevention by)
 IT 50-02-2 50-04-4 50-33-9 53-03-2 61-68-7 83-43-2 127-31-1
 129-20-4
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
 (Uses)
 (atherosclerosis prevention by)
 IT 50-78-2 58-15-1
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (atherosclerosis prevention in relation to)

=>

- (6) Carr, A; Arterioscler Thromb Vasc Biol 2000, V20, P1716 CAPLUS
- (7) Catapano, A; Curr Opin Cardiol 2000, V15, P355 MEDLINE
- ✓(8) Chisolm, G; J Biol Chem 1999, V274, P2959
- (9) Chong, P; Drugs 2000, V60, P55 CAPLUS
- (10) Diplock, A; Free Rad Res 2000, V33(suppl), PS21
- (11) Heinecke, J; J Lab Clin Med 1999, V133, P321 CAPLUS
- ✓(12) Hogg, N; Biochimica et Biophysica Acta 1999, V1411, P378 CAPLUS
- ✓(13) Kapiotis, S; Arterioscler Thromb Vasc Biol 1997, V17, P2855 CAPLUS
- ✓(14) Kinlay, S; J Cardiovasc Pharm 1998, V32(suppl 3), PS62
- ✓(15) Nenseter, M; Arterioscler Thromb Vasc Biol 1995, V15, P1338 CAPLUS
- (16) Rice-Evans, C; Free Rad Res 2000, V33(suppl), PS59
- ✓(17) Rogers, L; Free Rad Biol Med 1999, V27, PS108 — *Adams*
- ✓(18) Ross, R; N Engl J Med 1999, V340, P115 MEDLINE
- (19) Salonen, J; Free Rad Res 2000, V33(suppl), PS41
- (20) Slater, T; Eicosanoids, lipid peroxidation and cancer 1988, P137
- (21) Taylor, A; Circulation 1999, V100, PI
- ✓(22) Taylor, A; Naunyn Schmiedeberg's Arch Pharmacol 1998, V358(suppl 2, no 1), PI *Adams*
- ✓(23) Tsujimoto, Y; Gen Pharmacol 1998, V31, P405 CAPLUS *Adams*

L12 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2002 ACS

AN 2001:380616 CAPLUS

DN 135:10004

TI Compositions and methods for counteracting effects of reactive oxygen species and free radicals

IN Shashoua, Victor E.

PA Ceremedix, Inc., USA

SO PCT Int. Appl., 102 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM C07K007-06

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 1, 17

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001036454	A1	20010525	WO 2000-US31764	20001117
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1232174	A1	20020821	EP 2000-978811	20001117
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRAI	US 1999-166381P	P	19991118		
	WO 2000-US31764	W	20001117		
OS	MARPAT 135:10004				
AB	Peptide compds. and methods for upregulating expression of a gene encoding an antioxidative enzyme, such as superoxide dismutase or catalase, to counteract harmful oxidative effects of reactive oxygen species and other free radicals are described. The peptide compds. may be used to treat or prevent diseases and conditions characterized by undesirable elevation of reactive oxygen species and other free radicals, to upregulate AP-1 gene expression, and to treat pain. The peptide compds. may be used as components of pharmaceuticals and dietary supplements.				
ST	free radical scavenger antioxidant gene expression				

IT Transcription factors
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (AP-1 (activator protein 1); compns. and methods for counteracting effects of reactive oxygen species and free radicals)

IT Nervous system
 (Huntington's chorea; compns. and methods for counteracting effects of reactive oxygen species and free radicals)

IT Nervous system
 (amyotrophic lateral sclerosis; compns. and methods for counteracting effects of reactive oxygen species and free radicals)

IT Antiarteriosclerotics
 (antiatherosclerotics; compns. and methods for counteracting effects of reactive oxygen species and free radicals)

IT Enzymes, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (antioxidant, genes encoding; compns. and methods for counteracting effects of reactive oxygen species and free radicals)

IT Gene, animal
 RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (antioxidant-encoding; compns. and methods for counteracting effects of reactive oxygen species and free radicals)

IT Polycyclic compounds
 RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
 (arom. hydrocarbons; compns. and methods for counteracting effects of reactive oxygen species and free radicals)

IT Alzheimer's disease
 Anti-Alzheimer's agents
 Anti-inflammatory agents
 Antiarthritics
 Anticonvulsants
 Antidiabetic agents
 Antipsychotics
 Arthritis

Atherosclerosis

Burn
 Cataract
 Diabetes mellitus
 Down's syndrome
 Epilepsy
 Herb
 Inflammation
 Leukemia
 Parkinson's disease
 Radical scavengers
 Radiotherapy
 Schizophrenia
 Tea (Camellia sinensis)
 Tranquilizers
 (compns. and methods for counteracting effects of reactive oxygen species and free radicals)

IT Quinones
 RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
 (compns. and methods for counteracting effects of reactive oxygen species and free radicals)

IT Reactive oxygen species
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (compns. and methods for counteracting effects of reactive oxygen species and free radicals)

IT Peptides, biological studies

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(compns. and methods for counteracting effects of reactive oxygen species and free radicals)

- IT Nervous system
(degeneration; compns. and methods for counteracting effects of reactive oxygen species and free radicals)
- IT Gene
(expression; compns. and methods for counteracting effects of reactive oxygen species and free radicals)
- IT Microorganism
Plant (Embryophyta)
(for dietary supplements; compns. and methods for counteracting effects of reactive oxygen species and free radicals)
- IT Antioxidants
(genes encoding; compns. and methods for counteracting effects of reactive oxygen species and free radicals)
- IT Deer
Elk
Ruminant
(green velvet antler of; compns. and methods for counteracting effects of reactive oxygen species and free radicals)
- IT Body, anatomical
(horn, antler, green velvet; compns. and methods for counteracting effects of reactive oxygen species and free radicals)
- IT Heart, disease
(infarction; compns. and methods for counteracting effects of reactive oxygen species and free radicals)
- IT Reperfusion
(injury; compns. and methods for counteracting effects of reactive oxygen species and free radicals)
- IT Brain, disease
(ischemia; compns. and methods for counteracting effects of reactive oxygen species and free radicals)
- IT Eye, disease
(macula, degeneration; compns. and methods for counteracting effects of reactive oxygen species and free radicals)
- IT Aromatic hydrocarbons, biological studies
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(polycyclic; compns. and methods for counteracting effects of reactive oxygen species and free radicals)
- IT Newborn
(premature, oxygen toxicity in; compns. and methods for counteracting effects of reactive oxygen species and free radicals)
- IT Aging, animal
(premature; compns. and methods for counteracting effects of reactive oxygen species and free radicals)
- IT Kidney
(reperfusion injury; compns. and methods for counteracting effects of reactive oxygen species and free radicals)
- IT Aging, animal
(senility; compns. and methods for counteracting effects of reactive oxygen species and free radicals)
- IT Shock (circulatory collapse)
(septic; compns. and methods for counteracting effects of reactive oxygen species and free radicals)
- IT Brain, disease
(stroke; compns. and methods for counteracting effects of reactive oxygen species and free radicals)
- IT Diet

(supplements; compns. and methods for counteracting effects of reactive oxygen species and free radicals)

IT Nervous system
(tardive dyskinesia; compns. and methods for counteracting effects of reactive oxygen species and free radicals)

IT Brain, disease
Head
Spinal cord
(trauma; compns. and methods for counteracting effects of reactive oxygen species and free radicals)

IT Intestine, disease
(ulcerative colitis; compns. and methods for counteracting effects of reactive oxygen species and free radicals)

IT Natural products, pharmaceutical
RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(wuzi yanzong; compns. and methods for counteracting effects of reactive oxygen species and free radicals)

IT 50-53-3, Chlorpromazine, biological studies 54-85-3, Isoniazid
56-23-5, Carbon tetrachloride, biological studies 56-38-2, Parathion
57-27-2, Morphine, biological studies 57-47-6, Physostigmine 58-15-1, Aminopyrine 59-87-0, Nitrofurazone 60-56-0, Methimazole 64-17-5, Ethanol, biological studies 67-20-9, Nitrofurantoin 83-34-1, 3-Methylindole 87-17-2, Salicylanilide 92-87-5, Benzidine 100-63-0, Phenylhydrazine 103-90-2, Acetaminophen 150-76-5, 4-Hydroxyanisole 154-93-8, Bcnu 443-48-1, Metronidazole 671-16-9, Procarbazine 1404-00-8, Mitomycin 4685-14-7, Paraquat 5786-21-0 7720-78-7, Ferrous sulfate 11056-06-7, Bleomycin 15663-27-1, Cisplatin 20830-81-3, Daunomycin 23214-92-8, Doxorubicin 23288-49-5, Probulcol 33419-42-0, Etoposide 65271-80-9, Mitoxantrone
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(compns. and methods for counteracting effects of reactive oxygen species and free radicals)

IT 7782-44-7D, Oxygen, reactive species
RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(compns. and methods for counteracting effects of reactive oxygen species and free radicals)

IT 3790-51-0 146877-90-9 236110-08-0, CMX 9236 341969-11-7
341969-12-8 341969-13-9 341969-14-0 341969-15-1 341969-16-2
341969-17-3 341969-18-4 341969-19-5 341969-20-8 341969-21-9
341969-22-0 341969-23-1
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(compns. and methods for counteracting effects of reactive oxygen species and free radicals)

IT 146877-89-6 236110-07-9 340813-25-4 340813-26-5 340813-27-6
340813-28-7 340813-29-8 340813-30-1 340813-31-2 340813-32-3
340813-34-5 340813-35-6 340813-36-7 340813-38-9 340813-39-0
340813-40-3 340813-41-4 340813-42-5 340813-43-6 340813-44-7
340813-45-8 340813-46-9 340974-51-8 340974-67-6
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. and methods for counteracting effects of reactive oxygen species and free radicals)

IT 197881-53-1, 3: PN: EP1136567 SEQID: 3 unclaimed DNA 243717-75-1,
GenBank AR053203 340837-10-7 340837-11-8 340837-12-9 340837-13-0
340837-14-1 340837-15-2
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL

(Biological study)

(comps. and methods for counteracting effects of reactive oxygen species and free radicals)

IT 9001-05-2, Catalase 9054-89-1, Superoxide dismutase

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(gene encoding; comps. and methods for counteracting effects of reactive oxygen species and free radicals)

IT 57-10-3, palmitic acid, biological studies 64-19-7, acetic acid, biological studies 6217-54-5

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(peptide capping group; comps. and methods for counteracting effects of reactive oxygen species and free radicals)

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Hartman; US 5455029 A 1995 CAPLUS

(2) Mao; US 5112870 A 1992 CAPLUS

(3) Reussner; US 4277464 A 1981 CAPLUS

(4) Thomas; US 5538878 A 1996 CAPLUS

L12 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2002 ACS

AN 1999:783925 CAPLUS

DN 132:22753

TI Preparation of N-(arylsulfonylphenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide derivatives for the elevation of pyruvate dehydrogenase (PDH) activity

IN Butlin, Roger John; Nowak, Thorsten; Burrows, Jeremy Nicholas; Block, Michael Howard

PA Zeneca Limited, UK

SO PCT Int. Appl., 211 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K031-165

ICS C07C317-40; C07C317-44; C07C323-65; C07D213-89; C07D295-08

CC 25-12 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)



Section cross-reference(s): 1

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	WO 9962506	A1	19991209	WO 1999-GB1669	19990526
	W:				
	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2331685	AA	19991209	CA 1999-2331685	19990526
	AU 9940524	A1	19991220	AU 1999-40524	19990526
	AU 740909	B2	20011115		
	BR 9910821	A	20010213	BR 1999-10821	19990526
	EP 1082110	A1	20010314	EP 1999-923767	19990526
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002516854	T2	20020611	JP 2000-551762	19990526
	NO 2000006010	A	20010126	NO 2000-6010	20001128
PRAI	GB 1998-11427	A	19980529		
	WO 1999-GB1669	W	19990526		

OS MARPAT 132:22753

GI



- AB Aryl Ph sulfone and sulfoxide derivs. (I) [where ring D = (un)substituted Ph, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, or other 6-membered N-contg. heteroaryl ring; R¹ = (hetero)arylsulfonyl, (hetero)arylsulfinyl, (hetero)arylcarbonyl, (halo)alkyl, (halo)alkoxy, alkenyloxy, cyano, NO₂, halo, S-CF₃, OH, or a variety of (un)substituted functional groups; n = 1 or 2; R² and R³ = independently (halo)alkyl or 3-5 membered (halo)cycloalkyl ring; A-B = NH-C(O), O-CH₂, S-CH₂, (trans)-vinylene, ethynylene, NH-C(S), or C(O)-CH₂; R⁴ = H, OH, halo, NH₂, or Me], and pharmaceutically acceptable salts or in vivo hydrolysable esters thereof, were prep'd. Pharmaceutical compns., methods, and processes for prepn. of compds. of formula I are also described. For example, (R)-(+)-2-hydroxy-2-methyl-3,3,3-trifluoropropanoic acid (prepn. given) was mixed with oxalyl chloride and added to 4-(4-acetamidophenylsulfonyl)-2-chloroaniline (prepn. given) in DCM to yield (R)-N-[4-(4-acetamidophenylsulfonyl)-2-chlorophenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide (R)-(II). Title compds. elevate pyruvate dehydrogenase (PDH) activity (no data) and are useful in the treatment of diabetes mellitus, peripheral vascular disease, cardiac failure and certain cardiac myopathies, myocardial ischemia, cerebral ischemia and perfusion, muscle weakness, hyperlipidemias, Alzheimer's disease, and/or **atherosclerosis**.
- ST pyruvate dehydrogenase activity elevation arylphenyl sulfone sulfoxide prepn; PDH activity elevation arylsulfonylphenyl propanamide prepn; antidiabetic arylsulfonylphenyl propanamide prepn
- IT Antiarteriosclerotics
(antiatherosclerotics; prepn. of N-(arylsulfonylphenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide derivs. for elevation of pyruvate dehydrogenase (PDH) activity)
- IT Heart, disease
(failure, treatment; prepn. of N-(arylsulfonylphenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide derivs. for elevation of pyruvate dehydrogenase (PDH) activity)
- IT Artery, disease
(intermittent claudication, treatment; prepn. of N-(arylsulfonylphenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide derivs. for elevation of pyruvate dehydrogenase (PDH) activity)
- IT Brain, disease
Heart, disease
(ischemia, treatment; prepn. of N-(arylsulfonylphenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide derivs. for elevation of pyruvate dehydrogenase (PDH) activity)
- IT Blood vessel, disease
(peripheral, treatment; prepn. of N-(arylsulfonylphenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide derivs. for elevation of pyruvate

dehydrogenase (PDH) activity)

IT Anti-Alzheimer's agents
Antidiabetic agents
Hypolipemic agents
(prepn. of N-(arylsulfonylphenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide derivs. for elevation of pyruvate dehydrogenase (PDH) activity)

IT Muscle, disease
(weakness, treatment; prepn. of N-(arylsulfonylphenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide derivs. for elevation of pyruvate dehydrogenase (PDH) activity)

IT 252019-46-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(intermediate; prepn. of N-(arylsulfonylphenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide derivs. for elevation of pyruvate dehydrogenase (PDH) activity)

IT 615-16-7P 16353-27-8P 40644-14-2P 51834-67-4P 56073-93-9P
76105-38-9P 76105-39-0P 83948-53-2P 84437-63-8P 242139-43-1P
242139-49-7P 242139-58-8P 242139-61-3P 242139-62-4P 242139-67-9P
242139-68-0P 242139-86-2P 242140-03-0P 243982-46-9P 244144-51-2P
252019-28-6P 252019-30-0P 252019-31-1P 252019-32-2P 252019-33-3P
252019-34-4P 252019-35-5P 252019-36-6P 252019-37-7P 252019-38-8P
252019-39-9P 252019-40-2P 252019-41-3P 252019-42-4P 252019-43-5P
252019-44-6P 252019-45-7P 252019-47-9P 252019-48-0P 252019-49-1P
252019-50-4P 252019-51-5P 252019-52-6P 252019-53-7P 252019-54-8P
252019-55-9P 252019-56-0P 252019-57-1P 252019-58-2P 252019-59-3P
252019-60-6P 252019-61-7P 252019-62-8P 252019-63-9P 252019-64-0P
252019-65-1P 252019-66-2P 252019-67-3P 252019-68-4P 252019-69-5P
252019-70-8P 252019-71-9P 252019-72-0P 252019-73-1P 252019-74-2P
252019-75-3P 252019-76-4P 252019-77-5P 252019-78-6P 252019-79-7P
252019-80-0P 252019-81-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of N-(arylsulfonylphenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide derivs. for elevation of pyruvate dehydrogenase (PDH) activity)

IT 44864-47-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant (data on a salt from resoln.); prepn. of N-(arylsulfonylphenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide derivs. for elevation of pyruvate dehydrogenase (PDH) activity)

IT 62-53-3, Benzenamine, reactions 95-51-2 97-52-9, 2-Methoxy-4-nitroaniline 99-52-5 103-71-9, Phenyl isocyanate, reactions **103-90-2** 106-88-7, 1,2-Epoxybutane 106-95-6, Allyl bromide, reactions 108-98-5, Thiophenol, reactions 109-90-0, Ethyl isocyanate 110-91-8, Morpholine, reactions 115-19-5, 2-Methyl-3-butyn-2-ol 121-87-9, 2-Chloro-4-nitroaniline 537-91-7 558-30-5, 1,2-Epoxy-2-methylpropane 577-19-5, 2-Bromo-1-nitrobenzene 627-18-9 1066-54-2, Trimethylsilylacetylene 1074-36-8, 4-Mercaptobenzoic acid 1122-97-0 1126-81-4, 4-Acetamidothiophenol 1193-02-8, 4-Aminothiophenol 1635-61-6, 5-Chloro-2-nitroaniline 2557-78-0, 2-Fluorothiophenol 2675-89-0 3268-49-3 4556-23-4, 4-Mercaptopyridine 4892-02-8, Methyl thiosalicylate 5003-71-4, 3-Aminopropyl bromide hydrobromide 5326-47-6, 2-Amino-5-iodobenzoic acid 7501-56-6, 3-Chloro-4-nitrobenzophenone 7661-34-9 7665-72-7, tert-Butyl glycidyl ether 7764-95-6 10198-98-8, 2-(4-Bromophenyl)pyrimidine 18162-48-6, tert-Butyldimethylsilyl chloride 29632-74-4, 2-Fluoro-4-iodoaniline 37577-28-9 40635-66-3 42016-93-3, 2-Chloro-4-iodoaniline 42753-71-9 60811-24-7, 3,4-Difluorobenzenethiol 136434-77-0 139487-04-0 139487-06-2 147696-72-8 156275-96-6, Triisopropylsilanethiol 157695-16-4 157695-23-3 159390-06-4 167156-16-3 252019-83-3 252019-84-4 252019-85-5

RL: RCT (Reactant); RACT (Reactant or reagent)
 (reactant; prepn. of N-(arylsulfonylphenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide derivs. for elevation of pyruvate dehydrogenase (PDH) activity)

IT	242139-87-3P	242139-88-4P	242140-02-9P	242140-05-2P	252014-87-2P
	252014-89-4P	252014-90-7P	252014-92-9P	252014-93-0P	252014-94-1P
	252014-95-2P	252014-96-3P	252014-97-4P	252014-98-5P	252015-68-2P
	252015-75-1P	252015-86-4P	252015-89-7P	252015-90-0P	252015-98-8P
	252015-99-9P	252016-13-0P	252016-17-4P	252016-62-9P	252016-66-3P
	252016-67-4P	252016-68-5P	252016-69-6P	252016-71-0P	252016-72-1P
	252016-81-2P	252016-82-3P	252016-84-5P	252016-85-6P	252016-86-7P
	252016-87-8P	252016-90-3P	252016-91-4P	252016-92-5P	252016-93-6P
	252016-95-8P	252016-96-9P	252016-98-1P	252016-99-2P	252017-00-8P
	252017-21-3P	252017-23-5P	252017-26-8P	252017-27-9P	252017-28-0P
	252017-29-1P	252017-38-2P	252017-39-3P	252017-40-6P	252017-41-7P
	252017-42-8P	252017-43-9P	252017-45-1P	252017-46-2P	252017-49-5P
	252017-50-8P	252017-51-9P	252017-52-0P	252017-53-1P	252017-54-2P
	252017-56-4P	252017-57-5P	252017-59-7P	252017-60-0P	252017-61-1P
	252017-62-2P	252017-63-3P	252017-64-4P	252017-65-5P	252017-66-6P
	252017-67-7P	252017-68-8P	252017-71-3P	252017-74-6P	252017-75-7P
	252017-77-9P	252017-78-0P	252017-79-1P	252017-80-4P	252017-87-1P
	252017-88-2P	252017-95-1P	252017-96-2P	252017-97-3P	252017-98-4P
	252018-01-2P	252018-14-7P	252018-15-8P	252018-22-7P	252018-23-8P
	252018-24-9P	252018-25-0P	252018-26-1P	252018-27-2P	252018-28-3P
	252018-29-4P	252018-30-7P	252018-31-8P	252018-32-9P	252018-33-0P
	252018-34-1P	252018-38-5P	252018-45-4P	252018-46-5P	252018-47-6P
	252018-48-7P	252018-49-8P	252018-75-0P	252018-82-9P	252018-84-1P
	252018-85-2P	252018-87-4P	252018-88-5P	252018-90-9P	252018-91-0P
	252018-93-2P	252018-94-3P	252018-95-4P	252018-96-5P	252018-98-7P
	252019-00-4P	252019-01-5P	252019-02-6P	252019-04-8P	252019-05-9P
	252019-06-0P	252019-07-1P	252019-08-2P	252019-09-3P	252019-10-6P
	252019-11-7P	252019-12-8P			

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(target compd.; prepn. of N-(arylsulfonylphenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide derivs. for elevation of pyruvate dehydrogenase (PDH) activity)

IT	242139-90-8P	242140-06-3P	242142-53-6P	243982-50-5P	252014-88-3P
	252014-91-8P	252014-99-6P	252015-00-2P	252015-01-3P	252015-02-4P
	252015-03-5P	252015-04-6P	252015-05-7P	252015-06-8P	252015-07-9P
	252015-08-0P	252015-09-1P	252015-10-4P	252015-11-5P	252015-12-6P
	252015-13-7P	252015-14-8P	252015-15-9P	252015-16-0P	252015-17-1P
	252015-18-2P	252015-19-3P	252015-20-6P	252015-21-7P	252015-22-8P
	252015-23-9P	252015-24-0P	252015-25-1P	252015-26-2P	252015-27-3P
	252015-28-4P	252015-29-5P	252015-30-8P	252015-31-9P	252015-32-0P
	252015-33-1P	252015-34-2P	252015-35-3P	252015-36-4P	252015-37-5P
	252015-38-6P	252015-39-7P	252015-40-0P	252015-41-1P	252015-42-2P
	252015-43-3P	252015-44-4P	252015-45-5P	252015-46-6P	252015-47-7P
	252015-48-8P	252015-50-2P	252015-51-3P	252015-52-4P	252015-53-5P
	252015-54-6P	252015-55-7P	252015-56-8P	252015-57-9P	252015-58-0P
	252015-59-1P	252015-60-4P	252015-61-5P	252015-62-6P	252015-63-7P
	252015-64-8P	252015-65-9P	252015-66-0P	252015-67-1P	252015-69-3P
	252015-70-6P	252015-71-7P	252015-73-9P	252015-77-3P	252015-79-5P
	252015-81-9P	252015-83-1P	252015-87-5P	252015-88-6P	252015-91-1P
	252015-92-2P	252015-93-3P	252015-94-4P	252015-95-5P	252015-96-6P
	252015-97-7P	252016-00-5P	252016-01-6P	252016-02-7P	252016-03-8P
	252016-04-9P	252016-05-0P	252016-06-1P	252016-07-2P	252016-08-3P
	252016-09-4P	252016-10-7P	252016-11-8P	252016-12-9P	252016-14-1P
	252016-15-2P	252016-16-3P	252016-18-5P	252016-19-6P	252016-20-9P
	252016-21-0P	252016-22-1P	252016-23-2P	252016-24-3P	252016-25-4P

OS MARPAT 120:163728

=> d 112 7-12 all

L12 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2002 ACS

AN 2001:905774 CAPLUS

DN 137:72333

TI Effect of acetaminophen on **atherosclerosis**

AU Chong, Pang H.; Kezele, Bob; Pontikes, Pamala J.

CS Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, IL, 60612-3736, USA

SO Annals of Pharmacotherapy (2001), 35(11), 1476-1479

CODEN: APHRER; ISSN: 1060-0280

PB Harvey Whitney Books Co.

DT Journal; General Review

LA English

CC 1-0 (Pharmacology)

AB A review. OBJECTIVE: To evaluate the antioxidant effects of acetaminophen in **atherosclerosis**. DATA SOURCES: Exptl. literature and abstrs. accessed through MEDLINE (1966-Feb. 2001). DATA SYNTHESIS:

Atherosclerosis is an inflammatory disorder assocd. with coronary events. The oxidative stress burden resulting from excess pro-oxidant free radical formation contributes to oxidative modification of low-d. lipoprotein (lipid peroxidn.) and is assocd. with **atherosclerosis**. Acetaminophen (phenol-like compd.) may limit these key processes that are involved. The findings of earlier exptl. lab. tests and abstrs. are evaluated. CONCLUSIONS: In vitro data suggest that acetaminophen may reduce lipid peroxidn., whereas animal data showed decreased progression of **atherosclerosis**. Further animal model and human studies are required to confirm these earlier findings.

ST review acetaminophen antioxidant **atherosclerosis**

IT Antioxidants

Atherosclerosis

Human

(acetaminophen antioxidant effect on **atherosclerosis**)

IT Radicals, biological studies

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(acetaminophen antioxidant effect on **atherosclerosis**)

IT Antiarteriosclerotics

(antiatherosclerotics; acetaminophen antioxidant effect on **atherosclerosis**)

IT Peroxidation

(lipid; acetaminophen antioxidant effect on **atherosclerosis**)

IT Lipoproteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(low-d.; acetaminophen antioxidant effect on **atherosclerosis**)

IT Lipids, biological studies

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(peroxidn.; acetaminophen antioxidant effect on **atherosclerosis**)

IT 103-90-2, Acetaminophen

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(acetaminophen antioxidant effect on **atherosclerosis**)

RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE

(1) Anon; Physicians' desk reference. 52nd ed 1998, P2061

(2) Aviram, M; Free Rad Res 2000, V33(suppl), PS85

(3) Bergendi, L; Life Sci 1999, V65, P1865 CAPLUS ?

(4) Bloodsworth, A; Arterioscler Thromb Vasc Biol 2000, V20, P1707 CAPLUS ?

(5) Brown, A; Atherosclerosis 1999, V142, P1 CAPLUS

CS Inst. Pharmacol., N. Copernicus Acad. Med., Krakow, Pol.
SO Cardiol.: Int. Perspect., [Proc. World Congr.], 9th (1984), Meeting Date
1982, Volume 2, 1157-62. Editor(s): Chazov, E. I.; Smirnov, V. N.;
Oganov, R. G. Publisher: Plenum, New York, N. Y.
CODEN: 53HTA8
DT Conference
LA English

L20 ANSWER 760 OF 800 CAPLUS COPYRIGHT 2002 ACS
AN 1985:147933 CAPLUS
DN 102:147933
TI Effect of .alpha.-tocopherol in vivo on the structure and function of
calcium-ATPase from skeletal muscle sarcoplasmic reticulum in
hypercholesterolemia
AU Timofeev, A. A.
CS USSR
SO Deposited Doc. (1984), VINITI 1728-84, 17 pp. Avail.: VINITI
DT Report
LA Russian

L20 ANSWER 761 OF 800 CAPLUS COPYRIGHT 2002 ACS
AN 1985:147927 CAPLUS
DN 102:147927
TI Effect of vitamin E on **atherosclerosis** in lipid-fed rabbits
AU Lee, Min Hyuk; Koo, Kook Hwae; Lee, Yong Woo
CS Coll. Med., Hanyang Univ., Seoul, S. Korea
SO Hanyang Uidae Haksulchi (1984), 4(2), 461-76
CODEN: HIHAD3; ISSN: 0254-5942
DT Journal
LA Korean

L20 ANSWER 762 OF 800 CAPLUS COPYRIGHT 2002 ACS
AN 1984:528263 CAPLUS
DN 101:128263
TI Effect of .alpha.-tocopherol and hyperbaric oxygen on the fatty acid
composition of blood plasma in rabbits with hypercholesterolemia
AU Kosukhin, A. B.
CS Inst. Physiol., Alma-Ata, USSR
SO Voprosy Meditsinskoi Khimii (1984), 30(4), 36-9
CODEN: VMDKAM; ISSN: 0042-8809
DT Journal
LA Russian

L20 ANSWER 763 OF 800 CAPLUS COPYRIGHT 2002 ACS
AN 1984:488274 CAPLUS
DN 101:88274
TI Bioelectric theory of pathogenesis of **atherosclerosis**
AU Lipinski, Boguslaw
CS Found. Study Bioelectr., Boston, MA, 02135, USA
SO Journal of Bioelectricity (1984), 3(1-2), 177-91
CODEN: JOUBDX; ISSN: 0730-823X
DT Journal
LA English

L20 ANSWER 764 OF 800 CAPLUS COPYRIGHT 2002 ACS
AN 1984:208221 CAPLUS
DN 100:208221
TI Tocopherol and **atherosclerosis**
AU Radak, Djordje; Djordjevic-Denic, Gordana
CS I Hir. Klin., Med. Fak., Belgrade, Yugoslavia
SO Medicinski Podmladak (1983), 35(3-4), 299-303
CODEN: MPODAC; ISSN: 0369-1527

IT 121-43-7, Trimethyl borate
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction with lithiotoluene, in prepn. of phenoxyalkylamine derivs. as drugs)
IT 152719-50-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction with potassium cyanate, in prepn. of phenoxyalkylamine derivs. as drugs)

=> d his

(FILE 'HOME' ENTERED AT 15:16:16 ON 02 DEC 2002)

FILE 'REGISTRY' ENTERED AT 15:16:24 ON 02 DEC 2002

L1 122 S ACETAMINOPHEN
L2 0 S ASPRIN
L3 50 S ASPIRIN ✓
E STATIN
L4 1577 S E3
L5 29 S VITAMIN C
L6 77 S VITAMIN E
L7 8 S ATORVASTATIN —
E STANOL
L8 12 S E3
L9 3 S TIROFIBAN

FILE 'CAPLUS' ENTERED AT 15:25:14 ON 02 DEC 2002

E ATHEROSCLEROSIS
L10 33111 S E3
L11 10111 S L1
L12 12 S L11 AND L10

=> s l3

L13 15536 L3 ✓

=> s l13 and l10

L14 196 L13 AND L10

=> d l14 150-196

L14 ANSWER 150 OF 196 CAPLUS COPYRIGHT 2002 ACS
AN 1991:199344 CAPLUS
DN 114:199344
TI Aspirin reduces the growth of medial and neointimal thickenings in
balloon-injured rat carotid arteries
AU Voelker, Wolfgang; Faber, Verona
CS Inst. Arterioscleros. Res., Univ. Muenster, Muenster, D-4400, Germany
SO Stroke (1990), 21(12, Suppl.), IV-44-IV-45
CODEN: SJCCA7; ISSN: 0039-2499
DT Journal
LA English

L14 ANSWER 151 OF 196 CAPLUS COPYRIGHT 2002 ACS
AN 1991:22375 CAPLUS
DN 114:22375
TI Interleukin-4 (IL-4) in method and compositions for degradation and
prevention of fibrin deposits associated with pathological conditions
IN Hamilton, John Allan; Hart, Prudence Hamilton
PA University of Melbourne, Australia
SO PCT Int. Appl., 23 pp.
CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9007932	A1	19900726	WO 1990-AU13	19900119
	W: AU, CA, JP, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, IT, LU, NL, SE				
	CA 2045574	AA	19900721	CA 1990-2045574	19900119
	AU 9049645	A1	19900813	AU 1990-49645	19900119
	AU 639903	B2	19930812		
	EP 454736	A1	19911106	EP 1990-902120	19900119
	R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE				
	JP 04503062	T2	19920604	JP 1990-502488	19900119
	JP 06011706	B4	19940216		
	US 5236705	A	19930817	US 1991-720868	19910918
PRAI	AU 1989-2356		19890120		
	WO 1990-AU13		19900119		

L14 ANSWER 152 OF 196 CAPLUS COPYRIGHT 2002 ACS

AN 1990:565161 CAPLUS

DN 113:165161

TI Prevention of myocardial lesions in JCR:LA-corpulent rats by nifedipine

AU Russell, James C.; Koeslag, Dorothy G.; Dolphin, Peter J.; Amy, Roger M.

CS Dep. Surg. Pathol., Univ. Alberta, Edmonton, AB, T6G 2G3, Can.

SO Arteriosclerosis (Dallas) (1990), 10(4), 658-64

CODEN: ARTRDW; ISSN: 0276-5047

DT Journal

LA English

L14 ANSWER 153 OF 196 CAPLUS COPYRIGHT 2002 ACS

AN 1990:549899 CAPLUS

DN 113:149899

TI The oxidative modification of low-density lipoproteins by macrophages

AU Leake, David S.; Rankin, Sara M.

CS Div. Biomed. Sci., King's Coll. London, London, WC2R 2LS, UK

SO Biochemical Journal (1990), 270(3), 741-8

CODEN: BIJOAK; ISSN: 0306-3275

DT Journal

LA English

L14 ANSWER 154 OF 196 CAPLUS COPYRIGHT 2002 ACS

AN 1990:196102 CAPLUS

DN 112:196102

TI Changes of adrenoceptor density in heart and brain and the reactivity of isolated pulmonary artery ring in atherosclerotic rabbit

AU Zeng, Guiyun; Sun, Yading; Tian, Baohong; Wang, Zhong; Hu, Yanhua; An, Yan

CS Inst. Mater. Med., Chin. Acad. Med. Sci., Beijing, 100050, Peop. Rep. China

SO Zhongguo Yaoli Xuebao (1990), 11(1), 18-21

CODEN: CYLPDN; ISSN: 0253-9756

DT Journal

LA Chinese

L14 ANSWER 155 OF 196 CAPLUS COPYRIGHT 2002 ACS

AN 1989:592441 CAPLUS

DN 111:192441

TI Platelet-neutrophil-smooth muscle cell interactions: lipoxygenase-derived mono- and dihydroxy acids activate cholesteryl ester hydrolysis by the cyclic AMP dependent protein kinase cascade

AU Hajjar, David P.; Marcus, Aaron J.; Etingin, Orli R.

CS Med. Coll., Cornell Univ. Med. Coll., New York, NY, 10021, USA

SO Biochemistry (1989), 28(22), 8885-91
CODEN: BICHAW; ISSN: 0006-2960
DT Journal
LA English

L14 ANSWER 156 OF 196 CAPLUS COPYRIGHT 2002 ACS
AN 1989:437279 CAPLUS
DN 111:37279
TI Fatty acids, platelets and monocytes. Something to do with atherogenesis
AU Oesterud, B.; Hansen, J. B.
CS Inst. Med. Biol., Univ. Tromso, Tromso, Norway
SO Annals of Medicine (Stockholm, Sweden) (1989), 21(1), 47-51
CODEN: ANMDEU; ISSN: 0785-3890
DT Journal
LA English

L14 ANSWER 157 OF 196 CAPLUS COPYRIGHT 2002 ACS
AN 1989:18333 CAPLUS
DN 110:18333
TI Diminished platelet residence time on active human atherosclerotic lesions in vivo - evidence for an optimal dose of aspirin?
AU Sinzinger, H.; Kaliman, J.; Fitscha, P.; O'Grady, J.
CS Dep. Nucl. Med., Univ. Vienna, Vienna, Austria
SO Prostaglandins, Leukotrienes and Essential Fatty Acids (1988), 34(2), 89-93
CODEN: PLEAEU; ISSN: 0952-3278
DT Journal
LA English

L14 ANSWER 158 OF 196 CAPLUS COPYRIGHT 2002 ACS
AN 1988:431853 CAPLUS
DN 109:31853
TI Effect of anticoagulant and antiplatelet drugs on in vitro smooth muscle cell proliferation
AU Lindblad, Bengt; Burkell, William E.; Graham, Linda M.; Darvishian, David; Harrell, Karyn; Sell, Ruth; Stanley, James C.
CS Med. Sch., Univ. Michigan, Ann Arbor, MI, USA
SO Artery (Fulton, MI, United States) (1988), 15(4), 225-33
CODEN: ARTEDR; ISSN: 0098-6127
DT Journal
LA English

L14 ANSWER 159 OF 196 CAPLUS COPYRIGHT 2002 ACS
AN 1988:431848 CAPLUS
DN 109:31848
TI Epinephrine potentiation of in vivo stimuli reverses aspirin inhibition of platelet thrombus formation in stenosed canine coronary arteries
AU Folts, John D.; Rowe, George G.
CS Sect. Cardiol., Univ. Wisconsin Hosp., Madison, WI, 53792, USA
SO Thrombosis Research (1988), 50(4), 507-16
CODEN: THBRAA; ISSN: 0049-3848
DT Journal
LA English

L14 ANSWER 160 OF 196 CAPLUS COPYRIGHT 2002 ACS
AN 1988:431846 CAPLUS
DN 109:31846
TI Effects of low-dose aspirin on endogenous eicosanoid formation in normal and atherosclerotic men
AU Knapp, Howard R.; Healy, Cynthia; Lawson, John; FitzGerald, Garret A.
CS Div. Clin. Pharmacol., Vanderbilt Univ., Nashville, TN, 37232, USA
SO Thrombosis Research (1988), 50(3), 377-86

CODEN: THBRAA; ISSN: 0049-3848

DT Journal
LA English

L14 ANSWER 161 OF 196 CAPLUS COPYRIGHT 2002 ACS

AN 1988:404713 CAPLUS

DN 109:4713

TI Shear-induced platelet aggregation can be mediated by vWF released from platelets, as well as by exogenous large or unusually large vWF multimers, requires adenosine diphosphate, and is resistant to aspirin

AU Moake, Joel L.; Turner, Nancy A.; Stathopoulos, Nikos A.; Nolasco, Leticia; Hellums, J. David

CS Biomed. Eng. Lab., Rice Univ., Houston, TX, 77251, USA

SO Blood (1988), 71(5), 1366-74

CODEN: BLOOAW; ISSN: 0006-4971

DT Journal

LA English

L14 ANSWER 162 OF 196 CAPLUS COPYRIGHT 2002 ACS

AN 1988:219504 CAPLUS

DN 108:219504

TI Experimental studies on vascular contraction induced by coagulation system and platelets. With special reference to **atherosclerosis**

AU Kimura, Nobuhiko

CS Dep. Intern. Med., Hyogo Coll. Med., Nishinomiya, 663, Japan

SO Hyogo Ika Daigaku Igakkai Zasshi (1987), 12(1), 25-38

CODEN: HIDZDO; ISSN: 0385-7638

DT Journal

LA Japanese

L14 ANSWER 163 OF 196 CAPLUS COPYRIGHT 2002 ACS

AN 1988:130424 CAPLUS

DN 108:130424

TI Effect of dietary lipids on arterial thrombus formation: rationale for the support of drug therapy by diet

AU Hornstra, Gerard

CS Dep. Biochem., Limburg Univ., Maastricht, 6200 MD, Neth.

SO Seminars in Thrombosis and Hemostasis (1988), 14(1), 59-65

CODEN: STHMBV; ISSN: 0094-6176

DT Journal; General Review

LA English

L14 ANSWER 164 OF 196 CAPLUS COPYRIGHT 2002 ACS

AN 1988:16117 CAPLUS

DN 108:16117

TI The effects of acetylsalicylic acid and tolbutamide on cultured human endothelial cells with special reference to prostacyclin synthesis analyzed by platelet aggregation

AU Kawaguchi, Kenji

CS Med. Sch., Kumamoto Univ., Kumamoto, 860, Japan

SO Kumamoto Medical Journal (1987), 40(1), 37-44

CODEN: KUMJAX; ISSN: 0023-5326

DT Journal

LA English

L14 ANSWER 165 OF 196 CAPLUS COPYRIGHT 2002 ACS

AN 1987:568493 CAPLUS

DN 107:168493

TI The effect of antiplatelet drugs on graft **atherosclerosis** in rat heterotopic cardiac allografts

AU Muskett, A.; Burton, N. A.; Eichwald, E. J.; Shelby, J.; Hendrickson, M.; Sullivan, J. J.

CS Sch. Med., Univ. Utah, Salt Lake City, UT, USA
 SO Transplantation Proceedings (1987), 19(4, Suppl. 5), 74-6
 CODEN: TRPPA8; ISSN: 0041-1345
 DT Journal
 LA English

L14 ANSWER 166 OF 196 CAPLUS COPYRIGHT 2002 ACS
 AN 1987:451201 CAPLUS
 DN 107:51201
 TI The role of arachidonic acid metabolites in cardiovascular homeostasis.
 Biochemical, histological and clinical cardiovascular effects of
 non-steroidal anti-inflammatory drugs and their interactions with
 cardiovascular drugs
 AU Goodman, DeWitt S.
 CS Coll. Physicians Surg., Columbia Univ., New York, NY, 10032, USA
 SO Drugs (1987), 33(Suppl. 1), 47-55
 CODEN: DRUGAY; ISSN: 0012-6667
 DT Journal; General Review
 LA English

L14 ANSWER 167 OF 196 CAPLUS COPYRIGHT 2002 ACS
 AN 1987:432862 CAPLUS
 DN 107:32862
 TI Surprising effects of the sequential administration of pentoxifylline and
 low dose acetylsalicylic acid on thrombus formation
 AU Seiffge, Dirk; Weithmann, K. Ulrich
 CS Hoechst A.-G., Wiesbaden, 6200/12, Fed. Rep. Ger.
 SO Thrombosis Research (1987), 46(2), 371-83
 CODEN: THBRAA; ISSN: 0049-3848
 DT Journal
 LA English

L14 ANSWER 168 OF 196 CAPLUS COPYRIGHT 2002 ACS
 AN 1987:18881 CAPLUS
 DN 106:18881
 TI Triterpenyl esters of organic acids and hypolipemic agents composed of
 them
 IN Kimura, Goro; Hirose, Yoshihiko; Yoshida, Kumi; Kuzuya, Fumio; Fujita,
 Katsunari
 PA Amano Pharmaceutical Co., Ltd., Japan
 SO Eur. Pat. Appl., 260 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 166542	A2	19860102	EP 1985-303839	19850530
	EP 166542	A3	19860709		
	EP 166542	B1	19900808		
	R: BE, CH, DE, FR, GB, IT, LI, NL, SE				
	JP 60258198	A2	19851220	JP 1984-115306	19840604
	JP 01040040	B4	19890824		
	JP 60258119	A2	19851220	JP 1984-115307	19840604
	JP 01040014	B4	19890824		
	JP 61243099	A2	19861029	JP 1985-85254	19850419
	JP 05033713	B4	19930520		
	JP 61243022	A2	19861029	JP 1985-85255	19850419
	CA 1265785	A1	19900213	CA 1985-481808	19850517
	AU 8543130	A1	19851212	AU 1985-43130	19850530
	AU 598724	B2	19900705		
	US 4748161	A	19880531	US 1985-739183	19850530

	FI 8502216	A	19851205	FI 1985-2216	19850603
	DK 8502469	A	19851205	DK 1985-2469	19850603
	NO 8502246	A	19851205	NO 1985-2246	19850603
	SU 1538892	A3	19900123	SU 1985-3913136	19850603
	ES 544466	A1	19870701	ES 1985-544466	19850604
	CN 85109752	A	19861217	CN 1985-109752	19851220
	US 4748161	B1	19911015	US 1990-90001980	19900404
PRAI	JP 1984-115306		19840604		
	JP 1984-115307		19840604		
	JP 1985-85254		19850419		
	JP 1985-85255		19850419		
	JP 1984-115406		19840604		
	US 1985-739183		19850530		
L14	ANSWER 169 OF 196 CAPLUS COPYRIGHT 2002 ACS				
AN	1984:483760 CAPLUS				
DN	101:83760				
TI	Effect of antiplatelet therapy on restenosis after experimental angioplasty				
AU	Faxon, David P.; Sanborn, Timothy A.; Haudenschild, Christian C.; Ryan, Thomas J.				
CS	Univ. Hosp., Boston Univ., Boston, MA, 02118, USA				
SO	American Journal of Cardiology (1984), 53(12), 72-6				
	CODEN: AJCDAG; ISSN: 0002-9149				
DT	Journal				
LA	English				
L14	ANSWER 170 OF 196 CAPLUS COPYRIGHT 2002 ACS				
AN	1984:207791 CAPLUS				
DN	100:207791				
TI	Cyclical abnormalities in the bactericidal function, superoxide production, and lysozyme activity of neutrophils obtained from a healthy woman during menstruation: reversal by pretreatment with aspirin				
AU	Berger, Elaine M.; Harada, Ruth N.; Vatter, Albert E.; Bowman, C. Michael; Repine, John E.				
CS	Health Sci. Cent., Univ. Colorado, Denver, CO, 80262, USA				
SO	Journal of Infectious Diseases (1984), 149(3), 413-19				
	CODEN: JIDIAQ; ISSN: 0022-1899				
DT	Journal				
LA	English				
L14	ANSWER 171 OF 196 CAPLUS COPYRIGHT 2002 ACS				
AN	1984:96410 CAPLUS				
DN	100:96410				
TI	Effect of various doses of aspirin on the development of experimental atherosclerosis				
AU	Berisha, Sali; Bocari, Gezim; Santo, Arben; Hasa, Donika				
CS	Univ. Tiranes, Tiranes, Albania				
SO	Buletin i Universitetit te Tiranes Enver Hoxha, Seria Shkencat Mjekesore (1983), 23(2), 103-8				
	CODEN: BUMJD5; ISSN: 0379-7643				
DT	Journal				
LA	Albanian				
L14	ANSWER 172 OF 196 CAPLUS COPYRIGHT 2002 ACS				
AN	1983:520209 CAPLUS				
DN	99:120209				
TI	Experimental studies on the mechanism of thrombus formation in hyperlipidemic and atherosclerotic rabbits				
AU	Suehiro, Akira				
CS	Dep. Intern. Med., Hyogo Coll. Med., Nishinomiya, 663, Japan				
SO	Hyogo Ika Daigaku Igakkai Zasshi (1982), 7(2), 77-90				

CODEN: HIDZDO; ISSN: 0385-7638

DT Journal
LA Japanese

L14 ANSWER 173 OF 196 CAPLUS COPYRIGHT 2002 ACS

AN 1983:482313 CAPLUS

DN 99:82313

TI Anti-proliferative effect of pyridinolcarbamate and of aspirin in the early stages of atherogenesis in swine

AU Kim, D. N.; Lee, K. T.; Schmee, J.; Thomas, W. A.

CS Dep. Pathol., Albany Med. Coll., Albany, NY, 12208, USA

SO Atherosclerosis (Shannon, Ireland) (1983), 48(1), 1-13

CODEN: ATHSBL; ISSN: 0021-9150

DT Journal
LA English

L14 ANSWER 174 OF 196 CAPLUS COPYRIGHT 2002 ACS

AN 1983:416261 CAPLUS

DN 99:16261

TI Experimental evaluation of venosclerosis of aortocoronary femoral vein bypass graft in control and aspirin-persantine-treated dogs: correlation with **atherosclerosis**

AU Dewanjee, Mrinal K.

CS Radiopharm. Lab., Mayo Clin., Rochester, MN, USA

SO Radiat. Cell. Response, Rep. John Lawrence Interdiscip. Symp. Phys. Biomed. Sci., 2nd (1983), Meeting Date 1981, 61-82. Editor(s): Scott, George P.; Wahner, Heinz W. Publisher: Iowa State Univ. Press, Ames, Iowa. CODEN: 49OAAH

DT Conference
LA English

L14 ANSWER 175 OF 196 CAPLUS COPYRIGHT 2002 ACS

AN 1982:538426 CAPLUS

DN 97:138426

TI Prevention of lipid accumulation in experimental vein bypass grafts by antiplatelet therapy

AU Bonchek, Lawrence I.; Boerboom, Lawrence E.; Olinger, Gordon N.; Pepper, John R.; Munns, James; Hutchinson, Lawrence; Kissebah, Ahmed H.

CS Dep. Cardiothor. Surgery Med., Med. Coll. Wisconsin, Milwaukee, WI, USA

SO Circulation (1982), 66(2), 338-41

CODEN: CIRCAZ; ISSN: 0009-7322

DT Journal
LA English

L14 ANSWER 176 OF 196 CAPLUS COPYRIGHT 2002 ACS

AN 1982:210581 CAPLUS

DN 96:210581

TI Comparison of the effects of aspirin and indomethacin on aortic atherogenesis induced in rabbits

AU Jouve, Remy; Juhan-Vague, Irene; Aillaud, Marie Françoise; Serment-Jouve, Marie Pierre; Payan, Henri

CS Sch. Med., Univ. Marseille, Marseille, Fr.

SO Atherosclerosis (Shannon, Ireland) (1982), 42(2-3), 319-21

CODEN: ATHSBL; ISSN: 0021-9150

DT Journal
LA English

L14 ANSWER 177 OF 196 CAPLUS COPYRIGHT 2002 ACS

AN 1982:155256 CAPLUS

DN 96:155256

TI Effect of aspirin on cholesterol-induced platelet activation in rabbits

AU Splawinski, J.; Corell, T.; Hasselmann, G.; Mruk, J.

CS Dep. Pharmacol., Dumex, Copenhagen, DK-2300, Den.
SO Thrombosis Research (1982), 25(1-2), 155-61
CODEN: THBRAA; ISSN: 0049-3848
DT Journal
LA English

L14 ANSWER 178 OF 196 CAPLUS COPYRIGHT 2002 ACS
AN 1982:155205 CAPLUS
DN 96:155205
TI The effect of low-dose aspirin and dipyridamole upon
atherosclerosis in the rabbit
AU Koster, J. K., Jr.; Tryka, A. F.; H'Doubler, P.; Collins, J. J., Jr.
CS Dep. Surg., Harvard Med. Sch., Boston, MA, 02115, USA
SO Artery (Fulton, MI, United States) (1981), 9(6), 405-13
CODEN: ARTEDR; ISSN: 0098-6127
DT Journal
LA English

L14 ANSWER 179 OF 196 CAPLUS COPYRIGHT 2002 ACS
AN 1982:135752 CAPLUS
DN 96:135752
TI Enhancement of experimental **atherosclerosis** by aspirin
AU Debons, Albert F.; Fani, Kazem; Jimenez, Fidelio A.
CS VA Med. Cent., State University New York, Brooklyn, NY, USA
SO Journal of Toxicology and Environmental Health (1981), 8(5-6), 899-906, 1
plate
CODEN: JTEHD6; ISSN: 0098-4108
DT Journal
LA English

L14 ANSWER 180 OF 196 CAPLUS COPYRIGHT 2002 ACS
AN 1982:46039 CAPLUS
DN 96:46039
TI Evaluation of the effect of acetylsalicylic acid on the thromboplastin
activity of human erythrocytes
AU Ashkinazi, I. Ya.
CS USSR
SO Deposited Doc. (1980), VINITI 3752-80, 14 pp. Avail.: VINITI
DT Report
LA Russian

L14 ANSWER 181 OF 196 CAPLUS COPYRIGHT 2002 ACS
AN 1981:597384 CAPLUS
DN 95:197384
TI Endothelial damage induced by polyethylene catheter in the rat
AU Vilageliu, J.; Arano, A.; Bruseghini, L.
CS Spain
SO Methods and Findings in Experimental and Clinical Pharmacology (1981),
3(5), 279-81
CODEN: MFEPDX; ISSN: 0379-0355
DT Journal
LA English

L14 ANSWER 182 OF 196 CAPLUS COPYRIGHT 2002 ACS
AN 1981:564988 CAPLUS
DN 95:164988
TI Studies of human platelet .alpha.-granule release in vivo
AU Files, Joe C.; Malpass, Thomas W.; Yee, Esther K.; Ritchie, James L.;
Harker, Laurence A.
CS Sch. Med., Univ. Washington, Seattle, WA, USA
SO Blood (1981), 58(3), 607-18
CODEN: BLOOAW; ISSN: 0006-4971

DT Journal
LA English


L14 ANSWER 183 OF 196 CAPLUS COPYRIGHT 2002 ACS
AN 1981:490646 CAPLUS
DN 95:90646
TI The effect of platelet regulatory drugs in experimental models of thrombosis, **atherosclerosis** and myocardial ischemia
AU White, A. M.; Butler, K. D.
CS Ciba-Geigy Pharm. Div., Horsham/West Sussex, RH12 4 AB, UK
SO Clin. Pharmacol. Ther. Proc. Plenary Lect., Symp. Ther. Sess. World Conf., 1st (1980), 213-23. Editor(s): Turner, Paul. Publisher: Macmillan, London, Engl.
CODEN: 46BIAN
DT Conference; General Review
LA English

L14 ANSWER 184 OF 196 CAPLUS COPYRIGHT 2002 ACS
AN 1981:400037 CAPLUS
DN 95:37
TI AAS and Anturan: their effects on the clinical complications of **atherosclerosis**
AU Packhama, M. A.; Mustard, J. F.
CS Dep. Biochim., Univ. Toronto, Toronto, ON, Can.
SO Medecine Moderne du Canada (1981), 36(4), 453-8
CODEN: MMCNAT; ISSN: 0025-6803
DT Journal; General Review
LA French

L14 ANSWER 185 OF 196 CAPLUS COPYRIGHT 2002 ACS
AN 1981:167566 CAPLUS
DN 94:167566
TI A new approach to the treatment of **atherosclerosis** and trapidil as an antagonist to platelet-derived growth factor
AU Ohnishi, H.; Yamaguchi, K.; Shimada, S.; Suzuki, Y.; Kumagai, A.
CS Tokyo Res. Lab., Mochida Pharm. Co., Ltd., Tokyo, 115, Japan
SO Life Sciences (1981), 28(14), 1641-6
CODEN: LIFSAK; ISSN: 0024-3205
DT Journal
LA English

L14 ANSWER 186 OF 196 CAPLUS COPYRIGHT 2002 ACS
AN 1981:96215 CAPLUS
DN 94:96215
TI Platelets, sulfinpyrazone and organ graft rejection
AU Jamieson, Stuart W.; Burton, Nelson A.; Reitz, Bruce A.
CS Dep. Cardiovasc. Surg., Stanford Univ. Hosp., Stanford, CA, USA
SO Cardiovasc. Actions Sulfinpyrazone: Basic Clin. Res., Proc. Int. Symp. (1980), Meeting Date 1979, 229-47. Editor(s): McGregor, Maurice; Mustard, J. Fraser; Oliver, Michael F. Publisher: Symp. Spec., Miami, Fla.
CODEN: 45CDA6
DT Conference
LA English

L14 ANSWER 187 OF 196 CAPLUS COPYRIGHT 2002 ACS
AN 1981:58302 CAPLUS
DN 94:58302
TI The effect of acetylsalicylic acid (ASA) on the development of atherosclerotic lesions in miniature swine
AU Clopath, P.
CS Pharm. Div., CIBA-GEIGY Ltd., Basel, CH-4002, Switz.
SO British Journal of Experimental Pathology (1980), 61(4), 440-3



CODEN: BJEPAS; ISSN: 0007-1021

DT Journal
LA English

L14 ANSWER 188 OF 196 CAPLUS COPYRIGHT 2002 ACS

AN 1979:413847 CAPLUS

DN 91:13847

TI Aspirin inhibits development of coronary **atherosclerosis** in cynomolgus monkeys (*Macaca fascicularis*) fed an atherogenic diet

AU Pick, Ruth; Chediak, Juan; Glick, Gerald

CS Cardiovasc. Inst., Michael Reese Hosp., Chicago, IL, 60616, USA

SO J. Clin. Invest. (1979), 63(1), 158-62

CODEN: JCINAO; ISSN: 0021-9738

DT Journal
LA English

L14 ANSWER 189 OF 196 CAPLUS COPYRIGHT 2002 ACS

AN 1979:180165 CAPLUS

DN 90:180165

TI Studies on the progression and regression of coronary and peripheral **atherosclerosis** in the cynomolgus monkey. I. Effects of dipyridamole and aspirin

AU Hollander, William; Kirkpatrick, Barbara; Paddock, John; Colombo, Marilyn; Nagraj, Siva; Prusty, Somnath

CS Med. Cent., Boston Univ., Boston, Mass., USA

SO Exp. Mol. Pathol. (1979), 30(1), 55-73

CODEN: EXMPA6; ISSN: 0014-4800

DT Journal
LA English

L14 ANSWER 190 OF 196 CAPLUS COPYRIGHT 2002 ACS

AN 1979:145804 CAPLUS

DN 90:145804

TI Anti-inflammatory drugs in experimental **atherosclerosis**. Part 4. Inhibition of **atherosclerosis** in vivo and thromboxane synthesis and platelet aggregation in vitro

AU Bailey, J. Martyn; Makheja, A. N.; Butler, Jean; Salata, K.

CS Sch. Med. Health Sci., George Washington Univ., Washington, D. C., USA

SO Atherosclerosis (Shannon, Irel.) (1979), 32(2), 195-203

CODEN: ATHSBL; ISSN: 0021-9150

DT Journal
LA English

L14 ANSWER 191 OF 196 CAPLUS COPYRIGHT 2002 ACS

AN 1977:527635 CAPLUS

DN 87:127635

TI The possible antithromboplastic effect of aspirin. Preliminary communication

AU Dincol, Koray; Ozkan, Emir; Oner, Adil; Okur, Omer; Ekmekci, Ali; Buyukozturk, Kemalettin; Ozcan, Remzi

CS Dep. Intern. Med., Istanbul Fac. Med., Istanbul, Turk.

SO Med. Bull. Istanbul Med. Fac. (Istanbul Univ.) (1976), 9(1), 11-15

CODEN: MBIFDT

DT Journal
LA English

L14 ANSWER 192 OF 196 CAPLUS COPYRIGHT 2002 ACS

AN 1977:187267 CAPLUS

DN 86:187267

TI Platelet and fibrinogen survival in coronary **atherosclerosis**. Response to medical and surgical therapy

AU Ritchie, James L.; Harker, Laurence A.

CS Sch. Med., Univ. Washington, Seattle, Wash., USA
SO Am. J. Cardiol. (1977), 39(4), 595-8
CODEN: AJCDAG
DT Journal
LA English

L14 ANSWER 193 OF 196 CAPLUS COPYRIGHT 2002 ACS
AN 1975:93102 CAPLUS
DN 82:93102
TI Suppression of atheromatous fibrous plaque formation by antiproliferative and antiinflammatory drugs
AU Hollander, William; Kramsch, Dieter M.; Franzblau, Carl; Paddock, John; Colombo, Marilyn A.
CS Med. Cent., Boston Univ., Boston, Mass., USA
SO Circ. Res., Suppl. (1974), 34(5, Suppl. 1), 131-41
CODEN: CIRSAF
DT Journal
LA English

L14 ANSWER 194 OF 196 CAPLUS COPYRIGHT 2002 ACS
AN 1974:534149 CAPLUS
DN 81:134149
TI Arterial and venous thromboembolism. Kinetic characterization and evaluation of therapy
AU Harker, Laurence A.; Slichter, Sherrill J.
CS Sch. Med., Univ. Washington, Seattle, Wash., USA
SO Thromb. Diath. Haemorrh. (1974), 31(2), 188-203
CODEN: TDHAAT
DT Journal
LA English

L14 ANSWER 195 OF 196 CAPLUS COPYRIGHT 2002 ACS
AN 1973:500515 CAPLUS
DN 79:100515
TI Antiinflammatory drugs in experimental **atherosclerosis**. 1. Relative potencies for inhibiting plaque formation
AU Bailey, J. Martyn; Butler, Jean
CS Sch. Med., George Washington Univ., Washington, DC, USA
SO Atherosclerosis (1973), 17(3), 515-22
CODEN: ATHSBL
DT Journal
LA English

L14 ANSWER 196 OF 196 CAPLUS COPYRIGHT 2002 ACS
AN 1967:9364 CAPLUS
DN 66:9364
TI Influence of antiinflammatory agents on experimental **atherosclerosis**
AU Bailey, John Martyn; Butler, Jean
CS Sch. of Med., George Washington Univ., Washington, D. C., USA
SO Nature (London) (1966), 212(5063), 731-2
CODEN: NATUAS
DT Journal
LA English

=> s 14

L15 50997 L4

=> s 115 and 110

L16 327 L15 AND L10

=> d 116 300-327

L16 ANSWER 300 OF 327 CAPLUS COPYRIGHT 2002 ACS

AN 1976:162877 CAPLUS

DN 84:162877

TI Physiologically active compounds

IN Endo, Akira; Kuroda, Masao; Tsujita, Yoshio; Terahara, Akira; Tamura, Chihiro

PA Sankyo Co., Ltd., Japan

SO Ger. Offen., 23 pp.

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2524355	A1	19751218	DE 1975-2524355	19750602
	DE 2524355	C2	19830721		
	JP 50155690	A2	19751216	JP 1974-64823	19740607
	JP 56012114	B4	19810318		
	GB 1453425	A	19761020	GB 1975-23035	19750523
	SE 7506498	A	19751208	SE 1975-6498	19750606
	SE 425253	B	19820913		
	SE 425253	C	19821230		
	DK 7502553	A	19751208	DK 1975-2553	19750606
	DK 136485	B	19771017		
	AT 7504304	A	19771015	AT 1975-4304	19750606
	FR 2313035	B1	19781110	FR 1975-17687	19750606
	FR 2313035	A1	19761231		
	CA 1046439	A1	19790116	CA 1975-228761	19750606
	BE 830033	A1	19751209	BE 1975-157165	19750609
	NL 7506848	A	19751209	NL 1975-6848	19750609
	NL 176872	B	19850116		
	NL 176872	C	19850617		
	US 4049495	A	19770920	US 1975-637673	19751204
PRAI	JP 1974-64823		19740607		
	US 1975-576651		19750512		

L16 ANSWER 301 OF 327 CAPLUS COPYRIGHT 2002 ACS

AN 1975:512072 CAPLUS

DN 83:112072

TI Significant role of adrenaline and noradrenaline in thrombogenesis and myocardial infarction. Experimental studies in rhesus monkeys

AU Chakravarti, R. N.

CS Dep. Exp. Med., Post-Grad. Inst. Med. Educ. Res., Chandigarh, India

SO Proc. Asia Oceania Congr. Endocrinol., 5th (1974), Volume 2, 518-30.

Editor(s): Rastogi, G. K. Publisher: Endocr. Soc. India, Chandigarh, India.

CODEN: 30KMAT

DT Conference

LA English

L16 ANSWER 302 OF 327 CAPLUS COPYRIGHT 2002 ACS

AN 1975:81043 CAPLUS

DN 82:81043

TI Role of extra- and intracellular coagulation in **atherosclerosis** development

AU Kuznik, B. I.; Rusyaev, V. F.; Kuchuk, V. M.

CS Chit. Med. Inst., Chita, USSR

SO Kardiologiya (1974), 14(11), 66-72

CODEN: KARDA2

DT Journal

LA Russian

L16 ANSWER 303 OF 327 CAPLUS COPYRIGHT 2002 ACS
 AN 1974:503560 CAPLUS
 DN 81:103560
 TI Influence of nicotinic acid on quantitative lactate dehydrogenase and glucose-6-phosphate dehydrogenase changes in the blood and tissues of rats subjected to an experimental atherogenic diet
 AU Leporda, Gh.; Haler, Constanta; Freund, S.; Zilberman, Lucia
 CS Inst. Sanatate Publica si Cercet. Med., Iasi, Rom.
 SO Rev. Med.-Chir. (1974), 78(1), 105-9
 CODEN: RMNIBN
 DT Journal
 LA Romanian

L16 ANSWER 304 OF 327 CAPLUS COPYRIGHT 2002 ACS
 AN 1973:533131 CAPLUS
 DN 79:133131
 TI Reaction of the vascular wall to biogenic amines in experimentally induced **atherosclerosis**
 AU Trinus, F. P.
 CS Kiev Res. Inst. Pharmacol. Toxicol., Kiev, USSR
 SO Byull. Eksp. Biol. Med. (1973), 76(8), 30-2
 CODEN: BEBMAE
 DT Journal
 LA Russian

L16 ANSWER 305 OF 327 CAPLUS COPYRIGHT 2002 ACS
 AN 1973:461722 CAPLUS
 DN 79:61722
 TI Biochemical and morphological alterations induced by long-term administration of epinephrine, metanephrine, and thyroxine in rats
 AU Trzeciak, Henryk I.
 CS Dep. Pharmacol., Silesian Sch. Med., Zabrze, Pol.
 SO Toxicol. Appl. Pharmacol. (1973), 25(3), 315-22
 CODEN: TXAPA9
 DT Journal
 LA English

L16 ANSWER 306 OF 327 CAPLUS COPYRIGHT 2002 ACS
 AN 1973:119379 CAPLUS
 DN 78:119379
 TI Effect of pyridinol carbamate on rat adipose tissue free fatty acids
 AU Grafnetter, D.; Shimamoto, T.; Numano, F.
 CS Div. Cardiovasc. Dis., Inst. Clin. Exp. Med., Prague, Czech.
 SO Atherosclerosis (1972), 16(2), 185-91
 CODEN: ATHSBL
 DT Journal
 LA English

L16 ANSWER 307 OF 327 CAPLUS COPYRIGHT 2002 ACS
 AN 1972:547651 CAPLUS
 DN 77:147651
 TI Influence of experimental **atherosclerosis** and various vasoactive drugs on cerebrospinal fluid pressure in rabbits
 AU Cohen, I.; Levinger, I. M.; Herzberg, M.
 CS Dep. Life Sci., Bar-Ilan Univ., Ramat Gan, Israel
 SO Confin. Neurol. (1971), 33(6), 334-41
 CODEN: CONEAT
 DT Journal
 LA English

L16 ANSWER 308 OF 327 CAPLUS COPYRIGHT 2002 ACS
 AN 1972:428896 CAPLUS
 DN 77:28896
 TI Effect of catechol amines on coronary blood circulation during experimental renal-steroid and renal-salt hypertonia, and **atherosclerosis**
 AU Khomazyuk, A. I.; Neshcheret, A. P.; Yavorskii, L. A.; Zaritskii, G. V.
 CS Kiev, USSR
 SO Fiziol., Biokhim. Patol. Endokr. Sist. (1971), No. 1, 33-5
 CODEN: FBPEAF
 DT Journal
 LA Russian

L16 ANSWER 309 OF 327 CAPLUS COPYRIGHT 2002 ACS
 AN 1972:81105 CAPLUS
 DN 76:81105
 TI Antiatherosclerotic agents. 6. Effect of 1,3-propanediol bis(.alpha.-p-chlorophenoxyisobutyrate) (simfibrate) on lipolysis
 AU Nakanishi, Michio; Kobayakawa, Toshihiro; Yasuda, Hiroshi; Okada, Tadao
 CS Res. Lab., Yoshitomi Pharm. Ind., Ltd., Fukuoka, Japan
 SO Oyo Yakuri (1970), 4(5), 761-5
 CODEN: OYYAA2
 DT Journal
 LA Japanese

L16 ANSWER 310 OF 327 CAPLUS COPYRIGHT 2002 ACS
 AN 1972:44374 CAPLUS
 DN 76:44374
 TI Hormones, arterial wall, and atherosclerotic involvement. I. Catecholamines
 AU Velican, C.
 CS "N. Gh. Lupu" Inst. Intern. Med., Bucharest, Rom.
 SO Rev. Roum. Endocrinol. (1971), 8(3), 195-206
 CODEN: RRENAR
 DT Journal; General Review
 LA English

L16 ANSWER 311 OF 327 CAPLUS COPYRIGHT 2002 ACS
 AN 1971:74133 CAPLUS
 DN 74:74133
 TI Dynamics of changes of lipid and monoamine metabolism and the blood coagulating system during experimental **atherosclerosis** caused by restriction of movement
 AU Gvishiani, G. S.; Kobakhidze, N. G.
 CS USSR
 SO Soobshch. Akad. Nauk Gruz. SSR (1970), 60(2), 445-7
 CODEN: SAKNAH
 DT Journal
 LA Georgian

L16 ANSWER 312 OF 327 CAPLUS COPYRIGHT 2002 ACS
 AN 1971:40530 CAPLUS
 DN 74:40530
 TI Cardiovascular reactions in old animals with experimental **atherosclerosis**
 AU Kostyuk, L. V.; Cherkasskii, L. P.
 CS Kiev, USSR
 SO Starenie Fiziol. Sist. Organizma, Tr. Vses. Konf. Gerontol. Geriat., 2nd (1969), 79-85. Editor(s): Chebotarev, D. F. Publisher: Inst. Gerontol., Akad. Med. Nauk SSSR, Kiev, USSR.
 CODEN: 22NSAT
 DT Conference

AN 1967:9364 CAPLUS
 DN 66:9364
 TI Influence of antiinflammatory agents on experimental atherosclerosis
 AU Bailey, John Martyn; Butler, Jean
 CS Sch. of Med., George Washington Univ., Washington, DC, USA
 SO Nature (London, United Kingdom) (1966), 212(5063), 731-2
 CODEN: NATUAS; ISSN: 0028-0836
 DT Journal
 LA English
 CC 12 (Mammalian Pathological Biochemistry)
 AB Daily supplements of cholesterol (1 g.) in rabbit diets increased plasma lipid concns. 10-20-fold and induced atherosclerotic plaques in the thoracic aortas within 12 weeks. The addn. of 1 or 5 mg. of cortisone acetate (I) to rabbit diets contg. cholesterol increased plasma lipids, but reduced the development of atherosclerotic plaques by about 75%. Phenylbutazone (100 mg. daily) decreased plaque formation; 44% of the animals developed no plaques at all. The phenylbutazone-induced decreased plaque formations did not alter serum lipid patterns. The severity of atherosclerosis in animals treated with 100 mg. of aminopyrine was slightly less than in the controls; plasma cholesterol was considerably lower. Vitamin C (100 mg.) produced no decrease in the no. of plaques, and acetyl salicylate increased the incidence of atherosclerosis 17.1%. Rabbits fed a diet contg. 1% cholesterol for 12 weeks produced extensive plaques which did not regress during the following 12 weeks on a cholesterol-free diet, with or without daily supplementation with 5 mg. of I, indicating that I acts in the early stages of plaque formation through its antiinflammatory properties rather than through its lipemic effects.
 ST LIPIDS ATHEROSCLEROSIS; ANTIINFLAMMATORIES ATHEROSCLEROSIS; CORTISONE ATHEROSCLEROSIS; ATHEROSCLEROSIS CORTISONE; STEROIDS ATHEROSCLEROSIS; CORTISONE ATHEROSCLEROSIS; ATHEROSCLEROSIS CORTISONE; LIPIDS ATHEROSCLEROSIS; ANTIINFLAMMATORIES ATHEROSCLEROSIS; STEROIDS ATHEROSCLEROSIS
 IT Lipids
 RL: BIOL (Biological study)
 (in blood plasma, inflammation inhibitor effect on)
 IT Atherosclerosis
 (inflammation inhibitor effect on)
 IT 50-78-2, biological studies
 RL: BIOL (Biological study)
 (atherosclerosis in response to)
 IT 50-04-4 50-33-9 58-15-1
 RL: BIOL (Biological study)
 (atherosclerosis in response to)

=>

AN 1967:9364 CAPLUS
 DN 66:9364
 TI Influence of antiinflammatory agents on experimental atherosclerosis
 AU Bailey, John Martyn; Butler, Jean
 CS Sch. of Med., George Washington Univ., Washington, DC, USA
 SO Nature (London, United Kingdom) (1966), 212(5063), 731-2
 CODEN: NATUAS; ISSN: 0028-0836
 DT Journal
 LA English
 CC 12 (Mammalian Pathological Biochemistry)
 AB Daily supplements of cholesterol (1 g.) in rabbit diets increased plasma lipid concns. 10-20-fold and induced atherosclerotic plaques in the thoracic aortas within 12 weeks. The addn. of 1 or 5 mg. of cortisone acetate (I) to rabbit diets contg. cholesterol increased plasma lipids, but reduced the development of atherosclerotic plaques by about 75%. Phenylbutazone (100 mg. daily) decreased plaque formation; 44% of the animals developed no plaques at all. The phenylbutazone-induced decreased plaque formations did not alter serum lipid patterns. The severity of atherosclerosis in animals treated with 100 mg. of aminopyrine was slightly less than in the controls; plasma cholesterol was considerably lower. Vitamin C (100 mg.) produced no decrease in the no. of plaques, and acetyl salicylate increased the incidence of atherosclerosis 17.1%. Rabbits fed a diet contg. 1% cholesterol for 12 weeks produced extensive plaques which did not regress during the following 12 weeks on a cholesterol-free diet, with or without daily supplementation with 5 mg. of I, indicating that I acts in the early stages of plaque formation through its antiinflammatory properties rather than through its lipemic effects.
 ST LIPIDS ATHEROSCLEROSIS; ANTIINFLAMMATORIES ATHEROSCLEROSIS; CORTISONE ATHEROSCLEROSIS; ATHEROSCLEROSIS CORTISONE; STEROIDS ATHEROSCLEROSIS; CORTISONE ATHEROSCLEROSIS; ATHEROSCLEROSIS CORTISONE; LIPIDS ATHEROSCLEROSIS; ANTIINFLAMMATORIES ATHEROSCLEROSIS; STEROIDS ATHEROSCLEROSIS
 IT Lipids
 RL: BIOL (Biological study)
 (in blood plasma, inflammation inhibitor effect on)
 IT Atherosclerosis
 (inflammation inhibitor effect on)
 IT 50-78-2, biological studies
 RL: BIOL (Biological study)
 (atherosclerosis in response to)
 IT 50-04-4 50-33-9 58-15-1
 RL: BIOL (Biological study)
 (atherosclerosis in response to)

=>

AN 1979:145804 CAPLUS
 DN 90:145804
 TI Anti-inflammatory drugs in experimental **atherosclerosis**. Part
 4. Inhibition of **atherosclerosis** in vivo and thromboxane
 synthesis and platelet aggregation in vitro
 AU Bailey, J. Martyn; Makheja, A. N.; Butler, Jean; Salata, K.
 CS Sch. Med. Health Sci., George Washington Univ., Washington, DC, USA
 SO Atherosclerosis (Shannon, Ireland) (1979), 32(2), 195-203
 CODEN: ATHSBL; ISSN: 0021-9150
 DT Journal
 LA English
 CC 1-5 (Pharmacodynamics)
 Section cross-reference(s): 14
 AB Groups of New Zealand white male rabbits were fed atherogenic diets
 contg. 1% cholesterol. The diets of exptl. groups were supplemented
 addnl. with either aspirin [50-78-2], phenylbutazone
 [50-33-9], mefenamic acid [61-68-7], flufenamic acid [530-78-9],
 oxyphenylbutazone [129-20-4] or aminopyrine [58-15-1]. Blood
 cholesterol and phospholipids were measured at 3-4 wk intervals. After 12
 wk the animals were sacrificed and the severity of **atherosclerosis**
 in the thoracic aorta was measured. In sep. expts., rabbit platelets were
 incubated with each of the drugs individually and conversion of
 [14C]arachidonic acid to thromboxanes and related compds. was assayed.
 Inhibition of collagen and arachidonic acid-induced platelet aggregation
 by each drug was also measured. All drugs inhibited thromboxane synthesis
 and platelet aggregation in varying degrees with flufenamate and aspirin
 being most and aminopyrine least effective. The pattern of metabolite
 formation from [14C]arachidonate was consistent with a block in the
 cyclooxygenase reaction. Phenylbutazone, flufenamic acid, and
 oxyphenylbutazone produced significant redns. in atherosclerotic plaque
 formation without major changes in blood cholesterol levels or blood
 cholesterol-phospholipid ratios. Aspirin and aminopyrine were
 ineffective. The effectiveness of antiinflammatory drugs as inhibitors of
 thromboxane synthesis and platelet aggregation in vitro does not appear to
 afford a sufficient predictive index of their antiatherogenicity in vivo.
 The significance of these findings is discussed in terms of the possible
 involvement of cyclooxygenase derivs. in atherogenesis.
 ST inflammation inhibitor **atherosclerosis** thromboxane; blood
 platelet antiinflammatory drug
 IT Blood platelet
 (aggregation of, inflammation inhibitors inhibition of,
 antiatherogenicity in relation to)
 IT Thromboxanes
 RL: FORM (Formation, nonpreparative)
 (formation of, inflammation inhibitors inhibition of,
 antiatherogenicity in relation to)
 IT **Atherosclerosis**
 (inflammation inhibitors effect on, platelet aggregation and
 thromboxane formation inhibition in relation to)
 IT Inflammation inhibitors
 (platelet aggregation and thromboxane formation inhibition by,
 antiatherogenicity in relation to)
 IT 50-33-9, biological studies 50-78-2 58-15-1 61-68-7
 129-20-4 530-78-9
 RL: BIOL (Biological study)
 (platelet aggregation and thromboxane formation inhibition by,
 antiatherogenicity in relation to)

AN 1979:145804 CAPLUS
 DN 90:145804
 TI Anti-inflammatory drugs in experimental **atherosclerosis**. Part
 4. Inhibition of **atherosclerosis** in vivo and thromboxane
 synthesis and platelet aggregation in vitro
 AU Bailey, J. Martyn; Makheja, A. N.; Butler, Jean; Salata, K.
 CS Sch. Med. Health Sci., George Washington Univ., Washington, DC, USA
 SO Atherosclerosis (Shannon, Ireland) (1979), 32(2), 195-203
 CODEN: ATHSBL; ISSN: 0021-9150
 DT Journal
 LA English
 CC 1-5 (Pharmacodynamics)
 Section cross-reference(s): 14
 AB Groups of New Zealand white male rabbits were fed atherogenic diets
 contg. 1% cholesterol. The diets of exptl. groups were supplemented
 addnl. with either aspirin [50-78-2], phenylbutazone
 [50-33-9], mefenamic acid [61-68-7], flufenamic acid [530-78-9],
 oxyphenylbutazone [129-20-4] or aminopyrine [58-15-1]. Blood
 cholesterol and phospholipids were measured at 3-4 wk intervals. After 12
 wk the animals were sacrificed and the severity of **atherosclerosis**
 in the thoracic aorta was measured. In sep. expts., rabbit platelets were
 incubated with each of the drugs individually and conversion of
 [14C]arachidonic acid to thromboxanes and related compds. was assayed.
 Inhibition of collagen and arachidonic acid-induced platelet aggregation
 by each drug was also measured. All drugs inhibited thromboxane synthesis
 and platelet aggregation in varying degrees with flufenamate and aspirin
 being most and aminopyrine least effective. The pattern of metabolite
 formation from [14C]arachidonate was consistent with a block in the
 cyclooxygenase reaction. Phenylbutazone, flufenamic acid, and
 oxyphenylbutazone produced significant redns. in atherosclerotic plaque
 formation without major changes in blood cholesterol levels or blood
 cholesterol-phospholipid ratios. Aspirin and aminopyrine were
 ineffective. The effectiveness of antiinflammatory drugs as inhibitors of
 thromboxane synthesis and platelet aggregation in vitro does not appear to
 afford a sufficient predictive index of their antiatherogenicity in vivo.
 The significance of these findings is discussed in terms of the possible
 involvement of cyclooxygenase derivs. in atherogenesis.
 ST inflammation inhibitor **atherosclerosis** thromboxane; blood
 platelet antiinflammatory drug
 IT Blood platelet
 (aggregation of, inflammation inhibitors inhibition of,
 antiatherogenicity in relation to)
 IT Thromboxanes
 RL: FORM (Formation, nonpreparative)
 (formation of, inflammation inhibitors inhibition of,
 antiatherogenicity in relation to)
 IT **Atherosclerosis**
 (inflammation inhibitors effect on, platelet aggregation and
 thromboxane formation inhibition in relation to)
 IT Inflammation inhibitors
 (platelet aggregation and thromboxane formation inhibition by,
 antiatherogenicity in relation to)
 IT 50-33-9, biological studies 50-78-2 58-15-1 61-68-7
 129-20-4 530-78-9
 RL: BIOL (Biological study)
 (platelet aggregation and thromboxane formation inhibition by,
 antiatherogenicity in relation to)

CS The Queen's University of Belfast, Belfast, BT9 7BL, UK
SO Journal of Toxicology, Clinical Toxicology (1999), 37(4), 435-440
CODEN: JTCTDW; ISSN: 0731-3810
PB Marcel Dekker, Inc.
DT Journal
LA English
CC 18-3 (Animal Nutrition)
Section cross-reference(s): 1, 4, 63
AB Acetaminophen (paracetamol) poisoning is a major source of morbidity and mortality. It has been proposed that methionine be incorporated into acetaminophen tablets routinely as a protective mechanism. However, there has been some concern that chronic methionine supplementation may be assocd. with vascular disease. The aim of the study was to investigate if methionine supplementation causes changes in endothelial function, plasma homocysteine, or lipid peroxidn. which may be assocd. with **atherosclerosis**, using 16 healthy volunteers. Methionine supplementation did not impair endothelial-dependent vascular responses or increase lipid peroxidn. High-dose (100 mg/kg for 1 wk) supplementation caused elevation of plasma homocysteine, but doses similar to those used in combination prepsns. with acetaminophen did not affect plasma homocysteine concns.
ST methionine **atherosclerosis** acetaminophen toxicity
IT **Atherosclerosis**
(effect of methionine supplementation on endothelial function, plasma homocysteine, and lipid peroxidn. in relation to acetaminophen poisoning)
IT 103-90-2, Acetaminophen
RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(effect of methionine supplementation on endothelial function, plasma homocysteine, and lipid peroxidn. in relation to acetaminophen poisoning)
IT 6027-13-0, Homocysteine
RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence); PROC (Process)
(effect of methionine supplementation on endothelial function, plasma homocysteine, and lipid peroxidn. in relation to acetaminophen poisoning)
IT 63-68-3, L-Methionine, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(effect of methionine supplementation on endothelial function, plasma homocysteine, and lipid peroxidn. in relation to acetaminophen poisoning)
RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Araki, A; J Chromatogr 1987, V422, P43 CAPLUS
(2) Crome, P; Lancet 1976, V2, P829 MEDLINE
(3) Fau, D; J Nutr 1988, V118, P128 CAPLUS
(4) Gorog, P; J Clin Pathol 1991, V44, P765 MEDLINE
(5) Knight, J; Clin Chem 1988, V34, P2433 CAPLUS
(6) Krishnaswamy, K; Atherosclerosis 1977, V27, P253 CAPLUS
(7) McVeigh, G; Diabetologia 1992, V35, P771 MEDLINE
(8) Mrhova, O; Cor Vasa 1988, V30, P73 CAPLUS
(9) Neuvonen, P; Int J Clin Pharmacol Ther Toxicol 1985, V23, P497 CAPLUS
(10) Perry, I; Lancet 1995, V346, P1395 CAPLUS
(11) Renaud, S; Proc Soc Exp Biol Med 1966, V121, P452 CAPLUS
(12) Ross, R; N Engl J Med 1976, V295, P369 MEDLINE
(13) Stampfer, M; JAMA 1992, V268, P877 MEDLINE
(14) Toborek, M; Atherosclerosis 1995, V115, P217 CAPLUS

252016-26-5P	252016-27-6P	252016-28-7P	252016-29-8P	252016-30-1P
252016-31-2P	252016-32-3P	252016-33-4P	252016-34-5P	252016-35-6P
252016-36-7P	252016-37-8P	252016-38-9P	252016-39-0P	252016-40-3P
252016-41-4P	252016-42-5P	252016-43-6P	252016-44-7P	252016-45-8P
252016-46-9P	252016-47-0P	252016-48-1P	252016-49-2P	252016-50-5P
252016-51-6P	252016-52-7P	252016-53-8P	252016-54-9P	252016-55-0P
252016-56-1P	252016-57-2P	252016-58-3P	252016-59-4P	252016-60-7P
252016-61-8P	252016-63-0P	252016-64-1P	252016-65-2P	252016-70-9P
252016-73-2P	252016-74-3P	252016-75-4P	252016-76-5P	252016-77-6P
252016-78-7P	252016-79-8P	252016-80-1P	252016-83-4P	252016-88-9P
252016-89-0P	252016-94-7P	252016-97-0P	252017-01-9P	252017-02-0P
252017-03-1P	252017-04-2P	252017-05-3P	252017-06-4P	252017-07-5P
252017-08-6P	252017-09-7P	252017-10-0P	252017-11-1P	252017-12-2P
252017-13-3P	252017-14-4P	252017-15-5P	252017-16-6P	252017-17-7P
252017-18-8P	252017-19-9P	252017-20-2P	252017-22-4P	252017-24-6P
252017-25-7P	252017-30-4P	252017-31-5P	252017-32-6P	252017-33-7P
252017-34-8P	252017-35-9P	252017-36-0P	252017-37-1P	252017-44-0P
252017-47-3P	252017-48-4P	252017-55-3P	252017-58-6P	252017-69-9P
252017-70-2P	252017-72-4P	252017-73-5P	252017-76-8P	252017-81-5P
252017-82-6P	252017-83-7P	252017-84-8P	252017-85-9P	252017-86-0P
252017-89-3P	252017-90-6P	252017-91-7P	252017-92-8P	252017-93-9P
252017-94-0P	252017-99-5P	252018-00-1P	252018-02-3P	252018-03-4P
252018-04-5P	252018-05-6P	252018-06-7P	252018-07-8P	252018-08-9P
252018-09-0P	252018-10-3P	252018-11-4P	252018-12-5P	

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(target compd.; prepn. of N-(arylsulfonylphenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide derivs. for elevation of pyruvate dehydrogenase (PDH) activity)

IT	252018-13-6P	252018-16-9P	252018-17-0P	252018-18-1P	252018-19-2P
	252018-20-5P	252018-21-6P	252018-35-2P	252018-36-3P	252018-37-4P
	252018-39-6P	252018-40-9P	252018-41-0P	252018-42-1P	252018-43-2P
	252018-44-3P	252018-50-1P	252018-51-2P	252018-52-3P	252018-53-4P
	252018-54-5P	252018-55-6P	252018-56-7P	252018-57-8P	252018-58-9P
	252018-59-0P	252018-60-3P	252018-61-4P	252018-62-5P	252018-63-6P
	252018-64-7P	252018-65-8P	252018-66-9P	252018-67-0P	252018-68-1P
	252018-69-2P	252018-70-5P	252018-71-6P	252018-72-7P	252018-73-8P
	252018-74-9P	252018-76-1P	252018-77-2P	252018-78-3P	252018-79-4P
	252018-80-7P	252018-81-8P	252018-83-0P	252018-86-3P	252018-89-6P
	252018-92-1P	252018-97-6P	252018-99-8P	252019-03-7P	252019-14-0P
	252019-18-4P				

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(target compd.; prepn. of N-(arylsulfonylphenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide derivs. for elevation of pyruvate dehydrogenase (PDH) activity)

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Brown, F; US 5486515 A 1996 CAPLUS
- (2) Ohnmacht, C; Journal of Medicinal Chemistry 1996, V39(23), P4592 CAPLUS
- (3) Zeneca; EP 0617010 A 1994 CAPLUS
- (4) Zeneca; WO 9628151 A 1996 CAPLUS

L12 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2002 ACS

AN 1999:593675 CAPLUS

DN 132:121896

TI Effect of methionine supplementation on endothelial function, plasma homocysteine, and lipid peroxidation

AU McAuley, Daniel F.; Hanratty, Colm G.; McGurk, Colm; Nugent, Ailish G.; Johnston, G. Dennis

AN 1998:715148 CAPLUS
 DN 130:119083
 TI Effects of antipyretics on mortality due to influenza B virus in a mouse model of Reye's syndrome
 AU Crocker, John F. S.; Digout, Sharon C.; Lee, Spencer H.; Rozee, Ken R.; Renton, Ken; Field, Chris A.; Acott, Philip; Murphy, Mary G.
 CS Department of Pediatrics, Dalhousie University and the Izaak Walton Killam-Grace Health Centre, Halifax, NS, Can.
 SO Clinical and Investigative Medicine (1998), 21(4-5), 192-202
 CODEN: CNVMDL; ISSN: 0147-958X
 PB Canadian Medical Association
 DT Journal
 LA English
 CC 1-4 (Pharmacology)
 AB To det. the effects of acetylsalicylic acid (ASA) and acetaminophen on mortality due to influenza B infection in neonatal and weanling mice, as well as any synergistic, antagonistic or indifferent effects of the combined antipyretic and virus on mortality in mice pre-treated with low doses of an industrial surfactant, Toximul MP8, which has been shown to reproduce many of the features of Reye's syndrome. In vitro studies were done to det. whether ASA or acetaminophen altered the normal, interferon-mediated antiviral responses of mammalian cells. The involvement of ASA or other commonly used xenobiotics in the induction of Reye's syndrome following virus illness has not been resolved; to do so, and to elucidate the underlying metabolic mechanism, requires these studies in an animal model. Prospective animal study. Newborn (945) and weanling (840) Swiss white mice, divided into 12 subgroups. Some groups received Toximul MP8 before inoculation with a dose of mouse-adapted human influenza B that produces 30% mortality (LD30); after infection, each subgroup received either placebo, ASA or acetaminophen. Mortality counts were taken daily. The in vitro effects of the antipyretics on interferon response were detd. using std. virol. techniques. Mortality, analyzed by survival curves (log rank test) or cumulative daily mortality (.chi.2 anal.). **Plaque**-reducing dose (PRD50) was used to det. the outcome of the in vitro analyses. In neonatal mice, only subgroups given combined treatment with acetaminophen and Toximul MP8 had a statistically significant higher mortality rate than with the mice given influenza B alone. In weanling mice, it appeared that ASA shortened the time until death; however, this difference was not statistically significant. In vitro studies demonstrated that both ASA and acetaminophen decreased the interferon-induced antiviral responses of cultured mammalian cells. Antipyretics have the potential to exacerbate the consequences of a viral infection, although the specific effects are subtle and appear to be age-related.
 ST antipyretic ASA influenza B Reye's syndrome; acetaminophen toximul interaction antiviral interferon age
 IT Brain, disease
 Brain, disease
 (Reye's syndrome; effects of antipyretics on mortality due to influenza B virus in a mouse model of Reye's syndrome)
 IT Aging, animal
 Antipyretics
 Antiviral agents
 Influenza B virus
 Newborn
 (effects of antipyretics on mortality due to influenza B virus in a mouse model of Reye's syndrome)
 IT Interferons
 RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (effects of antipyretics on mortality due to influenza B virus in a

mouse model of Reye's syndrome)

IT Anti-inflammatory agents
(nonsteroidal; effects of antipyretics on mortality due to influenza B virus in a mouse model of Reye's syndrome)

IT Drug interactions
(synergistic; effects of antipyretics on mortality due to influenza B virus in a mouse model of Reye's syndrome)

IT 50-78-2, Acetylsalicylic acid
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(effects of antipyretics on mortality due to influenza B virus in a mouse model of Reye's syndrome)

IT 103-90-2, Acetaminophen 37341-79-0, Toximul MP8
RL: ADV (Adverse effect, including toxicity); BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); PROC (Process); USES (Uses)
(effects of antipyretics on mortality due to influenza B virus in a mouse model of Reye's syndrome)

RE.CNT 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Casteels-van Daele, M; Arch Dis Child 1997, V76, P79 MEDLINE
- (2) Crocker, J; Exp Neurol 1991, V111, P95 MEDLINE
- (3) Crocker, J; Lab Invest 1986, V54, P32 CAPLUS
- (4) Davis, L; Ann Neurol 1985, V18, P556 CAPLUS
- (5) Deshmukh, D; Proc Natl Acad Sci USA 1982, V79, P7557 CAPLUS
- (6) Doran, T; J Pediatr 1989, V114, P1045 MEDLINE
- (7) Fromenty, B; Pharam Ther 1995, V67, P101 CAPLUS
- (8) Godfrey, A; N Engl J Med 1985, V313, P450
- (9) Graham, N; J Infect Dis 1990, V162, P1277 MEDLINE
- (10) Halpin, T; JAMA 1982, V248, P687 MEDLINE
- (11) Hardie, R; Arch Dis Child 1996, V74, P400 MEDLINE
- (12) Hug, G; Lab Invest 1981, V45, P89 CAPLUS
- (13) Hurwitz, E; JAMA 1987, V257, P1905 MEDLINE
- (14) Hurwitz, E; N Engl J Med 1985, V313, P849 MEDLINE
- (15) Krawchuk, S; [dissertation] Dalhousie University 1989
- (16) Lee, S; Appl Environ Microbiol 1990, V40, P787
- (17) Levy, M; Drug Saf 1997, V16, P1 MEDLINE
- (18) Linnemann, C; Pediatr Res 1979, V13, P44 CAPLUS
- (19) Macdonald, M; Pediatr Res 1984, V18, P181 CAPLUS
- (20) Malamy, J; Science 1990, V250, P1002
- (21) Mantel, N; Cancer Chemother Rep 1966, V50, P163 MEDLINE
- (22) Metraux, J; Science 1990, V250, P1004 CAPLUS
- (23) Murphy, M; Biochim Biophys Acta 1996, V1315, P208 CAPLUS
- (24) Murphy, M; Biochim Biophys Acta 1997, V1361, P103 CAPLUS
- (25) Oehen, S; Science 1991, V251, P195 MEDLINE
- (26) Orlowski, J; Cleve Clin J Med 1990, V57, P323 MEDLINE
- (27) Poss, W; Arch Pediatr Adolesc Med 1994, V148, P879 MEDLINE
- (28) Remington, P; Pediatrics 1986, V77, P93 MEDLINE
- (29) Reye, R; Lancet 1963, V2, P749
- (30) Roe, C; Reye's syndrome Round Table Series, no 8 1988, P85
- (31) Rogers, M; Pediatrics 1985, V75, P260 MEDLINE
- (32) Rosenberg, D; South Med J 1977, V70, P660 MEDLINE
- (33) Rozee, K; CMAJ 1982, V126, P798 MEDLINE
- (34) Rozee, K; Canadian Pediatric Society meeting 1987
- (35) Shindell, S; Lancet 1993, V341, P119 MEDLINE
- (36) Smith, T; Scott Med J 1996, V41, P409
- (37) Stanley, E; JAMA 1975, V231, P1248 MEDLINE
- (38) Starko, K; Pediatrics 1980, V66, P859 MEDLINE
- (39) Stumpf, D; Brain Dev 1995, V17(Suppl), P77

- (40) Trauner, D; Neurology 1988, V38, P239
- (41) Vesentin, M; Drug Metab Rev 1995, V27, P517
- (42) Waldman, R; JAMA 1982, V247, P3089 MEDLINE
- (43) Yamashita, F; Reye's syndrome IV 1985, P47

=>

AN 1998:715148 CAPLUS
 DN 130:119083
 TI Effects of antipyretics on mortality due to influenza B virus in a mouse model of Reye's syndrome
 AU Crocker, John F. S.; Digout, Sharon C.; Lee, Spencer H.; Rozee, Ken R.; Renton, Ken; Field, Chris A.; Acott, Philip; Murphy, Mary G.
 CS Department of Pediatrics, Dalhousie University and the Izaak Walton Killam-Grace Health Centre, Halifax, NS, Can.
 SO Clinical and Investigative Medicine (1998), 21(4-5), 192-202
 CODEN: CNVMDL; ISSN: 0147-958X
 PB Canadian Medical Association
 DT Journal
 LA English
 CC 1-4 (Pharmacology)
 AB To det. the effects of acetylsalicylic acid (ASA) and acetaminophen on mortality due to influenza B infection in neonatal and weanling mice, as well as any synergistic, antagonistic or indifferent effects of the combined antipyretic and virus on mortality in mice pre-treated with low doses of an industrial surfactant, Toximul MP8, which has been shown to reproduce many of the features of Reye's syndrome. In vitro studies were done to det. whether ASA or acetaminophen altered the normal, interferon-mediated antiviral responses of mammalian cells. The involvement of ASA or other commonly used xenobiotics in the induction of Reye's syndrome following virus illness has not been resolved; to do so, and to elucidate the underlying metabolic mechanism, requires these studies in an animal model. Prospective animal study. Newborn (945) and weanling (840) Swiss white mice, divided into 12 subgroups. Some groups received Toximul MP8 before inoculation with a dose of mouse-adapted human influenza B that produces 30% mortality (LD30); after infection, each subgroup received either placebo, ASA or acetaminophen. Mortality counts were taken daily. The in vitro effects of the antipyretics on interferon response were detd. using std. virol. techniques. Mortality, analyzed by survival curves (log rank test) or cumulative daily mortality (.chi.2 anal.). **Plaque-reducing dose (PRD50)** was used to det. the outcome of the in vitro analyses. In neonatal mice, only subgroups given combined treatment with acetaminophen and Toximul MP8 had a statistically significant higher mortality rate than with the mice given influenza B alone. In weanling mice, it appeared that ASA shortened the time until death; however, this difference was not statistically significant. In vitro studies demonstrated that both ASA and acetaminophen decreased the interferon-induced antiviral responses of cultured mammalian cells. Antipyretics have the potential to exacerbate the consequences of a viral infection, although the specific effects are subtle and appear to be age-related.
 ST antipyretic ASA influenza B Reye's syndrome; acetaminophen toximul interaction antiviral interferon age
 IT Brain, disease
 Brain, disease
 (Reye's syndrome; effects of antipyretics on mortality due to influenza B virus in a mouse model of Reye's syndrome)
 IT Aging, animal
 Antipyretics
 Antiviral agents
 Influenza B virus
 Newborn
 (effects of antipyretics on mortality due to influenza B virus in a mouse model of Reye's syndrome)
 IT Interferons
 RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (effects of antipyretics on mortality due to influenza B virus in a

mouse model of Reye's syndrome)

IT Anti-inflammatory agents
(nonsteroidal; effects of antipyretics on mortality due to influenza B virus in a mouse model of Reye's syndrome)

IT Drug interactions
(synergistic; effects of antipyretics on mortality due to influenza B virus in a mouse model of Reye's syndrome)

IT 50-78-2, Acetylsalicylic acid
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(effects of antipyretics on mortality due to influenza B virus in a mouse model of Reye's syndrome)

IT 103-90-2, Acetaminophen 37341-79-0, Toximul MP8
RL: ADV (Adverse effect, including toxicity); BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); PROC (Process); USES (Uses)
(effects of antipyretics on mortality due to influenza B virus in a mouse model of Reye's syndrome)

RE.CNT 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE

- (1) Casteels-van Daele, M; Arch Dis Child 1997, V76, P79 MEDLINE
- (2) Crocker, J; Exp Neurol 1991, V111, P95 MEDLINE
- (3) Crocker, J; Lab Invest 1986, V54, P32 CAPLUS
- (4) Davis, L; Ann Neurol 1985, V18, P556 CAPLUS
- (5) Deshmukh, D; Proc Natl Acad Sci USA 1982, V79, P7557 CAPLUS
- (6) Doran, T; J Pediatr 1989, V114, P1045 MEDLINE
- (7) Fromenty, B; Pharam Ther 1995, V67, P101 CAPLUS
- (8) Godfrey, A; N Engl J Med 1985, V313, P450
- (9) Graham, N; J Infect Dis 1990, V162, P1277 MEDLINE
- (10) Halpin, T; JAMA 1982, V248, P687 MEDLINE
- (11) Hardie, R; Arch Dis Child 1996, V74, P400 MEDLINE
- (12) Hug, G; Lab Invest 1981, V45, P89 CAPLUS
- (13) Hurwitz, E; JAMA 1987, V257, P1905 MEDLINE
- (14) Hurwitz, E; N Engl J Med 1985, V313, P849 MEDLINE
- (15) Krawchuk, S; [dissertation] Dalhousie University 1989
- (16) Lee, S; Appl Environ Microbiol 1990, V40, P787
- (17) Levy, M; Drug Saf 1997, V16, P1 MEDLINE
- (18) Linnemann, C; Pediatr Res 1979, V13, P44 CAPLUS
- (19) Macdonald, M; Pediatr Res 1984, V18, P181 CAPLUS
- (20) Malamy, J; Science 1990, V250, P1002
- (21) Mantel, N; Cancer Chemother Rep 1966, V50, P163 MEDLINE
- (22) Metraux, J; Science 1990, V250, P1004 CAPLUS
- (23) Murphy, M; Biochim Biophys Acta 1996, V1315, P208 CAPLUS
- (24) Murphy, M; Biochim Biophys Acta 1997, V1361, P103 CAPLUS
- (25) Oehen, S; Science 1991, V251, P195 MEDLINE
- (26) Orłowski, J; Cleve Clin J Med 1990, V57, P323 MEDLINE
- (27) Poss, W; Arch Pediatr Adolesc Med 1994, V148, P879 MEDLINE
- (28) Remington, P; Pediatrics 1986, V77, P93 MEDLINE
- (29) Reye, R; Lancet 1963, V2, P749
- (30) Roe, C; Reye's syndrome Round Table Series, no 8 1988, P85
- (31) Rogers, M; Pediatrics 1985, V75, P260 MEDLINE
- (32) Rosenberg, D; South Med J 1977, V70, P660 MEDLINE
- (33) Rozee, K; CMAJ 1982, V126, P798 MEDLINE
- (34) Rozee, K; Canadian Pediatric Society meeting 1987
- (35) Shindell, S; Lancet 1993, V341, P119 MEDLINE
- (36) Smith, T; Scott Med J 1996, V41, P409
- (37) Stanley, E; JAMA 1975, V231, P1248 MEDLINE
- (38) Starko, K; Pediatrics 1980, V66, P859 MEDLINE
- (39) Stumpf, D; Brain Dev 1995, V17(Suppl), P77

- (40) Trauner, D; Neurology 1988, V38, P239
- (41) Vesentin, M; Drug Metab Rev 1995, V27, P517
- (42) Waldman, R; JAMA 1982, V247, P3089 MEDLINE
- (43) Yamashita, F; Reye's syndrome IV 1985, P47

=>

Welcome to STN International! Enter x:x

LOGINID:sssptaul25rxt

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	Feb 24	PCTGEN now available on STN
NEWS	4	Feb 24	TEMA now available on STN
NEWS	5	Feb 26	NTIS now allows simultaneous left and right truncation
NEWS	6	Feb 26	PCTFULL now contains images
NEWS	7	Mar 04	SDI PACKAGE for monthly delivery of multifile SDI results
NEWS	8	Mar 24	PATDPAFULL now available on STN
NEWS	9	Mar 24	Additional information for trade-named substances without structures available in REGISTRY
NEWS	10	Apr 11	Display formats in DGENE enhanced
NEWS	11	Apr 14	MEDLINE Reload
NEWS	12	Apr 17	Polymer searching in REGISTRY enhanced
NEWS	13	Jun 13	Indexing from 1947 to 1956 added to records in CA/CAPLUS
NEWS	14	Apr 21	New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX
NEWS	15	Apr 28	RDISCLOSURE now available on STN
NEWS	16	May 05	Pharmacokinetic information and systematic chemical names added to PHAR
NEWS	17	May 15	MEDLINE file segment of TOXCENTER reloaded
NEWS	18	May 15	Supporter information for ENCOMPPAT and ENCOMPLIT updated
NEWS	19	May 19	Simultaneous left and right truncation added to WSCA
NEWS	20	May 19	RAPRA enhanced with new search field, simultaneous left and right truncation
NEWS	21	Jun 06	Simultaneous left and right truncation added to CBNB
NEWS	22	Jun 06	PASCAL enhanced with additional data
NEWS	23	Jun 20	2003 edition of the FSTA Thesaurus is now available
NEWS	24	Jun 25	HSDB has been reloaded
NEWS	25	Jul 16	Data from 1960-1976 added to RDISCLOSURE
NEWS	26	Jul 21	Identification of STN records implemented
NEWS	27	Jul 21	Polymer class term count added to REGISTRY
NEWS	28	Jul 22	INPADOC: Basic index (/BI) enhanced; Simultaneous Left and Right Truncation available
NEWS	29	AUG 05	New pricing for EUROPATFULL and PCTFULL effective August 1, 2003
NEWS EXPRESS			April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer